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and Calcium Supplementation 
on Morbidity and Mortality in 
Postmenopausal Women
During and after the perimenopausal 
years, hormone therapy (HT) is pre-
scribed to alleviate chronic climacteric 
symptoms, to improve quality of life, 
and to prevent osteoporosis. Under-
standing the risks and benefits of HT 
is critical to clinical decision making 
around menopause and beyond. In 
this large population-based study we 
investigated whether HT has effects on 
mortality and diabetes morbidity and 
whether calcium or calcium + vitamin 
D supplementation affect CHD mor-



















































































































































menopause and beyond. The purpose of this populationbased cohort study was to
investigate whether HT has an effect on mortality and diabetes morbidity and also to
investigate whether calcium or calcium+vitamin D supplementation has an effect on
CHD morbidity in ageing women. Agreement analysis was performed to verify the
accuracyofselfreportedestrogenuseversusprescriptiondata.Validityanalysisshowed
thatapostalinquiryisareliablemethodofrecordinglongtermHTuse.
 This study is part of the large Kuopio Osteoporosis Risk Factor and Prevention
(OSTPRE)populationbasedprospectivecohortstudy.Thestudypopulationconsistedof
11667 women resident in Kuopio Province and a postmenopausal subgroup of 9354
womenwhorespondedtopostalinquiriesin1989and1994andwhoseHTandcalciumor
calcium+vitaminD supplementation usewas verified.A total of 8483 postmenopausal
womenwhowerenondiabeticinMay1994alsorespondedtoathirdfollowupinquiryin








DM as follows: parttime use (< 2.5 years) by 47% (HR 0.53, 95% CI 0.24–1.15) and
continuoususe(2.55.0years)by69%(HR0.31,95%CI0.16–0.60).Inaddition,calciumor


























vaihdevuosien aikana ja jälkeen. Tämä laaja väestöpohjainen kohorttitutkimus selvitti
hormonihoidon vaikutusta kuolleisuuteen ja sokeritautisairastuvuuteen sekä tutki
kalsium tai kalsium + Dvitamiinilisän vaikutusta sepelvaltimotautisairastuvuuteen
ikääntyvillä naisilla. Lisäksi suoritettiin yhtäpitävyysanalyysi varmistamaan
itseraportoidun estrogeenin käytön yhtäpitävyyden suhde KELA:n reseptitiedostoon.
Validiteettianalyysi vahvisti, että postikysely on luotettava menetelmä kerätä tietoa
pitkäaikaisestahormoninkäytöstä.
 Tutkimus on osa laajaa Kuopion Osteoporoosin Vaaratekijät ja Ehkäisy (OSTPRE)
tutkimusta, jokaonväestöpohjainenprospektiivinenkohorttitutkimus.Tutkimusjoukko
muodostui 11667 itäsuomalaisesta naisesta, joista 9345 oli ohittanut vaihdevuodet.
Tutkimusjoukko vastasi vuosien 1989 ja 1994 postikyselyihin, joiden avulla pystyttiin
selvittämään hormonihoidon ja kalsium tai kalsium + Dvitamiinilisän käyttö.
Vaihdevuodet ohittaneiden ja sokeritautia sairastamattoman 8384 naisen osalta
seurantatutkimus jatkui vuodesta 1994 vuoteen 1999, jolloin toteutettiin kolmas
postikysely. Tämän tutkimusjoukon osalta selvitettiin hormonihoidon vaikutusta
sokeritautisairastuvuuteen. Tämän tutkimuksen tulokset osoittavat, ettei hormonihoidon
käyttöhistoriallaolevaikutustanaistenkokonais taisepelvaltimotautikuolleisuuteen.Yli
5vuodenhormonihoidonkäyttönäyttiomaavanvaikutustarintasyöpäkuolleisuuteen(HR
2.62, 95 % CI 0.98–7.00) koko seurantajoukossa. Vaihdevuodet ohittaneiden naisten
hormonihoidon käytöllä ei ollut vaikutusta rintasyöpäkuolleisuuteen. Tutkimuksen
tulokset osoittavat, että hormonihoidolla on hyödyllinen sokeritautia ennaltaehkäisevä
vaikutus. Vaihdevuodet ohittaneiden naisten aiempi hormonihoidon käyttö suojasi
sokeritaudilta 19 % verrattuna ei koskaan hormonihoitoa käyttäneisiin naisiin. Alle 2.5
vuoden hormonihoidon käyttö 5vuoden seurantaaikana suojasi sokeritaudilta 47 % ja
2.5–5.0 vuoden käyttö 69 %. Lisäksi kalsium tai kalsium + Dvitamiinilisä näyttäisi
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1. Letters, numbers and sign errors 
Page VII, lines 4, 13 ja 26 CORRECT: kalsium- ja D-vitamiinilisä 
Page 26 paragraph Primary prevention of coronary heart disease, line 6; CORRECT; invasive 
breast cancer (8 extra cases/10 000 person-years) NOT (7 extra cases/10 000 person-years) 
Page 33 Sub-subtitle 2.7.5.1; paragraph 2, line 5; CORRECT; (age-adjusted RR 0.83, 95% CI 0.43-
1.63) NOT (age-adjusted RR 0.83, 95% 0.43-1.63)) 
Page 58, Title 5.3, paragraph 4, line 3; CORRECT … and 2.16 NOT … and 2.61 
Page 60, Table 12, column Use of HT; row Continuous (≥ 2.5 years), column Multivariate (95% CI); 
CORRECT: 0.31 (0.16-0.60) NOT 0.31 (0.61-0.60) 
Page 61, paragraph 2, line 6; CORRECT: Overall, 368 cases of incident CHD NOT Overall, 363 
cases of incident CHD. 
 
2. Name error 
Page XII line 3 CORRECT; Ralph NOT Ralf 
 
3. Word or phrase missing 
Page 13, line 14; CORRECT; … for transdermal estradiol combined with micronized progesterone 
and 1.18 (95% CI 0.89-1.31) for transdermal estradiol and dydrogesterone. 
Page 42, The first chapter, lines 12 and 13; CORRECT; …calcium levels between 2.3 and 
2.45mml/L. For those with serum calcium between 2.5 and 2.55 mmol/L, the odds ratio of death 
was 1.5 (95% CI 1.3-1.8) NOT …calcium levels between 2.3 and 2.45mml/L, the odds ratio of 
death was 1.5 (95% CI 1.3-1.8). 
Page 55, Table 9, Column Study, row II, Column Main Results; CORRECT; History of HT use; no 
effect on CHD or overall mortality, > 5 yrs of HT use may increase the risk of breast cancer 
mortality 
 
4. Incorrect word or phrase 
Page XII number IV, line 4; CORRECT; Maturitas 2009; 63: 73–78 NOT Menopause 2008 Mar-Apr; 
15(2): 282-9. 
Page 11 last paragraph lines 2 and 3; CORRECT; “ratios (HRs) of 1.85 (95% CI 1.18-2.90) for prior 
EPT users (n= 4,311), and 1.02 (95% 0.77-1.36) among 12,297 non-prior users”. NOT  “ratios (HRs) 
of 1.85 (95% CI 1.18-2.90) for prior EPT users (n= 4,311) and 1.09 (95% CI 0.86-1.39) among 12,297 
non-prior users”. 
Page 23, Table 3; study Nurses’s Health Study Grodstein et al. 2000; results: CORRECT; HT 
current use vs. never RR 0.61 (0.52-0.71) NOT HT ever vs. never RR 0.61 (0.52-0.71) 
page 25, the third paragraph, line 1; CORRECT; ”within the cohort of 2763 ” NOT “within the 
cohort of 2448”. 
Page 35, Table 6; study de Lauzon-Guillan et al. 2009 E2N Cohort; Results: CORRECT; Any HT: 
Ever vs. never NOT Any HT: Never vs. ever 
Page 59, Title 5.9, paragraph 3, lines 8 and 9: CORRECT;”incidence was 3.85 per 1000 person-
years in the whole cohort, 5.26 per 1000 person-years in the HT never-users, 4.45 per 1000 
person-years in past HT-only users, 2.34 per 1000 person-years” NOT ”incidence was 3.85 per 
1000 person-years in HT never-users, 4.45 per 1000 person-years in past HT-only users, 2.32 per 
1000 per 1000 person-years”. 
 
1Introduction







 In2003hormone therapy (HT)wasusedby34%of45 to64yearoldwomenandby
15%of65to84yearoldwomeninFinland(TheFinnishMedicalSocietyDuodecim&the
Finnish Academy 2005). Originally, estrogen substitution was started to treat harmful






around the world. In Finland, every second postmenopausal women has CHD and on
averageonethirdofthemwilldieofit(Kaaja2003);itistheleadingcauseofdeathamong
womenovertheageof65(Niemeläetal.2009).
 The results of numerous observational studies have suggested an inverse association
betweenHTwithestrogen (ET)orcombined therapywithestrogenandprogestin (EPT)
versusincidenceofordeathfromCHD,andallcausemortality.Ithasbeenestimatedthat





 Calcium supplementation is widely used for the prevention of osteoporosis in
postmenopausal women and in men (Reid et al. 2010). Despite the fact that calcium
supplementationslowsdownbonelossinbothsexes(Reidetal.2006,Reidetal.2008),its
effect on fracture risk are less certain (Tang et al. 2007, Reid et al. 2008), and it is
appropriatetoconsiderpossibleadverseeffects.
 Foralongtimetherehasbeenspeculationconcerningapossibleelevatedriskofbreast
cancer in connection with HT. According to reanalysis of 51 epidemiological studies
(ColloborativeGrouponHormonalFactorsinBreastCancer1997),theestimatedrelative
riskofbreastcancerwas1.35forwomenwhohadusedHTfor5yearsorlonger,andthe
risk increased with increasing duration of use (Speroff & Fritz 2005). Similar results
regardingtheriskofbreastcancerwereseenintheWHITrial(Rossouwetal.2002),inthe






to 366million in 2030 globally (Wild et al. 2004). Steroid hormonesmay influenceDM
onset. Impairedglucose toleranceand insulin resistanceareknown to increasewithage
(Iozzoetal.1999),butitisstillunclearifmenopausepersemodifiesthisincrease(Bentley
Lewis et al. 2007).Randomized controlled studies (HERS (Kanaya et al. 2003) andWHI
Trials(Margolisetal.2004,Bondsetal.2006))andsomeobservationalstudies(Hammond
etal.1979b,Mansonetal.1992)haveshownpositiveeffectsofHTonDM.
 Longer life expectancy raises many economic and health concerns. What are the
methodswhich can help the ageingwomen to remain healthy through themenopausal
yearstopostmenopausalyears?PerhapsHTmaybeonethesolutionstothisquestion.The
present studywasessentiallydesigned to investigate theeffectsofHTonmortalityand








Menopause is derived from the Greek words men (month) and pausis (cessation).
Menopause is definedby theWorldHealthOrganization as thepermanent cessation of
mensesasa resultof the lossofovarian follicular functionorof surgical removalof the
ovaries (WHO Scientific Group 1996). Natural menopause is defined as spontaneous
cessationofnaturalmenstruation for12 consecutivemonthsat 4555years (medianage
51.3years)(McKinlayetal.1992).TheaverageageatmenopauseforFinnishwomenhas
been51yearsfordecades(Luotoetal.1994).However,approximately10%ofwomenin
the general population are menopausal by the age of 45 (The Finnish Medical Society
Duodecim& the FinnishAcademy 2005). Prematuremenopause can bedue to bilateral
oophorectomy,radiotherapy,chemotherapyorseveregeneral illnesses.Currentsmoking
hasbeendocumentedasacauseofearliermenopause–ashiftofapproximately1.5years





not begin to decline until about a year before menopause (Burger et al. 2000). The
circulating estradiol level after menopause is usually 10–20 pmol/L, most of which is
derived fromperipheral conversionofestrone (Juddetal. 1982).Thecirculatingestrone
level in postmenopausal women is usually under 300 pmol/L, and estrone in turn is
mainly derived from the peripheral aromatization of androstenedione. Most of this
postmenopausal androstenedione production occurs in the adrenal glands, and only a
smallamountissecretedintheovaries,althoughandrostenedioneandtestosteronearethe
principalsteroidssecretedbythepostmenopausalovary(Parkeretal.2000).Theenzyme





During the menopausal years, some women experience multiple severe climacteric
symptoms,while others showno reactions orminimal reactions that can go unnoticed.
Thenature andprevalenceofmenopausal symptomsare common tomostwomen, and
variations amongandwithin cultures reflectdifferences in attitudes, societies, lifestyles,
socioeconomicstatusandindividualperceptions,butnotinphysiology(Obermeyer2000).
Thereisonlylittlevarietyincirculatinghormonelevelsduringmenopausalyearsamong
different ethnic groups and these differences aremainly because of variable body sizes
(Randolphetal.2004).
4
 The symptomswhichmayoccurbeforeand/orwithin the firstmonthsofmenopause
are defined as immediate symptoms. They include vasomotor symptoms, such as hot
flushesandnightsweats,whicharethemostcharacteristicofmenopause(Oldenhaveet
al. 1993). Hot flushes have an adverse impact on the quality of sleep (Woodward &
Freedman 1994), and tiredness thereby diminishes the ability to handle the next day’s
problems and stresses. Depressed mood disorders increase during the menopausal
transition.Mood is largely affected by vasomotor symptoms and sleep disturbances, in
combinationwith lifeproblems (Avis et al. 2001).Vasomotor symptomsare the leading
reasontoinitiateHTuseinclinicalpractice.
 Normal ageing itself is associated with a number of health risks and estrogen
deprivation accelerates the normal ageing process. Longterm estrogen deprivation
consequences are atrophic changes in the skin and urogenital structures (Archer 2010),
osteoporosis (Sirola et al. 2003, American College of Obstetricians and Gynecologists
Womens Health Care Physicians 2004), cognition (Henderson 2008) and Alzheimer’s
disease (Shumaker et al. 2003, Henderson 2008),  and CVD (Mendelsohn 2005, Collins
2007).Atrophic changes andosteoporosis are important reasons touseHT. In addition,
calcium supplementation is widely used for the prevention of osteoporosis in
postmenopausalwomenandmen.

2.2 VALIDATION OF HORMONE THERAPY USE  

Thevalidity and reliabilityof selfreportedHTusehavebeenexamined (Horwitz&Yu
1985,Greendaleetal.1997,Merloetal.2000,Lipworthetal.2001),andmedical reports
(PaganiniHill&Ross1982,Goodmanetal.1990, Jainetal.1999,Banksetal.2001) and
pharmacy records (PaganiniHill & Ross 1982, Persson et al. 1987, West et al. 1995,
Lokkegaardetal.2004)havebeenusedasreferencematerial.Assessmentofcurrentuseof
HT has been investigated by using 7day personal diaries and selfadministered
questionnaires,showinggoodagreementbetweenthemethods(95.5%),andsensitivityof
84.9% and specificity of 97.7% (Merlo et al. 2000) (Table 1). However, in the study by
PaganiniHill andRoss (PaganiniHill&Ross 1982), sensitivity and the specificitywere
only42.1%and82.4%respectively. Inthestudieswhereprescriptiondatabaseswereused
as referencematerial, agreement varied considerably according to the type of data; for









 In a populationbased casecontrol study inwhich the effects ofHTon breast cancer











study byLucas et al. (2008), therewas an excellent agreement between two interviews;
agreementwas over 90% for selfreportedparity, hysterectomy, oophorectomy, andHT
(Lucasetal.2008)(Table1).
 Only a few studies have involved comparison of the validity of selfreported
medicationusewithprescriptionreimbursementdata.ADanishstudyrevealedrelatively
high validity of selfreported data on HT use (Lokkegaard et al. 2004) (Table 1). The
sensitivity and specificity of selfreported, current HT use in 1993were 78.4% (95% CI
75.4–81.4) and 98.4% (95%CI 97.8–98.9), respectively. In 1999, the estimateswere 74.8%
(95% CI 72.0–77.7) and 98.0% (95% CI 97.3–98.8), respectively. None of the factors
examined, including age, alcohol intake, physical activity, smoking, presence of
hypertension, and BMIwere strongly associatedwith validity. Furthermore, agreement
betweenselfreportedandregistrybaseddatawasnotstronglyassociatedwitharangeof
demographic and lifestyle factors (Lokkegaard et al. 2004). In 2001, excellent agreement




Table 1.Validity and reliability of self-reported HT use in agreement studies carried out after 
2000. 
 
Merlo et al. 2000 agreement between self-administered questionnaire for current use of HT:good (95.5%) kappa 0.84
and 7-day personal diary sensitivity 84.9%, specificity 97.7%.
Banks et al. 2001 agreement between self-administered questionnaire for current use of HT: excellent (96%) kappa 0.91
and prescription record for any use of HT: excellent (95%) kappa 0.90
current users: for type of HT (E,EPT or other):excellent  (97%) kappa 0.95
Lipworth et al. 2001 agreement between 2 interviews, 5 years apart self interview: for estrogen users; good (80%) kappa 0.86
all next-of-kin interview:for estrogen users: moderate (56%) kappa 0.71
Lokkegaard et al. 2004 compared validity of self-reported use of HT in 1993 the sensitivity and specificity were high, 78.4% and 98.4%
with prescription reimbursement data in 1999 the sensitivity and specificity were high, 74.8% and 98.0%
Kropp et al.  2007 agreement between self-reported use of HT for ever/never use; moderate (88.2%),kappa 0.72
and gynecologist data for mono-E 80.6%, for cyclical EPT 80.3%, for continous EPT 90.5%
high ICC for duration of use 0.82, for age at first and last use 0.88 and 0.98
Lucas et al. 2008 agreement between two interviews for self-reported use of HT: good (93%),kappa 0.81
mean evaluation time 5 years women with higher education reported HRT more reliably
ResultsStudy Study approach
 
Abbreviations: HT: hormone therapy, mono-E: estrogen-only therapy, EPT: estrogen-progestagen 
therapy, ICC: intraclass correlation coefficient 
6
2.3 HORMONE THERAPY 

In 1941 The US Food and Drug Administration (FDA) approved marketing of
diethylstilbestrol, and in 1942, conjugated equine estrogens (CEEs) for treatment of
menopausalsymptoms(Speroff&Fritz2005).IntheUS,CEEhaseversincebeenmainly
usedinestrogensubstitution,butinEuropethemainproducthasbeen17estradiol(E2).
 Estrogen sales tripled in the mid1960s to mid1970s. In 1975 reports of increased
endometrial cancer in estrogenonly users resulted in a dramatic decline. Estrogen use
increased again with evidence of protective effects of progestins on estrogeninduced
endometrial changes. Despite conflicting reports in 1985 regarding the relationship
between estrogens and CHD, the use of HT increased through the 1990s. The 2002




Finnish Medical Society Duodecim & the Finnish Academy 2005) and in 2008 various
formsofHTwereusedby352600womeninFinland(Paakkarietal.2009).
 ContraindicationsforHTincludehistoryofbreastcancerorotherhormonedependent
cancers, undiagnosed gynecological bleeding, thromboembolic disease, myocardial




Estrogens are classified into two types: natural and synthetic. The natural estrogens
produced inhumansareestradiol, estrone,andestriol.Their conjugates, i.e. the sulfuric





 The most potent human estrogen is E2 (Kuhl 2005). Estrogenonly therapy (ET) is
systemic use of estrogen. Estradiol can be administered orally, transdermally (patch or
gel),vaginally,intramuscularly*andintranasally*(*notavailableinFinland)(TheFinnish
MedicalSocietyDuodecim&theFinnishAcademy2005).AccordingtoFinnishguidelines




Postmenopausal HT initially consisted only of sequential regimens that imitated cyclic
estrogen andprogesteronepatterns in premenopausalmenstrual cycles (Speroff& Fritz
2005).TheonlyindicationfortheuseofprogestagensinHTisthepreventionofestrogen
induced endometrial hyperplasia, because longterm unopposed estrogen action on the
endometrium increases the risk of hyperplasia and cancer of the endometrium (Kuhl
7
2005).Nonhysterectomizedwomen and alsowomenwhohaveundergone endometrial
ablative techniques, since it cannot be certain that all endometrium has been removed,
requirecombinedtherapywithprogestagenandestrogentoreducetheincreasedriskof
hyperplasia and cancer of the endometrium (Shaw et al. 2003). In sequential regimens,
progestagens are administeredwith estrogens for 10–14 days of everymonth or for 14
dayseverythreemonths.Incontinuousregimensbothestrogenandprogestagenaregiven
daily(Shawetal.2003,Hickeyetal.2005).
 Progestagens can be divided into two types: natural progesterone and synthetic
progestagens.Progesterone is rapidlymetabolized in the intestinal tract, liverandmany





 Synthetic progestagens can be divided into progesterone derivatives (e.g.
medroxyprogesterone acetate (MPA),megestrol acetate), 19norprogesterone derivatives
(e.g.trimegestone),19nortestosteronederivatives(e.g.norethisteroneacetate,lynestrenol,
levonorgestrel), dienogest (19nortestosterone combining the properties of both the 19
nortestosterone family and derivatives of progesterone) and the spirolactone derivative
drospirenone (Speroff & Fritz 2005). Progestagens can be administered orally,
transdermally (percutaneously),vaginallyorviaan intrauterinedevice (Kuhl2005).The
“intrauterine system” (IUS) delivers intrauterine levonorgestrel and can provide the
progestagencomponentofHT(Shawetal.2003).The intrauterinepresenceofprogestin
effectively protects the endometrium against hyperplasia and cancer (Speroff & Fritz
2005). All progestagens exert progestagenic and – in some tissues  antiestrogenic
activities, but differ greatly in their hormone actions. According to their chemical
structure, they may act as weak androgens or antiandrogens, glucocorticoids or
antimineralocorticoids(Africanderetal.2011).

2.4 BENEFITS OF HORMONE THERAPY 

Certain small subgroups of patients should be specifically treatedwith an oral regimen
andotherswithatransdermalregimen,but,forthevastmajorityofpatients,itwillcome
down to personal preference. The availability of different combinations and doses of
hormones, aswell asdifferent routes of administration, allowsHT to be tailored to the
individual (Stevenson 2009b). Use of HT should be consistent with treatment goals,
benefits, and risks to the individual woman. The benefitrisk ratio for an individual
woman continually changes with her age and her menopauserelated symptoms (e.g.
vasomotor symptoms, sleep disturbance, vaginal atrophy, dyspareunia, or diminished
libido), any of which may have an adverse impact on quality of life. Risk factors are






Estrogen therapy with or without a progestagen, is the most effective treatment for





a dosedependent manner within 2–6 weeks and the addition of daily or sequential
progestagendoesnotaffectthisefficacy(MacLennanetal.2004,Nelson2004,Grady2006).
Lowerdosesofestrogen(examplesincludeconjugatedestrogen(0.3mg),micronizedoral






Threepublishedmetaanalysesofprospective randomized,placebocontrolled trials and








findings than oral estrogen (Suckling et al. 2006). Treatment usually consists of a daily






The efficacy of HT in conserving bone mass is well established (Lufkin et al. 1992,
Komulainenetal.1998).IntheWHIstudy(Rossouwetal.2002),fromwhichwomenwith
known osteoporosis were excluded (Anderson et al. 2004), those treated with either
combinedHTorestrogenonlyHTformorethan5yearsweresignificantlylesslikelythan
women on placebo to sustain a fracture. A reduced risk of fracture was also noted in
earlier observational studies (Kiel et al. 1987, Cauley et al. 1995) of postmenopausal
womenonHT.Hormonetherapyhasabeneficialeffectonfracturepreventioningeneral
andespecially indistal forearm fracture inearlypostmenopausalwomen (Randell et al.
2002). Some longterm protection against osteoporotic fractures is achieved with 7–10
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2.5 RISKS OF HORMONE THERAPY









most common form of cancer among women, comprising one fifth of all cancers
worldwide(Brayetal.2004).Thehighratesofbreastcancerindevelopedcountriesarethe
consequenceofahigherprevalenceofknownriskfactorsofthedisease,e.g.earlyageat






Early casecontrol studies on estrogen use and breast cancer indicated higher risks in
specialsubcategories,suchaswomenwithbenignbreastdisease,longdurationofuse,or
naturalversussurgicalmenopause(Speroff&Fritz2005). In1997aCollaborativeGroup
fromOxford reanalyzed the results of 51 observational studies ofHTandbreast cancer
including52705womenwithbreastcancer(ColloborativeGrouponHormonalFactorsin
Breast Cancer 1997). Among the 4460 women from whom data on the hormone
constituents of the treatment usedwere available, 80%had received estrogen only, and
12%hadreceivedEPT(ColloborativeGrouponHormonalFactorsinBreastCancer1997).
Thus,thedatalargelyrepresenttheuseofETonly.Theriskincreasedlinearlyby2.3%per
year (RR1.02,95%CI1.01–1.04peryear).Notably, thisperyear increaseparalleled that
observedforeachyearofdelayofmenopause(2.8%peryear(RR1.03,95%CI1.02–1.03)).
When limiting data to the subgroup receiving only estrogens (i.e. omitting the 12%
10
receivingEPT),noincreaseinriskoccurredasregardsuseforlessthan5yr(RR0.99±0.08






Eleven cohort studies published later generally confirmed the collaborative pooled
analysis (Schairer et al. 2000, Beral & Million Women Study Collaborators 2003,
Kerlikowskeetal.2003,Chenetal.2006,Leeetal.2006,Lyytinenetal.2006,Espieetal.
2007,Brintonetal.2008,Fournieretal.2008b,Prenticeetal.2008a,Calleetal.2009).Five




were reported, as best exemplified by the NHS study (Chen et al. 2006), a study by
Lyytinen et al. (Lyytinen et al. 2006), the EPIC study (Fournier et al. 2008b), and the
Million Women Study (MWS) (Beral & Million Women Study Collaborators 2003). A
comprehensive metaanalysis including all prior studies from 1989–2004 revealed an
overallRRof1.27(95%CI1.19–1.35)anda3.1%increaseperyearofuse(RR1.031[95%CI
1.023–1.039])(Greiseretal.2005).Ontheotherhand,Normanetal.(Normanetal.2010)




indicate differences in risk related to dose or type of estrogen (Beral&MillionWomen
StudyCollaborators2003,Lyytinenetal.2006).Becauseriskincreaseslinearlywithtime,
theminimal duration of use associatedwith an increase in breast cancer is difficult to






Four randomizedcontrolled trials (RCTs),WHI (Andersonetal.2004),WEST (Women’s
Estrogen for Stroke Trial) (Viscoli et al. 2001), ESPRIT (European/Australasian Stroke
Prevention inReversible IschemiaTrial) (Cherryetal.2002),andEPAT(Estrogen in the
PreventionofAtherosclerosisTrial)(Hodisetal.2001))havebeenreported.TheWHItrial
representsthelargestand,therefore,mostheavilyweighted(Stefanicketal.2006,Prentice
et al. 2008a).Data pooled from the four RCTs showed a RR of 0.79 (95%CI 0.61–1.02),
whichwasofstatisticallyborderlinesignificanceandrepresentedaparadoxicalreduction
inbreastcancerrisk(Collinsetal.2005).InaposthocWHIanalysis,statisticallysignificant























small to derive definitive data in the latter group,with only 58 cases of cancer and 86
controls. A qualitative review (Bush et al. 2001) later included articles accessed from
MedlineandDialogwebpublishedfrom1975to2000.Theauthors’conclusionwas“The




In July 2002, the first results of theWHI randomized controlled trial of continuous or
combined HT with CEE (0.625 mg daily) and MPA (2.5 mg daily) were published
(Rossouwetal.2002).TheWHItrial(Rossouwetal.2002,Mansonetal.2003,Rappetal.
2003, Shumaker et al. 2003,WassertheilSmoller et al. 2003) was stopped after a mean
followupperiodof5.2yearsbytheDataandSafetyMonitoringBoard,because the test
statisticsasregardsinvasivebreastcancerexceededthe“stopboundary”forthisadverse






 In2006 (Andersonet al. 2006), furtheranalysesofWHIdatagaveunadjustedhazard
ratios (HRs) of 1.85 (95%CI 1.18–2.90) forpriorEPTusers (n = 4,311) and 1.09 (95%CI
0.86–1.39) among 12,297 nonprior users. For nonprior users, annualized percentage
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those invited by theU.K.NationalHealth Service Breast Screening Programme to have
screeningmammographyevery3years (abouthalfhadusedHTatsometime) (Beral&
Million Women Study Collaborators 2003). The study data were collected from
questionnairesreturnedpriortotheinitialmammography,andthewomenwerefollowed
to determine cancer incidence and death. No increase in risk of breast cancer was
measured in past users of any hormone preparation, regardless of length of time since
discontinuationandregardlessofdurationofuse.Basedonanaveragefollowupperiod
of 2.6 years, the relative risk of invasive breast cancer was 2.00 (95% CI 1.91–2.09) in
currentEPusers.Overall,therelativeriskofbreastcancerincurrentEPusersatbaseline
increasedwith increasing total duration of use. Similar resultswere also reported after
comparing low and high doses of estrogen, preparations with different progestagens
(MPA, norethindrone, norgestrel/levonorgestrel), and users of sequential or continuous
regimens.Theriskofbreastcancerwasfoundonlyinwomenwhowerenotpriorusersof
HT (Beral&MillionWomenStudyCollaborators2003). In2011Beraletal. showed that
breast cancer risk is greater among users of EP than estrogenonly formulations and if
hormone therapy started at around the time of menopause than later. Among current
usersofEPformulations,therewasastatisticallysignificantlyincreasedbreastcancerrisk


















regardless of other HT use. Point estimates suggested no increased risk of fatal breast




with 10 ormore years of use. The 5year breast cancer riskwith norethindrone acetate
(NETA)(RR2.03,95%CI1.88–2.18)washigherthanforMPA(RR1.64,95%CI1.49–1.70).
Calle et al. (2009) reported similar results, indicating that, particularly for lobular




significant) for estrogenanddydrogesterone.This contrastedwithaRRof 1.69 (95%CI
1.50–1.91) for other synthetic progestagens, similar to the risks reported in other








Cardiovascular disease (CVD) embraces diseases of the heart and blood vessels, and
includes both the arterial and venous systems. Sex steroids influence factors that are
involved in the pathogenesis of atherosclerosis, and hence HT particularly influences
CHD,strokeandvenousthromboembolism(DVT).Cardiovasculardiseaseistheleading




Deepvenous thrombosis (DVT) is an important risk forwomen receivingHT.Estrogen
reducesthefibrinogenconcentrationinplasma,activatesfibrinolysisandthusitincreases
theriskofDVT(Braunsteinetal.2002).Bothobservationalandinterventionalstudieshave
shownsignificant increases inDVTriskamongcurrentHTusers (Santenetal. 2010)on




et al. 2002,Beral&MillionWomenStudyCollaborators 2003,Anderson et al. 2004).As
regardsrouteofadministration,astudybasedoncasecontrolstudies(Scarabinetal.1997)
and a metaanalysis of observational studies (Canonico et al. 2008) revealed that oral
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The resultsofobservational studies concerning the riskof stroke in relation toHThave
been inconsistent in. Some studies have indicated an increased risk of ischemic stroke







period of 5.5 years (maximum 8.4 years) (Prentice et al. 2005). In trials among older
womenwithelevatedstrokeriskduetocoronaryorcerebralvasculardisease,HTdidnot
reducestrokeincidence(Simonetal.2001,Viscolietal.2001).Findingsinotherstudiesare
consistent. Recent metaanalyses showed a 30% increased risk of stroke, identical for
estrogens alone or in combinationwithprogestagen (Bath&Gray 2005,Magliano et al.
2006,Sareetal.2008).IntheNurses’HealthStudy,aprospectiveobservationalstudy,the




 In 2010 Renoux et al. published a populationbased nested casecontrol study with
15710 females with strokematched to 59958 controls aged 50–79 years (Renoux et al.
2010).TheadjustedRRofstrokeassociatedwithcurrentuseoftransdermalHTwas0.95
(95%CI0.75–1.20)relativetonouse.Theriskofstrokewasnotincreasedwithuseoflow
dose estrogen patches (containing 50 g of estrogen) (RR 0.81, 95% CI 0.62–1.05))
comparedwithnouse,whereastheriskwasincreasedwithhighdosepatches(containing
>50gestrogen)(RR1.89,95%CI1.15–3.11).CurrentusersoforalHThadanincreased














dose and duration of use (PaganiniHill & Henderson 1996, Baldereschi et al. 1998).
Clinical trials of HT for Alzheimer’s disease have been small and of relatively short
duration. The results of several small trials suggested benefits as regards a subset of




 In the Women’s Health Initiative Memory Study vascular dementia incidence was
greaterinhormonegroupscomparedwithplacebo(RR2.05,95%CI1.21–3.48forwomen
withauterus,andRR1.49,95%CI0.83–2.66forwomenwithoutauterus)(Shumakeretal.
2003, Shumaker et al. 2004). On the other hand,metaanalyses of observational studies
imply reductions in Alzheimer’s disease risk of about one third (Yaffe et al. 1998,
Hogervorst et al. 2000,Maki&Hogervorst 2003). In ametaanalysis that included two
cohortstudiesand10casecontrolstudies,HTwasassociatedwitha34%reductioninthe
riskofdementia(summaryOR0.66,95%CI0.53–0.82)(LeBlancetal.2001).Accordingto










Coronary heart disease (CHD) remains the largest cause of morbidity and mortality




latest metaanalysis showed that premenopausal and postmenopausal women have a
similar or slightly higher prevalence of angina than men across countries with widely
differing rates of myocardial infarction mortality (Hemingway et al. 2008). The
Framingham Study in 1976 showed that cardiovascular disease rates were lower in
premenopausal than in postmenopausal women (Kannel et al. 1976). Among










gradually lead to the formation of atherosclerotic plaques within the arterial tree,
includingthecoronaryarteries.Coronaryheartdiseaseisamultifactorialdiseaseandthe
most important risk factorsofCHDappear tobeuniversal inbothgenders (Yusufetal.
2004).
 TheriskofdevelopingCHDisincreasednotonlybyhighcirculatingLDLcholesterol
concentrations but also by other risk factors (Kervinen 2010). According to the
INTERHEART study (Yusuf et al. 2004), nine risk factors are responsible for 90% of all
cases of CVD (SchenckGustafsson 2009). These factors are dyslipidemia, hypertension,
smoking, stress/depression, obesity (especially abdominal fat distribution), physical








causal factor in coronary heart disease (C Reactive Protein Coronary Heart Disease
GeneticsCollaboration(CCGC)etal.2011).
 There is growing evidence that inwomen,menopausal hot flushes and night sweats
may have an effect on the cardiovascular risk profile. Gast et al. (2011) reported that
vasomotor symptoms were related to an adverse CVD risk profile. Another study
(Tuomikoski et al. 2010b) showed no differences in the circulating levels of lipids,
lipoproteins,sexhormonebindingglobulin,orhighsensitiveCreactiveproteinbetween







Considerable evidence suggests that endogenous estrogen contributes to delaying the
onsetofatheroscleroticCVDeventsinwomen.Basicsciencestudiesandnumerousanimal


















 Oral estrogen inparticular increasingly inducesa change inLDL toward smaller and
denserparticles(vanderMoorenetal.1994),anditalsoincreasestheirclearancefromthe
circulation,allowinglesstimeforoxidationandacquisitionofcholesterol(Speroff&Fritz
2005).Hence, their shortened time in thecirculationcouldreduce the likelihoodof their
retention in the arterial wall. Transdermal HT does not change LDL particle size
(Stevensonetal.2004),butpossibleeffectsonclearanceratesareunknown.Smalldense
LDL particles may be more susceptible to oxidative damage, leading to foam cell
production and the eventual generation of atheromatous plaques. Estrogen appears to
help to protect LDL against oxidative damage (Sack et al. 1994) and estrogen also
improves the postprandial clearance of potentially atherogenic lipoprotein remnants
(Westerveld et al. 1995),which againwill help in the prevention of atheroma. Estrogen
with or without added progestagens lowers the circulating levels of lipoprotein (a) (a
CHDriskmarker)(Godsland2001),althoughisnotknownwhetherchanginglipoprotein
(a)levelshasanyclinicalimpactonCHDrisk(Stevenson2009a).
 Estrogen increasesHDL cholesterol levels, and particularly theHDL2 subfraction, by
inhibitinghepaticlipaseactivity,whichcovertsHDL2toHDL3(Speroff&Fritz2005)and
by increasingthehepaticsynthesisofapolipoproteinAI, themainproteincomponentof
HDLandHDL2 (Stevenson2009a).Transdermalestradiolappears tohavea lessmarked




 The dose and manner of administration of estrogen determine its effects on
triglycerides, which may be a considerable risk factor for CHD in women (Table 2).
Increasedendogenous triglyceride levelsareassociatedwith lowserumHDLandHDL2
cholesterol levels, insulin resistance and adverse changes in hemostatic parameters.
Conjugatedequineestrogens(CEEs)causeanincreaseintriglycerides(Crooketal.1992),
aneffectwhich ispharmacologicalanddosedependent, resulting fromthehepatic first
pass effect of this steroid.Orally administered estradiol has a slightly smaller effect on
18
raising triglycerides (Godsland 2001). Transdermal estradiol causes a reduction in
triglycerides(Crooketal.1992),whichisaphysiologicaleffectofestrogen.
 Progestagens have differing effects on lipids and lipoproteins, depending on their
androgenicity and perhaps on their overall dosage (Stevenson 2009a). The addition of
progestagenstoestrogentherapyhasnoadverseeffect intermsofchangingserumLDL
concentrations; although they may increase LDL production, they also increase its
clearance.CombinedEPTmayleadtoanincreaseinHDLbutattheexpenseofanincrease
intriglycerides,orleadtoadecreaseintriglyceridesbutattheexpenseofadecrease,orno
increase, in HDL. Which change is more important in terms of CHD benefit remains
unknown(Stevenson2009a).
 
Table 2. Effects of oral and transdermal estrogen replacement therapy on metabolic 
cardiovascular risk factors: () decrease, () minor decrease, () increase, () minor 




Very low-density lipoprotein cholesterol









































the early postmenopausal period gain fat mass and lose lean mass (Aloia et al. 1995).
Hormone therapy togetherwith exercisemay have beneficial effects on skeletalmuscle










it isdosedependent.This effecton coagulationactivationmaybe avoidedbyusing the
transdermal route (Scarabin et al. 2003, Stevenson et al. 2004), or reducedbyusing low
doses of oral estrogen (Collins et al. 2006). Continuous combined transdermal HT
administrationhasbeenreportedtoresultinasignificantdecreaseinfactorVIIc,andno












and thus increasing production of the potent vasodilator NO (Wingrove et al. 1999).
Estrogen reduces release of the potent vasoconstrictor endothelin1 (Wingrove &
Stevenson 1997). Oral ET has been reported to result in a lowering of plasminogen
activator inhibitorI (PAII) and Eselectin in hypercholesterolemic women (Koh et al.
1999).DecreasesincelladhesionmoleculesEselectinandvascularcelladhesionmolecule





There is also evidence that estrogens act independently on the endothelium. Estrogen
causesrelaxationincoronaryarteriesthataredenudedofepithelium(Chesteretal.1995).
This response is not prevented by the presence of inhibitors of NO synthase or
prostaglandin synthase. Thus, this vasodilation is achieved through a mechanism
independent of the vascular endothelium, perhaps acting on calciummediated events
(Collinsetal.1993).Thevasodilationproducedbysodiumnitroprussideisendothelium
independent. Estrogen affects vascular ion channels. Estradiol acts through calcium
dependent mechanisms. Estradiol also inhibits inward calcium currents and reduces
intracellularfreecalciuminisolatedcardiacmyocytes(Jiangetal.1992).Estrogenactivates
BKcachannels tocausecoronaryarteryrelaxation(Whiteetal.1995).However, thereare





Estrogen treatment increases left ventricular diastolic filling and stroke volume
(Voutilainen et al. 1993, Zegura et al. 2003).  It is thought that this effect is probably a
20
direct inotropicactionof estrogen thatdelays theagerelated change in compliance that
impairs cardiac relaxation (Giraud et al. 1996).According to the results of one 3month
study,MPA (5mg daily for 10 days eachmonth) did not attenuate the increase in left
ventricularoutput (systolic flowvelocity)observedwithET (Prelevic&Beljic 1994).On











involved in these processes are the matrix metalloproteinases (MMPs) and their tissue
inhibitors,andtheyhavebeenimplicatedinthedevelopmentofCVD(Dolleryetal.1995).
MMP enzymes are secreted by inflammatory cells and smooth muscle cells. These
enzymesdigest theproteins in the fibrouscapsof atheroscleroticplaques,making them
unstable andpredisposed to rupture (Galis et al. 1994).Estrogen inducesMPPenzymes








Oral estrogens elevate circulating hsCRP concentrations, which is not the case with
transdermalestradiol(Modenaetal.2002,Prelevicetal.2002,Vongpatanasinetal.2003).




 Increased circulating levels of homocysteine are correlated with increased risks of
atherosclerosisandthrombosis.Homocysteinelevelsincreaseaftermenopause(Speroff&
Fritz 2005) and they are significantly lowered by estrogen or estrogenprogestagen
treatment, administered either orally or transdermally (Hak et al. 2001, Chiantera et al.
2003).
 Estrogen has an impact on the reninangiotensinaldosterone system. Although





















cardiovascular events other than myocardial infarction (MI) and CHD, e.g. angina
pectoris,intermittentclaudication,andtransientischemicattack,andadjustmentforHDL
cholesterol, believed at the time to be connectedwith themost plausiblemechanism of
actionofestrogen(Stefanick2010).
 Observational studieson the effect ofHTonCHDhavebeenundertaken extensively
usingbothcasecontrolandcohortdesigns,andtheyhavemainlyshownabenefit.Several
cohort studies revealed a reducedCHD risk inHT users, including the Lipid Research
Clinics Prevalence Study 8½year followup (Bush et al. 1987), a Kaiser Permanente
programcohortof6093womenaged18–54 followed for10–13years (Petitti etal.1987),
and the Leisure World Study of 8841 women aged 40–101, followed for 5½ years









 In 1992, the American College of Physicians (American College of Physicians 1992)
published a position statement proposing that all postmenopausal women should be
offeredHTtopreventCHD.Thisstatementwasbasedontheresultsofametaanalysisby
Gradyetal.(1992)whichrevealedthatpostmenopausalhormoneusewasassociatedwith






predominant regimen) (BarrettConnor & Grady 1998). A similar risk reduction was
observed in the seven identified studies of women who reported treatment with E+P,
usuallycyclicMPA,relativetoneverusers(RR0.66,95%CI0.53–0.84)(BarrettConnor&
Grady1998).
 In three studiesofwomenundergoingangiography, a comparisonof coronaryartery
occlusion in users and nonusers of estrogen indicated a significant protective effect of
postmenopausalestrogen(Gruchowetal.1988,McFarlandetal.1989,Hongetal.1992).
ThereareinvestigatorswhohavereportedthatwomenusingHTatthetimeofmyocardial
infarctionorwithcongestiveheart failurehavean improvedrateof survival (Reisetal.
2000,Shlipaketal.2001)
 Oneof the largest of these studies, theNurses’Health Study (NHS) (Grodstein et al.
2000),with20yearsof followup, revealeda reduction inCHD incidenceof 39%which




due to protection against CHD, an effect that was present after adjusting for dietary
factors,alcoholintake,vitaminDoraspirinuse,andexercise(Grodsteinetal.1997).Inre








 Observational studies have also revealed a 20% to 45% decreased risk of allcause
mortality, consisting largely of reductions in cardiovascular mortality amongHT users
comparedwithnonusers(Hendersonetal.1991,Folsometal.1995,Ettingeretal.1996,
Grodsteinetal.1997,Strametal.2011).Incontrast,theprospectiveDanishNursescohort












These risk reductions greatly diminished, in a roughly linear fashion, with increasing
current age at baseline (for women of 85–94y; HR 0.94, 95% CI 0.81–1.10 for allcause
mortality).Similarresultswereseenforischemicheartdiseasedeaths(n=1464) (Stramet
al.2011).
 These observational studies have been criticized by arguing that ET is a marker of
variables(e.g.betterdietandbetterhealthcare)thatplacepostmenopausalestrogenusers
ina lowriskgroup forCVDand this findinghasbeenreferred toas the“healthyuser”
effect (Posthumaetal.1994,ClinicalSynthesisPanelonHRT1999).HTusers tendtobe
healthier, better educated, more physically active, leaner, and more moderate alcohol
users than otherwomen (Matthews et al. 1996,Rodriguez et al. 2001) andwomenwho
choosetouseHThavebeenreportedtohavebettercardiovascularriskprofilesthannon
users (Matthewsetal. 1996).According to epidemiologistsof theLipidResearchClinics
Study (Bushetal.1987), theLeisureWorldStudy (Hendersonetal.1991),and theNHS




Table 3. Outcomes of some of the largest observational and case-control studies carried out 
after 1997 in which the effects of HT have been assessed.
Population, 
Follow-up
Sourander et al. 1998 n=7 944 Cohort CVD death n=164 CVD: EPT current RR 0.21 (0.08-0.59)
8 years CHD death n=94 CHD: EPT current RR 0.19 (0.05-0.77)
Varas-Lorenzo et. al n= 164 769 Case-control MI n=1242 HT Current OR 0.7 (0.6-0.9)
2000 5 years ET Current OR 0.52 (0.35-0.78)
EPT Current OR 0.79 (0.59-0.1.08)
Swedish Cohort n= 9 236 Cohort MI n=213 ET RR 0.75 (0.56-0.99)
Grodstein et al. 1999 8 years EPT RR 0.69 (0.45-0.90)
Nurses' Health Study n= 70 533 Cohort non-fatal MI HT ever vs. never RR 0.61 (0.52-0.71)
Grodstein et al. 2000 20 years and CHD deaths n=1258 ET RR 0.55 (0.45-0.68)
EPT RR 0.64 (0.49-0.85)
Danish Nurses' Study n= 19 898 Cohort MI n= 108 IHD: ever vs never HR 1.27 (1.00-1.60)
Lokkegaard et al. 2003 5 years and IHD= 351 IHD: HT current HR 1.24 (0.94-1.65)
MI: ever vs never HR 0.95 (0.63-1.44)
MI:  HT current HR 0.97 (0.57-1.65)
WHI observational study n=53 054 Cohort CHD n=158 EPT: current HR 0.87 (0.72-1.05)
Prentice et al. 2005 5 years
The California Teachers n= 71 237 Cohort IHD  death n= 1391 HT: current HR 0.84 (95% CI 0.74-0.95)
Study, Stram  et al. 2010 5-7 years EPT only vs. ET only HR 0.84 (0.66-1.07)
ET and EPT vs ET only HR 0.87 (0.70-1.08)
Study Design Event Results, RR,OR,HR (95%CI)

Abbreviations: CI: confidence interval, CHD: coronary heart disease, ET: estrogenonly therapy, EPT: 
estrogen-progestagen therapy, HR: hazard ratio, IHD: ischemic heart disease, MI: myocardial infarction, 






The Postmenopausal EstrogenProgestin Interventions (PEPI) study was a randomized,
placebocontrolled trial among 875 postmenopausal women aged 45–64 (The Writing
GroupforthePEPITrial1995).ThestudyconcernedtheeffectsofdailyCEEat0.625mg/d,
taken alone orwith three different progestin regimens,MPA, taken daily (2.5mg/d) or
cyclically (10mgfor12daysamonth),orcyclicmicronizedprogesterone(200mgfor12
days a month) on four primary CHD risk endpoints, i.e. fasting HDLcholesterol,
fibrinogen, insulin and systolic blood pressure, over a threeyear period for each
participant, including women prior to hysterectomy and women with a uterus. The
womenwere randomized to five arms, includingCEEonly (TheWritingGroup for the
PEPI Trial 1995). Comparedwith placebo, CEE,with orwithout a progestin, increased
fasting HDLcholesterol and prevented fibrinogen from increasing over three years.
However, CEE alone was more effective in raising HDLcholesterol than CEE plus
progestin,particularlydailyorcyclicMPA(TheWritingGroupfor thePEPITrial1995).
There were no effects on systolic blood pressure or insulin, whereas all four hormone
regimens loweredLDLcholesterol, but also raised triglycerides (TheWritingGroup for




n=72)orwhowere regardedasasymptomatic (noor3mildhot flushes/day,n=78)
were studied at baseline and randomized to receive either transdermal estradiol (1
mg/day), oral estradiol (2mg/day) with or without MPA (5mg/day) or placebo for 6
months.Vascularhealthbeforeandafter the6month treatmentperiodwasassessedby
usinganumberofreliablevascularfunctionmarkers(Tuomikoskietal.2011).Theresults
of their study showed that the use of oral estradiol alone was accompanied by a
vasoconstrictiveresponseinwomenwithtolerablehotflushes,whereasnosucheffectwas
detected in women with intolerable hot flushes or with the other treatment regimens
(Tuomikoskietal. 2009a).Womenwith tolerablehot flushes responded tooral estradiol
withelevationsinboth24houranddaytimesystolicanddiastolicBP.Incontrast,useof
transdermal estradiol resulted in decreases in 24h and daytime BPs. In women with
intolerable hot flushes, decreases in BP were seen in connection with all treatment
regimens(Tuomikoskietal.2010a).Theresponsesofcirculatingconcentrationsof lipids,
lipoproteins, SHBG and hsCRP to oral and transdermal estradiol, the former with or











increasedriskofcoronaryevents (RR0.99,95%CI0.80–1.22)or totalmortality (RR1.08,
95%CI0.84–1.38).Therewas,however,asignificant trendover timeformorecoronary
eventsinHTusersduringthefirstyearsofuse(relativehazardyearI:1.52;yearII:1.00;
year III: 0.87; year IV: 0.67, p=0.009 for trend) (Hulley et al. 1998). Followup after
approximately6.8years showed that the lower ratesof coronaryeventsassociatedwith
prolongedHTusedidnotpersist(RR0.99,95%CI0.84–1.17)(Gradyetal.2002)(Table4a).
 RecentHERStrialdatarevealedthatamong16%ofwomenwithin thecohortof2448








alone or combined with 2.5 mgMPA/d (over 3.5 years of treatment), on angiographic
progression of disease in 309 women with angiographically verified coronary disease
(mean age 65.8 years; range 41.8–79.9). Half had had a previous MI. There were no
reported increases in cardiac events in any of the 3 treatment groups (Herrington et al.
2000).
 Another secondary prevention trial, the 3year Women’s Estrogenprogestin Lipid
LoweringHormoneAtherosclerosis Regression Trial (WELLHART),was carried out to
assesswhetherornotunopposedestradiolorasequentialregimenofestradiolandMPA
compared with placebo could slow the progression of atherosclerosis in 226
postmenopausal women (average age of 63.5, range 48–75) who had at least one
demonstratedcoronaryarterylesion(Hodisetal.2003).Theresultswerebasedonfollow
upangiograms.A reductionofLDLcholesterol to less than130mg/dlwas achievedby
dietaryintervention,butcoronaryangiographytomeasurechangesfrombaselinefailedto
demonstrateadifferencebetween the three treatmentgroups.The results indicated that










Table 4a. Main secondary prevention trials concerning HT.
Population, 
Follow-up
HERS I & II n=2 763 + CHD 0.625mg CEE + Nonfatal MI:overall: RR 0.99 (0.81-1.22)
Hulley et al. 1998 4.1-6.8 years 2.5mg MPA CHD death:overall: RR 1.20 (0.85-1.69)
Grady et al. 2002 CHD:overall: RR 0.99 (0.84-1.17)
Sudden death:overall: RR 0.98 (0.70-1.37)
ESPRIT n=1 017 + previous MI oral estradiol 2mg Transient ischaemic attack: RR1.13 (0.54-2.36)
Cherry et al. 2002 2 years Cardiac death: RR 0.68 (0.39-1.19)
PHASE n=225+ angiographically Transdermal estradiol Unstable angina, proven MI or cardiac death:
Clarke et al. 2002 proven CHD, 30.8 months 2mg±4mg cyclic NETA Rate-ratio: 1.49 (0.93-2.36)
WAVE n=423+CHD 0.625mg CEE+2.5mg MPA Death:HR 1.8 (0.75-4.3)
Waters et al. 2002 2.8 years and/or vitamin C or E Death, nonfatal MI or stroke: HR 1.9 (0.97-3.6)
Study Treatment Event, Results RR,HR (95% CI)
 
Abbreviations: MI: myocardial infarction, CHD: coronary heart disease, CI: confidence interval, CEE: 
conjugated equine estrogen, HR: hazard ratio, MPA: medroxyprogesterone acetate, NETA: norethindrone 
acetate, ±: with or without, +: with, OR: odds ratio, RR: risk ratio 
 
ESPRIT: Estrogen in the Prevention of Reinfarction Trial (Cherry et al. 2002), HERS I: Heart and 
Estrogen/progestin Study (Hulley et al. 1998), HERS II: Heart and Estrogen/progestin Study (Grady et al. 
2002), PHASE: Papworth HRT Atherosclerosis Study (Clarke et al. 2002), WAVE: Women’s Angiographic 




primary prevention trial of CHD, breast and colorectal cancer and fractures in healthy,
postmenopausalwomenbetweentheagesof50–79.Thetrialwasplannedtocontinuefor
8.5 years, but it was prematurely stopped at 5.2 years because of an increased risk of
invasivebreast cancer (7extracases/10000personyears),and the risksofCHD(7extra
cases/10 000 personyears) and stroke (8 extra cases/10 000 personyears) were also
elevated(Rossouwetal.2002).






results concerning of the E + P arm, based on centrally adjudicated outcomes over an
average of 5.6 years of followup, revealing a hazard ratio for CHD of 1.24 (95% CI
1.001.54),ofborderlinesignificance(Mansonetal.2003).Theelevationinriskwasmost
apparentandsignificantinthefirstyear(HR1.81,95%CI1.093.01)(Mansonetal.2003).




 The hazard ratio for stroke in similarly updated analyses (i.e. centrally adjudicated,
more cases), over ameanperiodof 5.6years of followup,was 1.31 (95%CI 1.021.68),
withaslightlyhigherHRforischemicstroke,1.44(95%CI1.091.90)(WassertheilSmoller




After theWHI E+P trial was stopped, the participants were followed up through the
planned termination of the trial toMarch 31, 2005.Except for stopping the intervention
and unmasking the study participants to their treatment assignment, the same trial
protocol was followed to identify and classify study outcomes. Postintervention data
wereavailableon95%ofallparticipantswhowerealiveatthetimeofstoppingthetrial,
withameanof2.4yearsoffollowup(Heissetal.2008).TheincreasedCHDriskobserved
early in the intervention period disappeared in the postintervention period, as did the








6.8 years of followup, revealing an increased risk of stroke and no evidence of CHD
benefitorharm(Andersonetal.2004).Thepreliminaryreport,publishedatthetimethe




(p=0.07) (Hsia et al. 2006). Special attentionwas paid to analyseswithin the subset of
womenaged50–59years,which showedanHRof 0.55 (95%CI 0.35–0.86) for coronary
revascularization, and reduced HRs for several composite outcomes (Hsia et al. 2006),
withthesuggestionofapossibleestrogenbenefit inwomenwhoinitiatedCEEcloser to
menopause. 
 The results ofpooled cohort analyses suggested thatwomenwho startHTwithin 10









Table 4b. WHI primary prevention studies on HT.
Population, 
Follow-up
WHI-EPT n= 16 608 CEE 0.625mg+2.5mg MPA Nonfatal MI and CHD death: RR 1.24 (1.00-1.54)
Manson et al. 2003 5.2 years Year of follow-up: 1st year RR 1.81 (1.09-3.01);
2nd year RR 1.34 (0.82-2.18)
WHI-ET n=10 739 hystrectomized CEE 0.625mg CHD: RR 0.91 (0.75-1.12)
Andersson et al. 2004 6.8 years CHD death: RR 0.94 (0.65-1.36)
Nonfatal MI: RR 0.89 ( 0.63-1.26)
Secondary analysis of WHI n=27 347 CEE 0.625mg±2.5mg MPA CHD:  time since menopause 
Rossouw et al. 2008 5 years <10 years;HR 0.76 (0.50-1.16)
10-19 years; HR 1.10 (0.84-1.45)
>20 years; HR 1.28 (1.03-1.58)
Study Treatment Event, Results RR,HR (95% CI)
Abbreviations: MI: myocardial infarction, CHD: coronary heart disease, CI: confidence interval, CEE: 
conjugated equine estrogen, HR: hazard ratio, MPA: medroxyprogesterone acetate, OR: odds ratio, RR: 
risk ratio 
 
 These results of primary prevention studies support the hypothesis that timing of
initiation can influence the effects of HT, with either beneficial or neutral effects in
younger, more recently menopausal women or harmful effects in older women with
longertimeelapsedsincemenopause.
 
2.7 HORMONE THERAPY AND DIABETES MELLITUS  
 
“Diabetes”coversagroupofmetabolicdiseasescharacterizedbyhyperglycemiaresulting
fromdefects in insulin secretion, insulin action, orboth.Most casesofdiabetes fall into
two categories: type 1 (T1DM) and type 2 (T2DM)diabetesmellitus. In type 1 diabetes
mellitus, thecause is inanabsolutedeficiencyof insulinsecretion fromthepancreas. In
type2diabetesmellitus,themostcommonformofdiabetes,thecauseisacombinationof




(OGTT;plasmaglucose 	 11.0mmol/L) (Table 5). Patientswith slightly elevated fasting
glucoselevelsarenowconsideredaseparateriskgroup.Impairedglucosetolerancerefers
tonormalorslightlyincreased(<7mmol/L)fastingvalueswithanelevatedOGTT2hour
value (plasma glucose 	 7.8 and <11.1mmol/L). TheseWHO criteria forDMdiagnosis
(WorldHealthOrganization2006)are the same inFinland (TheFinnishMedicalSociety
DuodecimandtheMedicalAdvisoryBoardoftheFinnishDiabetesSociety2009).
29
Table 5. Diagnostic threshold values of glucose concentrations (mmol/L) during fasting and 2 
hours after a glucose tolerance test with 75 g of glucose. (World Health Organization 2006, 






Impaired fasting glucose (IFG) Fasting value 6.16.9
and
2-hour value < 7.8
Impaired glucose tolerance (IGT) Fasting value < 7.0 
and
2-hour value 7.8 and <11.1
Diabetes mellitus Fasting value  7.0
or
2-hour value  11.1 

2.7.1Epidemiology
Diabetes mellitus is one of the most common chronic diseases in the world. Type 2
diabetesmellitusisincreasinglybeingrecognizedasacriticalhealthproblem,especiallyin
middleaged and elderly people (Mokdad et al. 2003). The increased prevalence of





Federation, accessed2008).TheWHOreports that 90%of these casesareT2DM(World
Health Organization, accessed 2009). Most people with diabetes live in the developing






(SjöbergTuominen& Tiitinen 2009). Earlier itwas suggested that age atmenopause in











the prevalence of previously diagnosed T2DM was 7.4% in men and 4.3% in women
(Peltonenetal.2006).ThetotalprevalenceofT2DM,includingbothpreviouslydiagnosed
andscreendetecteddiabeticswas15.7%inmenand11.2%inwomen.Theprevalenceof




Not all diabetics use medication, or they do not yet have the right to receive





activity. It is more common in individuals with a family history of the disease and in
membersofcertainracial/ethnicgroups,particularlyHispanicsandblackgroups.Itoccurs
morefrequently inwomenwithpriorgestationaldiabetesorpolycysticovarysyndrome






significantly aftermenopause in diabetic women (Wedisinghe & Perera 2009). Ameta
analysisbySalpeteretal. (2006b)showedreduced insulinresistanceandfastingglucose
levelsinHTtreateddiabeticwomen.Asmallrandomizedcontrolledtrialwascarriedout
to test the effects of lowdose continuous combined therapy (17estradiol, 1mg and
norethisterone,0.5mgdaily)onglucosehomeostasisinwomenwithT2DM(Kernohanet
al. 2007). Conventional HT with an androgenic progestin induced adverse effects on
glucoseclearance,triglyceridesandhighsensitiveCreactiveprotein.Incontrast,withthis
lowdose combination, HT appeared to decrease fasting glucose and total cholesterol
levelswithoutanyotherdetectableadverseeffects.TheconclusionwasthatthisHTmodel
reduces fasting glucose but not glucose clearance (Kernohan et al. 2007). Similarly, in
another small study (20 diabetic hypertensive patients and 21 wellcontrolled glucose
tolerant, hypertensive postmenopausal women), estradiol (0.05 mg/day) and cyclical
NETA(0.25mg/day)wereadministeredtransdermallytoT2DMpatients,andsignificant
decreasesinfastingglucosewereobserved(Fenkcietal.2003).





 In 2002 it was found that HT had a beneficial effect on vascular relaxation in
postmenopausalwomenwithT2DM(Pereraetal.2002).Ontheotherhand,anotherstudy





eithermakes no difference or does not confer any cardiovascular protection in diabetic
women(Haywardetal.2001,Scottetal.2004).
 DataontheeffectsofHTonCHDareconflictinganditseemsthatthemajorfactoris








T2DM (Cignarella et al. 2010). Thus, estrogen deficiency resulting from menopause,
through contributing to the development of abdominal obesity and insulin resistance,
couldrepresentamajorstep in theprocessofdiabetogenesis inwomen(Lhermiteetal.





increase in body fat, especially central (android) body fat (Poehlman et al. 1993,
Tremollieresetal.1996).Estrogentherapymayattenuatetheaccumulationofcentralfatin
postmenopausal women (Gambacciani et al. 1997, Davis et al. 2000, Gambacciani et al.
2001, Sorensen et al. 2001). Hormone therapy can have favorable effects on body fat
distribution and could reduce DM risk via this mechanism (Godsland 2005). In The
PostmenopausalEstrogenProgestin Interventions trial (PEPI) (Espelandet al. 1997), less
weightgainand/orslighter increases inwaistandhipcircumferenceswereregistered in
womenreceivedE+Ptherapycomparedwithplacebo.Similarly,inaDanishosteoporosis
prevention study (Jensen et al. 2003),HT use seemed to have aweightreducing effect.
This would inhibit the interaction between abdominal adiposity, hormones, insulin
resistance,hyperinsulinemia,bloodpressure,andanatherogeniclipidprofile.According
to the results of ametaanalysis of 107 trials, HT reduces insulin resistance, newonset
diabetes,lipids,abdominalobesity,bloodpressure,adhesionmoleculesandprocoagulant








Dahlman et al. 2008) have been identified. Physiological concentrations of estrogen, as




association of elevated concentrations of estrogen in the serum in states of insulin
resistance such as obesity. In obesity, expansion of adipose tissue is associated with
inflammation, leading to insulin resistance and increased synthesis of estrogen in these
tissues (Cignarella et al. 2010).High concentrations of estradiol inhibit insulinmediated
glucose transport in cultured adipocytes, whereas low concentrations increase glucose
uptake (Muraki et al. 2006). Physiological concentrations of estrogen therefore improve






are present in pancreatic cells (SutterDub 2002), and estrogen increases the release of
insulinincellculturemodels(Nadaletal.2004).Although17estradiolactsoncells
and interfereswith insulin releasemainly throughER












In healthy postmenopausal women, HT with CEE does not substantially alter glucose
tolerance; likewise oral or transdermal estradiol. Estradiol given either orally,




worsens insulin sensitivity (Wedisinghe & Perera 2009). Nonoral administration of
estrogentherapyhaslittleeffectoninsulinmetabolism.Thissuggeststhatthehepaticfirst
pass effect is important in this response, at least inhealthywomen.Reports concerning
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transdermal HT have indicated improvements in cases of insulin resistance and
hyperinsulinemia,butnoeffectinwomenwithnormalinsulinsensitivity(Cucinellietal.
1999,Duncanetal.1999).
 The mode of administration and type of progestin has a particular role in the
modificationofinsulin/glucosemetabolism.Progestinswithandrogenicpropertiestendto
increase insulin resistance. Administration of medroxyprogesterone acetate, and,
similarly, levonorgestrel, results in a deterioration of insulin resistance (Lhermite et al.
2008). Norethisterone has a neutral effect (Luotola et al. 1986). Dydrogesterone in
combination with estradiol can potentially reverse menopauseassociated changes in
insulin secretion and elimination (Godsland et al. 2004), and sensitivity (Dansuk et al.
2005).Thus,glucoseandinsulinmetabolismcanbeimprovedbyETbuttheadditionofan





nonusers (Kanaya et al. 2003). The results of a metaanalysis by Salpeter et al. (2006b)
suggestedthatHTreducestheincidenceofDM,irrespectiveofthehormonecombination





The largest observational cohort study (de LauzonGuillain et al. 2009) involved 63624
postmenopausal Frenchwomen and 10.4 years of followup.A total of 1220 newonset






as regards theprogestagensused in combinedHT (deLauzonGuillain et al. 2009).The




 In the Rancho Bernardo Health and Chronic Diseases Study (Gabal et al. 1997), 848
postmenopausalwomenaged50 through70yearswere followed foranaverageof 11.5
yearsandtherewere105newcasesofDM.Theageadjustedrelativeriskofdevelopment
ofDMwasnonsignificantlylowerforwomenwithcontinuousETusethanforneverusers
(ageadjusted RR 0.83, 95% CI 0.43–1.63)). After adjustment for major covariates, a
nonsignificant linear trendwith increasingduration ofETwas reversed (age andBMI
adjustedRR1.12,95%CI0.56–1.37forcurrentHTusers)(Gabaletal.1997).In2004Rossi
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et al. published the results of an observational studywhich involved 673 healthy, non
obesepostmenopausalwomen(meanage54±5years)duringameanfollowupperiodof
3.7±0.7years(Rossietal.2004).Inthehormonenonusersgroup,T2DMdevelopedin10%
(54 of 529women; equivalent to 26.5 cases/1000womenyears), and in the transdermal
users group, T2DMdeveloped in 4.16% (6 of 144women; equivalent to 12.1 cases/1000
womenyears).Useoftransdermal17estradiolforETwasassociatedwithasignificantly
reduced risk of developing T2DM (RR 2.19, 95% CI 1.79–3.56, p=0.006 for hormone
nonuserscomparedwithhormoneusers)(Rossietal.2004).
 A small observational 4year followup study, the Strong Heart Study (Zhang et al.
2002), concerned 857 postmenopausal American Indian women (3428 personyears of
followup).Postmenopausal estrogenusewasassociatedwith lower fastingglucose (0.2
mmol/L lower) but higher OGTT 2hour glucose levels (0.4 mmol/L higher) compared
withneverusers.The riskof type2DMwasstatisticallynonsignificant for currentHT
users(unadjustedOR0.66,95%CI0.391.12andadjustedOR1.11,95%CI0.621.97)when
using the DM criteria of fasting or OGTT 2hour glucose levels. The investigators also
foundthatincreasingdurationofestrogenusewasassociatedwithasignificantincreasein
the risk ofT2DM in currentuserswhenusing the criteria of fastingglucose andOGTT
2hourglucoselevels(OR1.10,95%CI1.011.18)(Zhangetal.2002).
 Hammondetal.(1979a)publishedtheresultsofaretrospectiveobservationalfollowup
study of hypoestrogenic women in a US hospital clinic. The study concerned of 610





TheWomen’sHealth Initiativeprovides themost recentdata froma large randomized,
doubleblindcontrolledtrial involvingcomparisonoftheeffectofdailyCEEs(0.625mg)
plus2.5mgMPAwiththatofplaceboduring5.6yearsoffollowup(Margolisetal.2004)




representeda21%relative reduction in the riskofDM(HR0.79,95%CI0.67–0.93).The
effectwas independentof the slight reduction inBMIandwaist circumferencenoted in
theHTgroup.TheprotectiveeffectofHTonDMriskwas lessapparentamongwomen
withsmallerwaistcircumferences,suggestingthatabdominallyobesewomenmaybenefit
more fromHTuse, or that baselinemetabolic statusmay influence the response toHT
(Margolisetal.2004).Amongwomenwhoused0.625mgCEEwithoutaprogestagen(10




0.072) (Bonds et al. 2006). These Women’s Health Initiative trials further showed a
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significant fall in insulin resistanceduring the first year of followup inwomen treated
withcombinedHTorestrogenalone(Margolisetal.2004,Bondsetal.2006).
 InTheHeartandEstrogen/progestinReplacementStudy(HERS) (Kanayaetal.2003),
2029 nondiabetic postmenopausalwomenwith coronary diseasewere followed for 4.1
yearsinconnectionwithincidentDM.Thewomenwererandomizedto0.625mgCEEplus
2.5mgofMPAdaily,orplacebo.Fastingglucoselevelsweremeasuredatbaseline,atyear
1, and at the end of the trial. Incident diabeteswasdefined by selfreporting ofDMor
disease complication, a fasting glucose level of 6.9mmol/L or greater (	126mg/dL), or
initiation of therapy with DM medication.  A slight but significant reduction in the
incidenceofT2DMincombinedHTuserswasreported.Fastingglucoselevelsincreased
significantly among women assigned to placebo but did not change among women
receivingHT.The incidenceofDMwas 6.2% in theHTgroup and9.5% in theplacebo
group(HR0.65,95%CI0.48–0.89,p=0.006)(Kanayaetal.2003).
 Taken together, thedata indicates that estrogenwith orwithoutprogestagenmaybe
associatedwithaslightdecreaseintheriskofT2DM,independentofitseffectsonBMI.

Table 6. Outcomes of some prospective studies carried out after 1991 in which the effects of 
HT have been assessed. (ModifiedfromGodsland2005,deLauzonGuillainetal.2009)

Study Population Results RR (95% CI)
follow-up
Manson et.al 1992 Observational 12-year follow-up Any HT: current users' RR 0.80 (0.67-0.96) (age- and BMI-adjusted)
Nurses' Health Study n = 21 028
Gabal et. Al 1997 Observational 11.5 year follow-up HT: current users' RR 0.83 (0.43-1.63) (age-adjusted),
Rancho Bernando Health n = 848 RR 1.12 (0.56-1.37) (age- and BMI-adjusted)
and Chronic Diseases study
Zhang et al. 2002 Observational 4-year follow-up Any HT: current users' RR 0.66 (0.39-1.12) (unadjusted),
Strong Heart Study n = 857 RR 1.11 (0.62-1.97) (adjusted)
Kanaya et al. 2003 Randomised placebo-controlled trial of HT EPT: 0.625 mg/day CEE + 2.5 mg/day MPA: current users' RR 0.65 (0.48-0.89)
Heart Estrogen Replacement in secondary prevention of CVD,with 5.7 years'
Study follow-up, n = 2029 (non-diabetic with CHD)
Margolis et al. 2004 Randomised placebo-controlled trial of HT EPT: 0.625 mg/day CEE + 2.5 mg/day MPA: current users' RR 0.79 (0.67-0.94)
WHI Study in primary prevention of CVD, with 5.2 years'
follow-up, n= 15 641 (with intact uterus)
Rossi et al. 2004 Observational mean 3.7 years' follow-up ET: never vs. transdermal 17-estradiol: never users' RR 2.19 (1.79-3.56)
n = 673 (healthy, non-obese) compared with transdermal users
de Lauzon-Guillain et al. 2009 Observational (mean duration 10.3 years) Any HT: Never vs. ever, RR 0.82 (0.72-0.93)
E2N Cohort n= 63 624 Oral HT: RR 0.68 (0.55-0.85)
Trasdermal HT: RR 0.87 (0.75-1.00)
Other route HT: RR 0.81 (0.59-1.11)

Abbreviations: HT: hormone therapy, BMI: body mass index, CI: confidence interval, CEE: conjugated 
equine estrogens, HR: hazard ratio, MPA: medroxyprogesterone acetate, OR: odds ratio, RR: risk ratio
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or poor absorption is one of several important causes of reduced bone mass and
osteoporosis(Cashman2002).Calciumsupplementationiswidelyusedforpreventionof
osteoporosis in postmenopausal women and men. Calcium supplements marginally
reduce the risk of fracture (BischoffFerrari et al. 2007, Tang et al. 2007) and most
guidelines recommend adequate calcium intake as an integral part of the prevention or




osteoporosis (Tang et al. 2007). It has also been suggested that there are other benefits
connected with the use of calcium supplements, including effects on blood pressure
(Bucher et al. 1996, Griffith et al. 1999),  body weight (Reid et al. 2005), colon cancer
(Chungetal.2009),andcardiovasculardisease(BargerLux&Heaney1994).Ontheother









intestine. Active transport of calcium into enterocytes and out on the serosal side is
dependent on the action of 1,25dihydroxyvitamin D (1,25(OH)2D), the active form of
vitamin D, and its intestinal receptors. This mechanism accounts for most of the
absorption of calcium at low and moderate intake levels (Standing Committee on the
ScientificEvaluationofDietaryReferenceIntakes,FoodandNutritionBoard,Instituteof
Medicine1997).Fractionalcalciumabsorptionvariesthroughoutlife;itishighest(about60





 Calcium is eliminated through feces, urine and sweat. Renal calcium excretion is a
function of the filtered load and the efficiency of reabsorption; the latter is regulated
primarily by levels of parathyroid hormone. With aging, the urinary loss of calcium










vitaminD3 (cholecalciferol) (StandingCommittee on the ScientificEvaluationofDietary
ReferenceIntakes,FoodandNutritionBoard,InstituteofMedicine1997).BothvitaminD2
andD3areavailable in thedietbutonlyvitaminD3 isproduced in the skin.VitaminD
withoutasubscriptrepresentseitherD2orD3orbothandisbiologically inert,requiring
two obligate hydroxylations to form its biologically active hormone, 1,25
dihydroxyvitaminD(1,25(OH)2D)(calcitriol)(DeLuca1988).Renalmetabolismofcalcitriol




 VitaminDisprincipallyexcretedinthebile.Althoughsomeof it isreabsorbedinthe
small intestine (Nagubandietal. 1980), theenterohepatic circulationofvitaminD isnot








Dietary reference intakes, developed in 1997, recommended calcium intakes of 1000 to
1500mg/dinhealthyindividuals,dependingonage(StandingCommitteeontheScientific
EvaluationofDietaryReferenceIntakes,FoodandNutritionBoard,InstituteofMedicine




Nutrition Recommendations and Nordic Nutrition Recommendations 2005, Valtion
ravitsemusneuvottelukunta 2010, Valtion ravitsemusneuvottelukunnan tiedote 10.1.2011
2011).
 Numerous calcium preparations are available on themarket and they differ only in
regardtotheirbioavailability.Thesedifferenceshavelittleclinicalsignificanceexceptfor
patientswith achlorhydria and elderlypersonswith lowgastric secretion (Nowak et al.










Food and Nutrition Board, Institute of Medicine 1997). Different calcium supplements





Supplemental vitamin D preparations contain ergocalciferol and cholecalciferol.
Cholecalciferol and ergocalciferol are converted in the liver to calcifediol, which is
converted in the kidney to calcitriol (1,25dihydroxyvitamin D), the major circulating
metabolitethatisactiveinstimulatingtheabsorptionofcalciumandphosphatefromthe
gastrointestinal tract. The circulating level of 1,25dihydroxyvitamin D is regulated by
calcium, phosphate and parathyroid hormone (Speroff & Fritz 2005). The use of
1,25(OH)2Danditsanalogsinchronickidneydiseaseandbonemineraldisordersiswell
established in the management of secondary hyperparathyroidism and osteomalacia.
Recently,therehasbeenincreasinginterestinmaintainingserum25(OH)vitaminDlevels
abovetheinsufficiencyrange(10to30ng/mL)toprevent lossofboneinhealthyelderly
populations (Peacock 2010). Patients with chronic kidney disease and bone mineral
disordersarelikelytobeinthevitaminDdeficiencyrangefromlackofsunlightandpoor
dietary vitamin D intake. For this reason, there has been great interest among




persons with insufficient serum 25hydroxyvitamin D levels does not improve insulin
sensitivity or secretion or the serum lipid profile. The association between vitamin D
statusandCVDisuncertain,butlowvitaminDlevelsmayrepresentanindependentand
modifiable cardiovascular risk factor (Temmerman 2011). The results of ametaanalysis





Table 7. Recommended intakes of calcium and vitamin D per day in Finland
(Based on Finnish Nutrition Recommendations 2011 (Finnish Nutrition Recommendations and 
Nordic Nutrition Recommendations 2005, Valtion ravitsemusneuvottelukunta 2010, Valtion 
ravitsemusneuvottelukunnan tiedote 10.1.2011))  

Age years  Calcium (mg/day) Vitamin D (g/day) 
 
011 months  540  10 
 
12  600  10 
 
25  600  7.5 
 
69  700  7.5 
 
1017  900  7.5 
 
1860  800*  7.5 
 
Over 60  800  1020 
 
Pregnant  900  10 
 
Lactating  900  10_______________ 
 
*1820 olds are recommended 900 mg calcium and 700 mg phosphorus per day  

2.8.3Benefitsandrisksofcalcium
Despite the smallbut clearbenefits of calciumandvitaminD supplementationonbone





Bones increase in size andmassduring childhoodandadolescence, reachingpeakbone
mass around the age of 30. The greater the peak bonemass, the longer one can delay
serious bone loss with increasing age. Everyone should therefore consume adequate
amounts of calcium and vitamin D throughout childhood, adolescence, and early
adulthood(Speroff&Fritz2005).
 Calcium absorption decreases with age because of a decrease in biologically active
vitaminD,anditbecomessignificantlyimpairedaftermenopause.Apositivebalanceof
calcium is mandatory to achieve adequate prevention against osteoporosis. Calcium
supplementation (1000 mg per day) reduces bone loss and decreases the incidence of











There is inconsistent but generally favorable evidence to suggest that higher intakes of






 The effects of calcium on blood pressure might depend upon the population being
studied. In hypertensive subjects, calcium supplementation appears to lower systolic
bloodpressureby2–4mmHg,whereasinnormotensivesubjects,calciumappearstohave
nosignificanteffectonsystolicordiastolicbloodpressure(Chungetal.2009).
 The results of some observational and experimental studies suggest that individuals
whoeatavegetariandiethighinminerals(suchascalcium,magnesium,andpotassium)
andfiberandlowinfattendtohavelowerbloodpressure(Rouseetal.1983,Margettset









less weight gain over time (Davies et al. 2000, Zemel 2002, Heaney 2003, Parikh &
Yanovski 2003). Two different explanations have been proposed. First, high calcium
intakesmight reducecalciumconcentrations in fat cellsbydecreasing theproductionof
twohormones (parathyroidhormoneandanactive formofvitaminD) that increase fat
breakdown in these cells and discourage fat accumulation (Parikh & Yanovski 2003).
Secondly,calciumfromfoodorsupplementsmightbindtosmallamountsofdietaryfatin
thedigestivetractandpreventitsabsorption(Parikh&Yanovski2003,Christensenetal.
2009). Dairy products, in particular,might contain additional components that have an
even greater effect on body weight than their calcium content alone would suggest
(Heaneyetal.2002,Zemeletal.2005a,Zemeletal.2005b).
 The results from clinical trials have been largely negative. In a metaanalysis of 13
randomizedcontrolled trials itwasconcluded thatneither calciumsupplementationnor
increased dairy product consumption has a statistically significant effect on weight
reduction (Trowman et al. 2006). A more recent clinical trial showed dietary
supplementation with 1500mg of calcium/day (from calcium carbonate) for 2 years to
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maintain body calcium levels, binds bile acids in the gut and increases their excretion
(Renaud et al. 1983, Newmark et al. 1984). Bile acidbinding resins, such as
cholestyramine,lowerbloodlevelsofcholesterolbyjustsuchamechanism,andtheiruse
hasbeen found to reduce the riskof ischemicheartdisease (TheLipidResearchClinics
CoronaryPrimaryPreventionTrialresults.I.1984).
 According to the results of animal and human observational studies, a high level of







and cardiovascular mortality is lower in hardwater areas (Marque et al. 2003), and in
personswithhighcalciumintakes(Bosticketal.1999,Nessetal.2001,Elwoodetal.2004).
Thus,takingthesefavorablefindingstogether,itispossiblethatcalciumusemightimpact
favorably on cardiovascular disease. On the other hand, calcium is present in





mmol/L to 1.30mmol/L following supplementationwith 1 g of calcium (in the 4 hours
following) (Reid et al. 1986), thereby possibly accelerating calcification in the vascular
wall.Vascularcalcificationispredictiveofvasculareventrates(Pletcheretal.2004).Ina
communitybasedstudyofoldermenandwomen,itwasfoundthatcarotidarteryplaque
thickness increased by onethird in subjects in the highest quintile of serum calcium
concentrations,incomparisonwiththoseinthelowestquintile(Rubinetal.2007).Reidet
al. reported (asyetunpublished results) in their review that theyhavequantifiedaortic
calcificationinDXAimagesfromwomenintheAucklandCalciumStudy,andfoundthat
foreachincreaseintotalserumcalciumof0.1mmol/L,theoddsratioforthepresenceof







similarly foundtopredictmyocardial infarction(Lindetal.1997). In theAtherosclerosis
Risk in Communities Study of 15732 men and women followed over 13 years, the
adjustedserumcalciumlevelatbaselinewassignificantlyrelatedtotheriskofmyocardial
infarction, stroke and death (Foley et al. 2008). Leifsson and Ahren (1996) assessed
mortality ofmen under 50 years in relation to their serum calcium concentrations, in a
populationbasedstudyof21131Swedishmenundertheageof50.Thedeathrateamong
thosewith serum calcium levels between 2.45 and 2.5mmol/Lwas 1.3 (95%CI 1.1–1.4)
timeshigherthanthatinmenwithbaselinecalciumlevelsbetween2.3and2.45mmol/L,
the odds ratio of death being 1.5 (95%CI 1.3–1.8). The excessmortality appeared to be
predominantlycardiovascularinnature(Leifsson&Ahren1996).
 Rasouli and Kiasari (2006) investigated the associations between serum calcium and
phosphorus concentrations and other cardiovascular risk factors in relation to the
existence and severity of CHD in 260 clinically stable, angiographically defined CHD
patientsaged40–70years.Theresultsdemonstratedthatserumcalciumandphosphorus
were associatedwith the prevalence and severity of CHD,whichmay bemediated via
atherogenic lipids and (apo)lipoproteins. Their study showed that serum calcium and
phosphorusandtheirionproductswerealsoindependentriskfactorsofCHD(Rasouli&





In 1986, Reid et al. reported that all individualswho had ingested two soluble calcium
preparations had ionized calcium concentrations above the upper end of the laboratory
reference range at 3 hours (Reid et al. 1986). The changes in serum calcium following
ingestionofacalciumsupplementweregreaterthantheserumcalciumdifferenceswhich
have been shown in observational studies to be associated with vascular pathology,
cardiovascularevents,andcardiovascularmortality.
 The above findings are inmarked contrast to the effects of dairy products on serum
calcium.According toGreenetal., ingestionof fortifiedskimmilk (1200mgofcalcium)
resulted in increases in totalserumcalciumofonly0.03mmol/Lat3hours (Greenetal.
2003),incontrasttothechangesinionizedcalciummentionedabove(Reidetal.1986).It
has also been reported that skim milk fortified with calcium carbonate causes larger
increasesinserumcalciumthandoesskimmilkfortifiedwith“milkcalcium”(Reidetal.





Hemodialysis patients are at increased risk of progressive coronary artery calcification.
However, the development and progression of this disease process in hemodialysis
patients is unknown (Block et al. 2005). Calcium supplements accelerate vascular
calcification and increase mortality in patients with renal failure, in both dialysis and
predialysispopulations (Goodmanet al. 2000,Blocket al. 2007,Russoet al. 2007).High
calcium intakes have also been associated with brain lesions (in magnetic resonance
imaginingscans)(Payneetal.2007),aorticandcoronaryarterycalcification(Chertowetal.
2002,Asmusetal.2005,Blocketal.2005),andmortality(Stevensetal.2004,Blocketal.
2007).Thus, there isagrowingawareness thatcalcium intake,vascularcalcificationand
mortalityarelinkedinpatientswithrenalfailure(Goldsmithetal.2004).

2.8.5 Clinical studies on calcium/calcium and vitamin D supplementation, coronary
heartdiseaseandcardiovascularevents
The results of previous interventional and epidemiological studies have suggested that
dietarycalciumintakemaydecreasetheincidenceofvascularevents(Knox1973,Bostick
et al. 1999, Iso et al. 1999). Recently, data has been produced that for the first time has
questioned the benefits (to bone) of calcium supplementation because of its possible
harmful cardiovascular effects (Reid et al. 2006, Bolland et al. 2008, Bolland et al. 2010,
Bollandetal.2011).
 MenintheHealthProfessionalsFollowupStudy(AlDelaimyetal.2003)whoreturned
a dietary questionnaire in 1986 (n= 39 800) were followed up for 12 years. Intakes of
calciumandothernutrientswereassessedin1986,1990,and1994.Theresultsofthisstudy
suggest that neither dietary nor supplemental intakes of calcium are appreciably
associatedwiththeriskofischemicheartdiseaseamongmen(AlDelaimyetal.2003).




lower ischemicheartdiseasemortality inpostmenopausalwomen,and the reduced risk
maybeachievablewhetherthehigherintakeofcalciumisattainedbydiet,supplements
or both.Themultivariateadjusted relative risk as regards thehighest versus the lowest
quartileof totalcalciumwas0.67 (95%CI0.47–0.94).Therelativerisksof ischemicheart
disease mortality were 0.63 (95% CI 0.40–0.98) for high dietary calcium but no












placebo (HR1.04,95%CI0.92–1.18) in thewhole cohort (Hsiaetal. 2007),but for those
withoutriskfactorsforCHDthehazardratiowas1.19(95%CI0.97–1.59)(Reidetal.2010).
Strokewasconfirmedamong362womenassignedtocalcium/vitaminDand377assigned
to placebo (HR 0.95, 95%CI 0.82–1.10). In subgroup analyses,womenwith higher total
calcium intake (dietplus supplements)atbaselinewerenotat ahigher riskof coronary
events (p=0.91 for interaction) or stroke (p=0.14 for interaction) if assigned to
calcium/vitaminD.ForthecombinedendpointofMI,CHDdeath,coronaryarterybypass
and percutaneous coronary intervention, the hazard ratio was 1.08 (95% CI 0.99–1.19)
(Hsiaetal.2007).Thevascular riskassociatedwithrandomization tocalcium/vitaminD
wasrelatedtoBMI(p=0.04)suchthatwomenwithhigherBMIwereatalowerriskwith
calcium/vitamin D supplementation. For participants with a BMI of 25–30 kg/m2, the
hazardratioforcoronaryarterydiseasewas1.18,andforBMI<25kg/m2itwas1.16(Hsia
etal.2007).





(95%CI 1.01–4.47), stroke 1.42 (95%CI 0.83–2.43), and suddendeath 1.01 (95%CI 0.20–
4.99).Whenunreportedeventsidentifiedinanationaldatabasewereadded,however,the
increased risk of MI (RR 1.49) and composite CVD endpoints (MI, stroke and sudden
death)(RR1.21)inthecalciumgroupwerenolongerstatisticallysignificant.
 TheRandomisedEvaluation ofCalciumOr vitaminD study (RECORD) (Grant et al.
2005), a secondary fracture prevention study (n= 5292, subjects aged 70 years ormore)
revealedatrendtowardshigherdeathratesinthoseallocatedtocalciumcomparedwith
placebo(18.5%vs.16.3%).Princeetal.(2006),inastudyof1460postmenopausalwomen
(mean age 75 years) randomized to calcium carbonate (1200mg/day) or placebo over a
fiveyear period, found the hazard ratio for a diagnosis of “incident ischemic heart
disease”was1.12(95%CI0.77–1.64).
 TheCalcium Intake FractureOutcomeStudy,CAIFOS, a 5year, randomizeddouble
blind placebocontrolled trial concerned calcium supplementation and the risks of
atheroscleroticvasculardiseaseinolderwomen(1460womenaged75.1±2.7(SD)yearsat
baseline in 1998) (Lewis et al. 2010). The participants of this trial were randomized to
receive1200mgofcalciumcarbonatedailyoranidenticalplacebo.Allhospitaladmissions
anddeathsduringthe5yearstudyandthe4.5yearfollowupperiodwerederivedfrom
the Western Australian Data Linkage Service. The intervention group, who received
calciumsupplementation,didnothaveahigherriskofdeathorfirsttimehospitalization
fromatheroscleroticvasculardisease ineither the5yearRCT (multivariateadjustedHR
0.94, 95% CI 0.69–1.28) or during the 9.5 years of observational study (multivariate
adjusted HR 0.92, 95% CI 0.74–1.15). Further analysis suggested that calcium
supplementation may reduce the risk of hospitalization and mortality in patients with
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preexisting atherosclerotic CVD. According to the results of this trial, calcium
supplementationof1200mgdailydoesnotsignificantlyincreasetheriskofatherosclerotic
vasculardiseaseinelderlywomen(Lewisetal.2010).
 Bolland et al. carried out twometaanalyses of cardiovascular events in randomized
trialsof calciumsupplements (Bollandetal. 2010,Bollandetal. 2011). In the firstmeta
analysis (Bolland et al. 2010) 15 trialswere eligible for inclusion, fivewithpatientlevel
data and 11with triallevel data. In the five studies contributing patientlevel data, 143
peopleallocatedtocalciumsufferedMIcomparedwith111allocatedtoplacebo(HR1.31,
95%CI1.02–1.67,p=0.035).Nonsignificant increasesoccurred in the incidenceof stroke
(HR 1.20, 95% CI 0.96–1.50, p=0.11), the composite endpoint of MI, stroke, or sudden
death (HR 1.18, 95% CI 1.00–1.39, p=0.057), and death (HR 1.09, 95% CI 0.96–1.23, p=
0.18).Metaanalysisofthetrialleveldatashowedsimilarresults;296peoplesufferedMI




on cardiovascular risk in theWomen’sHealth InitiativeCalcium/VitaminD (WHICaD)





vitaminDgroup ranged from1.13 to 1.22 (p=0.05 for clinicalMI or stroke,p=0.04 for
clinical MI or revascularization), whereas in the women taking personal calcium
supplementscardiovascularriskdidnotalterwithallocationtocalciumandvitaminD.In
theupdatedmetaanalysesofplacebocontrolledtrialsofcalciumorcalciumplusvitamin
D, complete triallevel data were available for 28 072 participants from eight trials of
calcium supplements and the WHI CaD participants not taking personal calcium
supplements. In total, 1384 individuals sufferedMI or stroke. Calcium or calcium plus
vitamin D increased the risk of MI (RR 1.24, 95% CI 1.07 to 1.45, p=0.004) and the
composite risk ofMI and stroke (RR 1.15, 95%CI 1.03 to 1.27, p=0.009) (Bolland et al.
2011).
 In 2010 Wang et al. carried out a systematic review of vitamin D and calcium
supplementation in prevention of cardiovascular events (Wang et al. 2010). Five
prospective studies of patients receiving dialysis and 1 study involving a general
population showed consistent reductions inCVDmortality among adultswho received
vitaminDsupplements.Fourprospectivestudiesofinitiallyhealthypersonsrevealedno
differences in the incidence of CVD between calcium supplement recipients and non
recipients.The resultsof secondaryanalysesof 8 randomized trials showeda slightbut
statisticallynonsignificantreductioninCVDrisk(pooledrelativerisk0.90[95%CI0.77–
1.05]) with vitamin D supplementation at moderate to high doses (approximately 1000
IU/d)butnotwithcalciumsupplementation(pooledrelativerisk1.14[95%CI0.92–1.41]),
or a combination of vitamin D and calcium supplementation (pooled relative risk 1.04
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[95%CI0.92–1.18])comparedwithplacebo.Theconclusionoftheinvestigatorswasthat
evidence from limited data suggests that vitamin D supplements at moderate to high
doses may reduce CVD risk, whereas calcium supplements seem to have minimal
cardiovasculareffects(Wangetal.2010).
 Taken together, the evidence fromprospectiveobservational studies and randomized
controlledtrialssuggestedearlierthatcalciumsupplementationseemstohavenoeffecton
CVD risk, but the results ofmore recent studies suggest that calcium supplementation
withorwithoutvitaminDcouldbeassociatedwithanincreasedincidenceofCVD.
 
Table 8. Outcomes of some observational and case-control studies and two meta-analyses 
carried out after 1998 in which the association between calcium supplement use and risk of 
CHD has been examined. 
 
Bostick et al. 1999 Prospective, over 8-year follow-up Death from IHD (n=387):
The Iowa Womens' health Study n=34 486 women Highest vs. lowest quartiles of total Ca,Vitamin D and milk intake RR:0.67 (0.47-0.94) 
High dietary Ca intake but no supplemental ca intake RR:0.63 (0.40-0.98)
High supplemental Ca but low dietary ca intake RR:0.66 (0.36-1.23)
Al-Delaimy et al. 2003 Prospective, 12-year follow-up IHD (nonfatal myocardial infarction and fatal IHD, n=1458):
Health Professional Follow-up Study n=38 800 men highest (median 1377mg/day) Ca intake vs. lowest (median 523mg/day) Ca intake  
RR: 0.97 (0.81-1.16)
Ca supplement users (median 1000 mg/day) vs. nonusers  RR:0.87 (0.64-1.19)
Prince et al. 2006 Placebo-controlled, 5-year follow-up IHD (n=56 (7.7%) in Ca group; n=51 (7.0%) in placebo group:
n= 1460 women Calcium supplementation vs. placebo, HR:1.12 (0.77-1.64)
Hsia et al. 2007 Pacebo-controlled, 7-year follow-up CHD or MI death (n=499 in ca/vitamin D group,n=475 in placebo group): 
WHI n=36 282 women Ca/vitamin D vs. placebo, HR:1.04 (0.92-1.18) 
Combined endpont of MI,CHD death, coronary aretery bypass and percutaneus
coronary intervention; Ca/Vitamin D vs. placebo, HR:1.08 (0.99-1.19)
Bolland et al. 2008 Placebo-controlled, 5-year follow-up MI (n=24 calcium group and 10 placebo group):
The Auckland Calcium Study n=1471 women Ca supplementation vs. placebo, RR:2.12 (1.01-4.47) 
Bolland et al. 2010 Patient-level and trial-level meta-analysis The composite endpoint of MI, stroke, or sudden death: Ca vs placebo, HR 1.18 (1.00-1.39)
MI: Ca supplementation vs. placebo, pooled RR:1.27 (1.01-1.59) 
Wang et al. 2010 Meta-analysis of randomized trials CVD: Vitamin D+Ca supplementation vs. placebo, pooled RR:1.04 (0.92-1.41)
CVD: Ca supplementation vs. placebo, RR 1.14 (0.92-1.41)
Bolland et al. 2011 Re-analysis of the WHI limited access dataset Re-analysis of the WHI CaD Study:
and meta-analysis In women not taking Ca supplements at the randomization, HR with Ca+Vitamin D 
1.16 (1.01-1.14) for composite endpoint of clinical MI or coronary revascularization,
HR:1.22 (1.00-1.50) for clinical MI
Updated meta-analysis :
Ca/Ca+Vitamin D supplementation vs. placebo, HR: 1.24 (1.07-1.45) for MI
Study Main findings RR,HR (95%CI)Population, Follow-up
n

Abbreviations: RR: risk ratio, HR: hazard ratio, CI: confidence interval, Ca: calcium, IHD: ischemic heart 





























 Of the 13100 responders in 1989, 11 055 (84.4%)werewilling to participate in bone
densitometry.A stratified sample of 3222 volunteerwomenwas selected, 2025 of them
randomly.Therestofthewomenwereselectednonrandomlytoincludeallwomenwho
belonged to certain osteoporosis risk groups or were of postmenopausal status. A
questionnaireconcerningdetailedinformationonfactorsrelatedtobonehealthwassent
tothese3222women.










HT use could not be clarified, the woman concernedwas excluded (n=131). Study IV
concernedwomenwhorespondedtobothbaselineand5yearfollowupinquiries(n=11
667)andwhoreportedthemselvestobeCHDfreein1994(n=10555).Thosewomenwho
reported having CHD in 1989 or 1994, womenwith CHD according to the Registry of
SpeciallyRefundedDrugsof theFinnishSocial Insurance Institution (SII) (n=1108)and
womenwhoseyearofdevelopingCHDcouldnotclarified(n=4)wereexcluded.StudyII,
concerningtheeffectofHTonmortality,andStudyIV,concerningtheeffectofcalciumor
calcium plus vitamin D on CHD were carried out among postmenopausal women
responding to both inquiries. Women whose menopausal status could not be defined
because of hysterectomy were excluded (n=1146) as well as women who were



















Study II HT use history in 1994, n= 11 667
National cause of death register
Study IV Free of CHD in 1994 Postmenopausal and Responded to 10-year







Figure 1. Study design and selection of study populations 


     
4.2 POSTAL INQUIRIES 

4.2.1Thebaselinepostalinquiry
The baseline postal inquiry (Appendix I) sent in 1989 to women living in the Kuopio
region(n=14220)includedquestionsaboutweight,height,healthdisordersdiagnosedby
a physician, fracture history, current use of prescribed drugs including calcium





InMay1994,a5yearpostal inquiry (Appendix II)was sentout towomen living in the
Kuopioregionwhohadrespondedatbaseline to the1989 inquiry.The5year followup
inquiry covered information about gynecological history, use of HT, gynecological




InMay1999,a10yearpostal inquiry (Appendix III)was sentout to thosewomenwho
had responded to the 1989 inquiry andwhowere alive in 1999, andhad a valid postal
address. The postal inquiry included questions about risk factors of osteoporosis and
fractures, history of fractures and falls, gynecological history, working status,




4.3 REGISTERS  

4.3.1TheNationalCauseofDeathRegister,StatisticsFinland
Thenationaldeathregistercontains informationonalldeaths in thecountry takenfrom
death certificates filled inby thephysicianswho take careofpatientsbeforedeath.The
certificate follows the international format issued by theWHO. The data are compared
with theCentralPopulationRegisterbymeansof thepersonal identificationcodeof the




help of statistical rules of theWHO.The causes of death are classified according to the
revisionoftheInternationalClassificationofDiseasesthatwasvalidinFinlandatthetime
of death (Statistics Finland 2002). Finnish mortality statistics have been shown to be
accurate(Lahti&Penttila2001).

4.3.2 The Registry of Specially Refunded Drugs of the Finnish Social Insurance
Institution
According to the National Sickness Insurance organization, the Social Insurance
Institution (SII)granted, in2007, 72%reimbursement fordrugcosts inabout40defined
chronic illnesses necessitating continuous medication, such as CHD. This National
Sickness Insurance is statutory and comprehensive and covers thewhole of the Finnish
population.SIIissupervisedbytheFinnishParliamentandthecostsofreimbursementare
financed by tax revenues. To acquire the reimbursement, one has to complete an






The Social Insurance Institution, according to the Finnish Sickness Insurance Act, pays
partial reimbursement for the costs of outpatient care, including prescribed drugs, for
every person living in the country. The Social Insurance Institution has collected
nationwidedataonprescriptionsfrompharmaciessince1995,withcoverageof97%.The
pharmaciessubmittheirdataelectronically inawaythat issufficientlydetailedtoallow
determination of the duration of availability of themedication on the basis of quantity
describedintheprescription,sothereferencedatabasecoversthenationwideuseofHT.
Based on the records of 1995 to 1999, we were able to calculate the availability of all
estrogencontainingpreparations forour cohortduring theperiod from January1996 to
May1999intermsofmonthsperyear.





















had been used. Currentmedication prescribed by a doctorwas also asked about in all
three followup inquiries. Thewomenwere asked to specify the names ofmedications,
durationofuseandthediseasesforwhichtheywerebeingtaken.UseofHTwasdefined




substances with estrogenic properties belonging to the G03C group of substances,
according to the ATC classification of 2001, as well as combinations of estrogens and
progestagens (G03F).Raloxifene, tibolone,and topicalapplicationsofestroneandestriol
52
wereexcluded.Estrogenusewascategorizedbymeansofselfreportedanswers:1)yes,2)















inquiries: the women were asked to specify the names of medications, durations of
treatment with medicine and the names of diseases for which they were taking
medication.In1994,currentregular(daily)useofcalciumorvitaminDasasupplementor
as a natural product was inquired about. Calcium or calcium and vitamin D
supplementation (hereafter referred to as calcium supplements) was classified to two
groups: 1) no use of calcium supplements and 2) use of calcium supplements in 1994.




Theendpointwas incidentCHDconsistingofdeath fromCHD(ICD9 codes41004149
andICD10codesI200I259)andchronicCHDdiagnosedduringfollowupaccordingto
theRegistryofSpeciallyRefundedDrugs.
 ExaminationsanddiagnosisofCHDmustbemadebyan internistor cardiologist. In
obviouscasesofCHDanopinionfromanotherphysicianwithlongtermfamiliaritywith
the patient is also acceptable. The criteria for reimbursement of medicines in chronic
coronaryarterydisease(ICD10codesI2022,I24.0,I25)areasfollows:
 Clearsymptomsofanginapectoris,whichcanbeprovenaschronicCHDbyclinical
examination and CHD responding to medication. CHD diagnosis has to be
confirmed by clinical strain test if rest ECG is questionable as regards CHD
diagnosis.
 Myocardial infarction, coronary artery bypass graft surgery, or percutaneous
balloon angioplasty or chest pain and significant coronary artery stenosis on
coronaryangiography.
 WhenCHDdiagnosishasbeenset,thespecialistwillwriteastatementconcerningthe






The endpoint was established DM during followup, ascertained via the Registry of
Specially Refunded Drugs of the SII. According to the National Sickness Insurance
organization, the SII granted 100% reimbursement for drug costs in defined chronic
illnessesnecessitatingcontinuousmedicationsuchasDM.
 According to the National Sickness Insurance organization, the criteria for







I. Thepatienthas the right to reimbursement forDM2medicationwhenhe/shehas
symptomstypicalofDM(polyuria,polydipsia,andglucosuria)andfastingglucose
in capillary or vein blood is at least 7.0 mmol/L or in blood plasma at least 8.0
mmol/L. If symptoms ofDM aremissing, DMdiagnosis has to be confirmed by
repeatedtesting.
II. Thepatienthas the right to reimbursement forDM2medicationwhenhe/shehas
hadat least6monthsofdietary treatmentbeforemedical treatment.Themedical
certificateconcerningDM2mustincludeinformationaboutthedurationofdietuse
and its effects on weight. Furthermore, the symptoms, findings, and blood and
urineglucosestatusandpossiblealbuminuria,especiallybeforemedicaltreatment,
should be described.WhenDM diagnosis has beenmade, amedical doctorwill





4.5 STATISTICAL METHODS  

TheKuopioOsteoporosis Risk Factor and Prevention (OSTPRE) Study informationwas
coded and recorded in the Bone andCartilageResearchUnit, Clinical ResearchCenter,









or as proportions (%). The chisquared test was used to compare categorical variable




hazard ratios (HRs),whichwere estimated bymeans of Cox regression (Studies II–IV).
Multivariate Cox regressionwas also used to adjust for putative confounders. Kaplan–
MeiersurvivalcurvesandthelogranktestwereusedtoexaminetheeffectofHTuseon
theincidenceofDM(StudyIII).Kaplan–Meiercurveswerealsousedforevaluationofthe
applicability of life tablemodels (which assume constant incidence of endpoint events)
(Study III).When using the Cox proportional hazard regressionmodel, followup time



















Table 9. The main results of Studies IIV. 
 
Study Aim of the study Study type and Main Results 
   subjects   

I Agreement of self- Cross-sectional, A postal inquiry is a reliable  
 reported estrogen use self-report/SII register method of recording long-term 
 with prescription data n = 11 377  HT use 
  
 
II HT effect on mortality Prospective, 19942001 History of HT use: 
   self-report/Statistics of no effect on CHD or overall  
   Finland register mortality, > 5 yrs of HT use 
   n =11 667  may increase the risk of breast  
     cancer  

III HT effect on diabetes Prospective, 19941999, Continuous HT use: decreased 
   SII register  T2DM by 69% 
   n = 8483 postmenopausal   
   women 
 
IV Effect of calcium  Prospective, 19942001 Calcium or Calcium + vitamin D  
 supplements on CHD SII register  supplementation increases 
   n =10 555  the risk of CHD by 2426% 
     
  
 
Abbreviations: SII: Social Insurance Institution, HT: hormone therapy, CHD: coronary heart disease 
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Table 10. Baseline characteristics of the study population (n = 11 667) according to history of 
HT use recorded in 1994 
 
Use of HT
No use 5 years use >5 years use Total
Characteristic (N=5519) (N=3945) (N=2203) (n=11667)
Mean age, years 57.5 (3.0) 56.8 (2.9)* 57.6 (2.7) 57.3 (2.9)
Mean height, cm 160.9 (5.4) (161.4 (5.2)* (161.3 (5.1)* 161.2 (5.3)
Mean weight, kg 71.5 (13.0) 70.5 (11.9)* 68.3 (10.2)* 70.5 (12.2)
Mean BMI, kg/m² 27.6 (4.8) 27.1 (4.3)* 26.1 (3.7)* 27.1 (4.5)
Mean parity  2.5 (1.7)  2.5 (1.5)  2.2 (1.4)*  2.4 (1.6)
Mean time since menopause, years  8.1 (4.4) 6.4 (4.0)* 9.3 (3.8)* 7.7 (4.3)
Postmenopausal women (%) 76.7 83.0 83.7** 80.2
No. of chronic health disorders
None (%) 27.9 26.1** 26.0** 26.9
One (%) 31.1 29.8** 27.5** 30.0
2-3 (%) 30.9 33.0** 35.3** 32.4
 4 (%) 10.1 11.2** 11.2** 10.7
Hysterectomy (%) 15.0 22.2** 34.2** 21.1
Bilateral oophorectomy,(%) 3.9 9.7** 19.5** 8.8
Smoking history, (%) 18.6 20.2 17.9 19.0
Self-reported hypertension (%) 18.3 17.4 15.5** 17.5
Self-reported hypercholesterolemia (%) 15.2 16.1 16.7 15.8
Self-reported diabetes (%) 3.6 1.8** 1.1** 2.5
Chronic hypertension (%) 26.8 26.5 24.5 26.2
Chronic diabetes (%) 4.2 2.1** 1.5** 3.0
Chronic hypercholesterolemia/dyslipidemia (%) 16.3 16.9 17.2 16.7
Chronic coronary heart disease, n (%) 558 (10.1%) 363 (9.2%) 191 (8.7%) 1112 (9.5%)
No. of non-users of calcium/calcium + D supplements, n (%) 4365 (79.1) 2792 (70.8 ) 1540 (69.9) 8697 (74.5)
No. of users of calcium/calcium + D supplements, n (%) 1154 (20.9) 1153 (29.2)** 663 (30.1)** 2970 (25.5)
Mean dietary calcium intake, mg/day 815.7 (388) 786.4 (397)* 796.1 (396) 802.1 (393)
HT use during follow-up 94-99  (n=10872) 5032 (46.3) 3749 (34.5) 2091 (19.2) 10872
Never (% ) 4552 (90.5) 0 0 4552 (41.9)
Past (% ) 0 2231 (59.5) 575 (27.5) 2806 (25.8)
Current < 2.5 years (%) 286 (5.7) 434 (11.6) 205 (9.8) 925 (8.5)















 Study III concerned 8483 nondiabetic postmenopausalwomenwho responded to all
three followup inquiries (in1989, in1994and in1999).PastuseofHTwasreportedby
27.3%andcurrentHTuseduringthefollowupperiodof5yearsby31.9%.Womenwho
used HT during the followup period were slightly younger, had lower BMI and had





Useof calciumsupplementswas reportedby25.8%of thesewomenatbaseline in1994.
Calcium supplementsuser had lowerBMI (mean 26.3 kg/m2) thannonusers (mean27.2




5.2 AGREEMENT BETWEEN SELF-REPORTED ESTROGEN USE AND 







in 1996 to 1999. Of these 3105 women, 3032 were confirmed by the SII to have been
prescribed HT during that time (positive predictive value of 97.6% and sensitivity of
63.6%).Inthesewomenthemediandurationofusewas32months(range1–41),according
toSIIdata.Anadditional30.6%(1738of5674)ofthewomenhadbeenprescribedHTfor
short periods, but thosewomendid not report it. Theduration of selfreportedHTuse
wascomparedwiththedurationofprescription.Adifferenceof3monthsorlessperyear
wasobservedin63.4%to77.0%ofwomenduringtheyears1996–1998.
 In a sample of 2833 women, the influence of educational level on accuracy of self
reports was investigated. In this mainly rural region, 36.1% had completed only
compulsoryeducation,thedurationofwhichwas6yearsin1940to1950.Atotalof59.9%
had also completed at most 2 years of supplementary school or occupational training,




use, HT prescription, and questionnaire sensitivity to detect HT users, according to
educationallevelwereasfollows(Table11):
58
Table 11. Self-reports of HT use, HT prescription, and sensitivity of self-reports to detect HT 
use, according to educational level
 
Mean duration of 
Educational level n Self-reported HT prescriptions, HT prescriptions,
HT use,% months
Compulsory schooling only (6 years) 739 18.8
Compulsory schooling + maximum 2 years of 1613 32.7
supplementary school or occupational training
High school + minimum 2 years of supplementary 345 45.2
school or professional training
University degree 136 48.5
Total 2833 31.4



























 A total of 361 deaths, including 58CHD and 29 breast cancer deathswere observed
during the7year followupperiod (1 June1994until 14May2001).Overall, 290deaths
occurredinthepostmenopausalsubgroup,including46deathsfromCHDand23deaths

















5.4 EFFECT OF HORMONE THERAPY ON INCIDENCE OF DIABETES 
MELLITUS (III)  

The resultsofStudy III arebasedon information collected from thebaseline (1989) and
1994 and 1999 followup postal inquiries, and from the Registry of Specially Refunded
Drugs.
 Therewere 9072 postmenopausal nondiabeticwomen in the study inMay 1994.  In
total,8483(of9072)postmenopausalwomenalsorespondedtothethird,10yearfollow
upinquiryinMay1999,andthesewomenformedthefinalstudypopulationofthisstudy.
Past use ofHTwas reportedby 27.3%andHTuseduring the followupperiodof five
yearsby31.9%ofthesewomen.ThemeandurationofHTuseduringthefollowupperiod
was 3.75 years and it was evenly distributed during the 5 years of followup. The
remaining 40.8% of women had neither used HT nor started it during the followup
period.Theaveragefollowuptimewas4.96years(range0.04–5.00years).
 During the followup period, 162 new DM events occurred. Data from the Social
InsuranceInstitutionincludedbothtype1andtype2DMunderthesamesocialinsurance
code(SVA103)andthereforedifferentiationbetweentype1andtype2DMcouldnotbe
carried out. The incidence of DM remained constant throughout the followup period.
Overall, 90 DM incidents were found in HT neverusers, 51 incidents in past HTonly




per 1000personyears in continuous (2.5–5.0years)HTusers respectively (Table 12 and
Figure2).
 The use of HT was associated with a decreased risk of DM in the postmenopausal
women. InmultivariateCox regression analysis, the risk ofDM (hazard ratio)was 0.81
(95%CI0.57–1.16)inthepastHTonlyusers,0.53(95%CI0.24–1.15)inwomenwhoused




Table 12. Relative risks of incident diabetes (DM) as hazard ratios with 95% confidence 
intervals (CIs) in relation to use of HT in postmenopausal women during 5-year follow-up

Use of HT DM (n) Age-adjusted
Never 90 1.0 1.0
Past 51 0.86 (0.61-1.21) 0.81 (0.57-1.16)
Part-time 8 0.46 (0.22-0.94) 0.53 (0.24-1.15)
(< 2.5 years)
Continuous 13 0.26 (0.15-0.47) 0.31 (0.61-0.60)
( 2.5 years)
Multivariate covariates: age, BMI (kg/m²), parity, hypertension (n/y), hysterectomy (n/y)






     

Figure 2. Remaining free of diabetes according to HT use (Kaplan–Meier survival curves,  
Log rank p <0.001).  















5.5 EFFECT OF CALCIUM OR CALCIUM + VITAMIN D 
SUPPLEMENTATION ON CORONARY HEART DISEASE (IV)
 




these CHDfree women were postmenopausal (n = 8427). Use of calcium or calcium +
vitamin D supplements was reported by 25.8% (2723 of 10555) of these women. The
average followup time was 6.55 years (range 0.01–6.75 years). During the followup







1.14 (95%CI 0.94–1.39) in calcium or calcium + vitaminD supplement users compared
withnonusers.Inmultivariateanalysis,thecorrespondinghazardratiowas1.24(95%CI
1.02–1.52) inwomenusingcalciumor calcium+vitaminDsupplements comparedwith
nonusers (Table 13A). A similar result was seen in the postmenopausal subgroup (n =
8427). In multivariate analysis of the postmenopausal CHDfree subgroup, the hazard
ratioforincidentCHDwas1.26(95%CI1.01–1.51)(Table13B).

Table 13A. Relative risk of CHD (HR with 95% CI) in relation to use of 




No 368 1.0 1.0




Table 13B. Relative risk of CHD (HR with 95% CI) in relation to use of 




No 302 1.0 1.0











mortality and risk of T2DM among Finnish postmenopausal women aged 52–61 at the
baseline in 1994. We evaluated the agreement between selfreported HT use and
prescription data and we also investigated the influence of educational level on the
accuracyofselfreports.Additionally,westudiedtheeffectsofcalcium/calcium+vitamin
DsupplementationontheriskofCHDamongpostmenopausalwomen.
 This study has several strengths. It was populationbased, and included detailed
informationaboutHTuse.Theoutcomesof studieswere taken from reliabledatabases;
causesofdeathregisterdatainFinlandandcarefuldiagnosesof incidentdiseasesbased
ontheSIIregistryofspeciallyrefundeddrugs.TheregistriesinFinlandhaveproventobe
reliable (Lahti& Penttila 2001, Lahti& Penttila 2003, Pajunen et al. 2005,Haukka et al.
2007, Rikala et al. 2010). The study population consisted of the entire perimenopausal
femalepopulation,aged47–56,ofKuopioprovince,EasternFinlandin1989(n=14200).
Thepopulationishomogeneousandstablewithlittlemobility.Finlandhasapopulation
registry and a causes of death registry, each with 100% coverage, and a Registry of
Specially RefundedDrugs. The SII has collected nationwide data on prescriptions from
pharmaciessince1995,withcoverageof97%.Thestudyalsohas theadvantageof long
term followupwith extremely high response rates (in 1994, 92% and in 1999, 88%). In
addition, responses to postal inquiries were partially checked at the time of bone
densitometryanddeficientorambiguous informationwascheckedby telephoneduring
thecodingphase.
 Ontheotherhand,several limitationsneedtobeconsidered.Mostof the information
used,includingHTanduseofcalcium/calcium+vitaminDsupplementation,wasbased




informationongynecological factors suchasHTandageatmenopause. In fact, lifetime
useofHT in theyears before thebaselineof this studywas recorded in the twopostal
inquiries in 1989 and 1994. Use of HT during the followup period was asked about






 Pharmacoepidemiology is the study of medication use and medication effects in
populations.EpidemiologicalstudiesconcerningtherelationshipbetweenexposuretoHT
and/orcalcium/calciumplusvitaminDandriskofdiseasegenerallyrelyonquestionnaire,
or interviewbased selfreported data. These datacollection methods are sometimes
combined,sothatsomepersonsinastudyareapproachedviaonemethodandothersvia




prescription reimbursement data. In a Danish study of HT carried out 1999, the




 Inour study, if therewere anymissingdataordiscrepancy in the informationabout
menopause,HTuse,orgynecologicaloperationsthewomanwascontactedbyphone,and
the informationwasobtained.Thus, even thoughHTusewas selfreported, it hasbeen
showntobeaccurateinourstudy(Sandinietal.2008).
 One of the limitations of our study was that we did not investigate the effects of
different types of HT (estrogen, estrogen+progesterone; tablets, plasters or gels) on
mortality or T2DM. In this population, the most common form of HT was an
estrogen/progesterone combination followed by estrogenonly for hysterectomized
women.
 Another limitation of our studywas thatwe could not determine the doseresponse
effect of calcium supplementation on CHD morbidity. The products contain different
dosesofcalciumandsomeproductscontaindifferentdosesofvitaminD.Therefore,itis
very difficult to determine the daily dose of calcium supplementation in this large
populationbasedcohortstudy.ItisalsoimpossibletoverifywhethertheincreasedCHD
riskispurelyrelatedtocalciumorvitaminD.
 There is also a chance of information bias due to possible misclassification of the
answers,orcodingerrorswhenrecordingsuchalargeamountofdata.However,itisvery
unlikely that such errors would have resulted in differential misclassification. In this
study,useofinformationfromlargeregisterdatabases(mortalitydatafromtheNational
Cause ofDeath Register,morbidity data from SII) has ensured thatmisclassification of
outcomes is very unlikely. Nondifferential misclassification, if presents, may result in
underestimationofthetrueeffectofexposuretosomeextentbutdoesnotgrosslybiasit.
WhenstudyingHT,evenwelldesignedcohortstudieswithadjustmentsforconfounding
factors are subject to healthy users’ effects that may result in overestimation of the










6.2 AGREEMENT BETWEEN SELF-REPORTED HORMONE THERAPY USE 
AND PRESCRIPTION DATA  
 
The results of the present agreement study indicate that a postal inquiry is a reliable
method of recording longterm HT use. Women reporting current or past HT in a
questionnaire and providing details about medication name and duration of use were
confirmedashavingbeenprescribedHTin97.6%ofcasesaccordingtotheSIIprescription
database.TheselfreportednonuseofHTwasalsoconfirmedbytheabsenceoforusually




In the Social Insurance Institution prescription database the proportion of women
having ever been prescribedHT in 1996 to 1998 increased only slightly, from 37.5% to
38.9%,indicatingthatthepercentageofHTpreparationscorrectlyidentifiedasestrogen
containing is due to better recall in the later years. Two thirds (66.4%) ofwomenwith
estrogen prescriptions covering a clinically significant period of at least 6 months
remembered their HT prescription, whereas accuracy was lower (11.0%) among short
term users. Comparison of information from both sources showed that many HT
prescriptions were left unreported or perhaps had never actually been used. We




biased in various ways. Although there may not be a general tendency to over or
underestimate exposure in recalled information from a large number of subjects, the
“noise” due to errors in recall leads to an underestimate of the association between
exposure and the outcome of interest (Breslow & Day 1987). Various methods for
gathering such types of information have been compared, and the recall accuracy as
regardsnameanddosehasbeenreportedtobeonly28%(Westetal.1995).Assessmentof




other studies, usingother selfreporteddata (Horwitz&Yu1985,Greendale et al. 1997,





studies, confirming the findings in our study. In a Danish Nurses study of HT, both
sensitivityandspecificitywerehigh,being74.8%and98.0%respectively(Lokkegaardet
al.2004).Theinvestigatorsfoundahighdegreeofagreementbetweenselfreporteddata
andregistrybaseddataaccording to typeofHTregimenand longtermdurationofHT
use. In contrast, PaganiniHill and Ross (PaganiniHill & Ross 1982) reported lower








HT prescriptions was 53.4% and the specificity was 89.0%. The very good positive
predictive value (97.6%) means that selfreported use can be trusted, but the lack of
sensitivity indicates that some women fail to report their HT use. For this group, the
durationofHTprescriptionswasupto6months,andthisshortdurationofprescription
was seen inonly 5.5%of selfreportedverifiedusers.Thegood specificity, on theother
hand, means that women who have never been prescribed HT will rarely erroneously
reportHTuse;intheotherwords,anegativeanswerreliablyruledoutanysignificantuse
of HT. In our study our reference database contains prescription data, which does not
necessarilymeanthat theHTwasusedastheprescribingphysicianandthepatienthad
togetherplanned.Analysisof theSIIprescriptiondatafor theperiodwhenselfreported
users indicatedan interruptionofestrogen treatment showed that,onaverage,50.9%of
thosewomenhadbeenprescribedHTduringthattime.




respectively. The overall prevalence ofHT use (23.7% of postmenopausalwomen) is in
accordancewithpreviouslypublishedFinnishdata(Topoetal.1999).
 During the years 1996 to 1999, 52.2% of selfreported users indicated continuous use
throughoutthe41monthperiod.AccordingtotheSIIdata,HTusewasprescribedfor41
monthstoonly2.6%ofthewomen.Thisdiscrepancymaybesimplyduetothefactthat
the women tended to round up the duration of treatment, considering perhaps that 9
months or more is virtually the same as a whole year. According to SII data, HTwas
availablefor9monthsormorefor69.9%oftheselfreportedusersin1997,whichsupports








was shorter than the HT prescription, the difference probably reflects interruption of
treatment.For72.1%ofsuchcases,thedifferencewasonly1to3months.Thisexplanation
isplausible inviewof theusual rateof interruptionof treatment,which isusually 40%
after4yearsof treatment (Eiken&Kolthoff1995).Useofdiariescouldhelpanswer this
question, and earlier agreement studies concerning selfreported use and medication




 Several studies on the influence of sociodemographic factors on the use of HT have
beencarriedoutandtheyhaveproducedcontradictoryresults(Rosenbergetal.1979,Brett
&Madans1997,Dennersteinetal. 1999,Keatingetal. 1999,Shahetal. 2001).However,
socioeconomic status based on education and household income is themost significant
correlate of noncontraceptive HT use other than sex, age, and race (Marks & Shinberg
1998). In the studyofDanishnurses thevalidityofHTusewasnot stronglyassociated
withbackgroundfactorssuchasage,alcoholintake,andsmoking(Lokkegaardetal.2004).
The incidenceofbreast cancerhasbeen shownconsistently tobehigheramongwomen
with a higher social position, as measured by educational level (Heck & Pamuk 1997,
Robert et al. 2004, Clegg et al. 2009, Larsen et al. 2011). The association between social




cancer among socially advantaged women is mediated by differences in exposure to
reproductive factors, HT and alcohol when social position is measured by educational
level (Larsen et al. 2011). Our analysis shows that higher educational levels were
associated with higher rates of selfreported HT use and a higher prevalence of HT
prescription.
 
6.3 HORMONE THERAPY AND MORTALITY  
 
Inthepresentstudy,ahistoryofHTdidnotaffectoverallorCHDmortality.Ontheother
hand,our results confirmed thatmore than5yearsof lifetimeHTusemay increase the
riskofbreastcancermortality.
 In2002aWomen’sHealthInitiativepublicationgaveverydifferentresultsforwomen
withameanageof 63years:EPT increased the riskof compositeoutcomes, termed the
globalindex,by13%comparedwithplacebo,withoutincreasingmortality(Rossouwetal.
2002). In 2004, a metaanalysis of randomized trials showed that HT reduced total
mortalityby40%intrialsamongpostmenopausalwomenwithameanageunder60years,





60 years.Hormone therapywasnot associatedwithmortality reduction amongwomen
who initiated HT at age 60 or older (Rossouw et al. 2007). Hence, the results of the
Women’s Health Initiative trials are consistent with those of observational studies
indicating thatHTmay reduce totalmortalitywhen initiated soon aftermenopause. A
recent costeffectiveness analysis showed that HT given to younger postmenopausal
women (50yearold) for530years resulted ina small increase in lifeexpectancyanda
substantialincreaseinqualityadjustedyearsoflife(Salpeteretal.2009a).
 In contrast to the results of early observational studies and metaanalyses, in our
prospectivepopulationbasedstudy,theuseofHTwasnotassociatedwithtotalmortality
in the entire study population or in the postmenopausalwomen. Themean age of our
study cohortwas 57.3 years (52.3–62.4 years) and the average followupperiodwas 6.7
years. The total mortality rate was 4.51 per 1000 personyears in our entire study
population(n=11667).Thetotalmortalityrateinnonusersofwas5.37per1000person
years, and in women who used HT  5 years 3.37 per 1000 personyears. The total
mortalityrateinwomenwhousedHT>5yearswas4.16yearsper1000personyears.In
1995, thenational totalmortalityratefor55 to59yearoldwomenwas4.4/1000person
years and for 60 to 64yearold women, 6.73 per 1000 personyears (Statistics Finland
1995). In2000, thenational totalmortalityratefor55 to59yearoldwomenwas4.1per
1000 personyears and for 60 to 64yearoldwomen it was 6.45 per 1000 personyears
(Statistics Finland 2000). Hence, our study population was very representative of the
Finnishfemalepopulation.
 A Bayesian metaanalysis of HT and mortality in younger postmenopausal women
(Salpeteretal.2009b), involving19randomizedtrials,with16000women(meanage55
years),showeda27%decreasedriskofmortality.Whendatafrom8observationalstudies
were added to the analysis, the resultant relative riskwas 0.72 (95%CI 0.62–0.82). The
probabilitythatHTreducestotalmortalityinyoungerwomenwasfoundtobealmost1
(Salpeteretal.2009b). Inourstudy,HTdidnotaffect totalmortality,although the total
followup timewas almost 7 years and themeanageof our cohortwasnot verymuch
higher(57.3years)thanthemeanageofthewomeninthemetaanalysis.
 In the California Teachers Study the results provide evidence that a reduced risk of
mortality associated with HT use is observed among younger users but not older
postmenopausalwomen,eventhosestartingtherapyclosetotheirtimeofmenopause.No
additionalsignificantmodifyingeffectsofageatfirstuse,durationofuse,orformulation
wereapparent (Strametal.2011). Inourstudy,HTdidnotappear toaffectallcauseor
CHDmortality, although thewomen’s ages in our study cohort at baselinewere 52–62
years.
 Although the rate of CHD mortality has decreased over the last few decades and
women’s life expectancy has increased, CHD is still the leading cause of death among
women and men in Finland (Niemelä et al. 2009). In 2006 26.8% of postmenopausal
womendiedofCHD(StatisticsFinland2006).AlthoughCHDisoftenconceptualizedasa
disease of special importance inmen, it is still the leading cause of death inwomen in
mostdevelopedcountries,accountingforalmost45%ofalldeaths(Kauletal.2007).
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 Coronary heart disease is amultifactorial disease and itsmost important risk factors
appear to be universal in both genders (Yusuf et al. 2004), although CHD appears in
womenwithadelayoftenyearsascomparedwithmen.Inwomen,diabetesandsmoking
increase the risk of developing the disease more than in men (Niemelä et al. 2009).
Womens coronary arteries are smaller in size, which previously affected the results of
invasive treatment. Treatment outcome with current techniques is equal in both sexes
(Niemelä et al. 2009). Up until recently it was thought that CHD rates are lower in
premenopausalwomenthaninmenofcomparableage,untiltheresultsofthelatestmeta
analysiswere published, byHemingway et al. (Hemingway et al. 2008),which showed





 Approximately 40 observational cohort and casecontrol studies have consistently
shown thatbothestrogenonly (Grodstein&Stampfer1995,Grodstein&Stampfer1998,
Prentice et al. 2006) andEPTs (Thompson et al. 1989, Falkeborn et al. 1992, Psaty et al.
1994, Grodstein et al. 1996) are associated with a reduced incidence of CHD and total
mortalityinpostmenopausalwomen.Althoughtheseobservationalstudieshaveshowna
30–50% reduction inCHDand totalmortality in users vs. nonusers ofHT, randomized
controlledtrials(RCTs)haveshownanulleffectontheseoutcomeswhenanalyzedamong
allwomenregardlessofage(Hodis&Mack2008).Thediscordanceinoutcomesbetween
observational studies and RCTs is likely to be explained in part by differences in the
characteristicsofthecohortsstudied(Hodis&Mack2008).
 Recentdataandanalysessince the initialpublicationsconcerning theHT trialsof the
WHIstudystronglysuggestthatthetimingof initiationofHTiscriticaltotheeffectsof
HTonCHD inpostmenopausalwomen.Healthywomenwho initiateHTwithin a few
years of menopause, typically for menopausal symptoms, may experience a beneficial
effectasregardsCHD.
 AwomanwhostopsHTwill later lose thebenefits itbrings.Thismaypartlyexplain
resultsofourstudy.AnywomanwhoreportedanyHT/estrogenuse(rangingfrom0.05–
35years)wasclassifiedasanHTuser.Hence,anHTuserinourstudy(either5yearsor
> 5 years) could thus be a formeruser, current user, parttime or continuoususer, or a
womanwhohadusedHTforsometimeandstoppedandrestarteduse.AnHTusermay
have stopped use of HT several years before the baseline in 1994. There is always a
possibilitythatthesewomenwhohadstoppedHTusehadlostthebenefitofit,andthat
mightbethereasonwhyinourstudyHTwasnotassociatedwithCHDdeath,although
we carried out several analyses byusingdifferentHTuse classifications. Like us, those
whocarriedouttheprospectiveDanishNursesstudy(Lokkegaardetal.2003)didnotfind
anHTeffectonoverallorCHDmortality, although they found thatHTuserswithDM







studieshavesuggested thatbreast cancersassociatedwithcombinedHThave favorable
characteristics (Holli et al. 1998, Chen et al. 2004, Rosenberg et al. 2008), less advanced
stage(Hollietal.1998,Newcombetal.2008),andareducedmortalityrisk(Christanteet
al. 2008, Newcomb et al. 2008, Rosenberg et al. 2008). The randomized WHI trial
confirmedtheriskofbreastcancerinconnectionwithCEEplusMPA(Chlebowskietal.
2003) but not as regardsCEEonly (Anderson et al. 2004). In theMillionWomenStudy
(Beral&MillionWomen StudyCollaborators 2003), estrogenprogestagen combinations
wereespeciallyassociatedwithanincreasedriskofincidentandfatalbreastcancer.Inthat
study,currentusersofHTwere1.7foldmorelikelythanneveruserstosuccumbtobreast






showeda2 to2.5fold riskofbreast cancerdeathcomparedwithnonusersofHT.This
risk tended towards a statistical significance in multivariate analysis. Women with an
intactuterusareadvisedtousecombinedHTinFinland.However,useofcombinedHT






an association between breast cancer death (29 deaths in whole cohort) and HT use.
However, we could adjust for multiple confounders, unlike Lyytinen et al, who used
recorddatawithonlyafewanthropometricvariables.
 Calleetal.(Calleetal.2009)reportedresultssimilartothosereportedbyLyytinenetal.
(Lyytinen et al. 2009), indicating that, particularly for lobular histology, risk began to
increasewithin 3 yr of initiation, although lobular tumors represent only about 20% of
breast cancers. Whether the risk varies with the type of progestagen has also been
questioned recently by Fournier et al. (Fournier et al. 2008a), who reported differences
betweenmicronizedprogesteroneanddydrogesterone.Overameanfollowupperiodof
8.1yr,2354casesofinvasivebreastcancerwereobservedamong80377postmenopausal
women in theFrenchE3Ncohort study.ComparedwithHTneveruse,useof estrogen
alonewasassociatedwithasignificant1.29foldincreasedbreastcancerrisk(95%CI1.02–
1.65). The association of EP combinations with breast cancer risk varied significantly
according to the type of progestagen: the RR was 1.00 (0.83–1.22) for estrogen
progesterone, 1.16 (0.94–1.43) for estrogendydrogesterone, and 1.69 (1.50–1.91) for
70
estrogen combined with other progestagens. The study revealed no evidence of an













 InastudybyNormanetal. (2010)HTprior tobreastcancerdiagnosis in278women





hormone use. Further, in theWomen’s Care dataset, among all breast cancer casesHT
usersappearedtohavemorefavorabletumorcharacteristicsthannonusers,withagreater
likelihood of lobular as opposed to ductal histology (Daling et al. 2002), a higher
proportion of ER andPRpositive tumors, and a lower proportion of latestagedisease
(Dalingetal.2003),butadjustment for recentscreeningattenuatedsomeof theseeffects




 In conclusion, our findings suggest against the results of several former and current
studies indicating thatahistoryofHTusemaynotbeassociatedwithoverallmortality
andCHDmortalityin52to70yearoldwomen.OurfindingthatlongtermHTuse,over
5 years, may increase breast cancer mortality is consistent with the results of recent
studies. Further information on the role of HT, according to route, administration and
doseinmodifyingthemortalityriskisneeded.










study we did not distinguish between unopposed estrogen and combined therapy or
betweenoralandtransdermalapplication.Accordingto theNationalSickness Insurance
organization, the criteria for reimbursement ofmedicines in DM included ICD9 codes
250.0–250.9andICD10codesE10–E14andE89.1andallthesecodeswereincludedunder
the same SII code forDM (SVA 103). This code does not allow differentiation between
T1DM and T2DM, but the age range of our population implies that incident cases
consideredinouranalysisweremostlyT2DM.
 Thisstudyareaisveryimportant,becausewomenwithDMhavea2to3foldriskof
dying from acutemyocardial infarction in comparisonwithdiabeticmen (Huxley et al.
2006).Thus,thebeneficialeffectofHTonDMcouldbetranslatedinthelongtermintoa
beneficialeffectonmortality.





randomized controlled trial, the HERS study (Kanaya et al. 2003), the corresponding
decreasewas35%.TheWomen’sHealthInitiativetrialrevealedan11–17%lowerriskof
DM inHTusers comparedwith nonusers (Margolis et al. 2004, Bonds et al. 2006). The






amongpostmenopausalwomenwho had ever usedHT comparedwith thosewho had
never used it. Adjustment for BMI during followup did not substantially modify this
association.Theinvestigatorsalsofoundthatanoralrouteofestrogenadministrationwas
associatedwithagreaterdecreaseinDMriskthanapercutaneousroute.Whentakinginto
account the typeofprogestagen incombinedHT,onlypercutaneousestrogencombined
withprogesterone,ororalestrogencombinedwithcyproteroneacetateornorethisterone
acetate were significantly associated with a lower risk of DM, although there was no
statistically significant heterogeneity between progestagenswith regard to diabetes risk
(de LauzonGuillain et al. 2009). A metaanalysis concerning components of metabolic
syndrome,which included107randomizedcontrolled trialsofat least8weeksduration
showed similarly that HT reduced the risk of newonset DM (by 30%) (Salpeter et al.
2006b).










et al. 1999) but it is still unclear ifmenopause per semodifies these increases (Bentley
Lewisetal.2007).Comparedwithpremenopausalwomen,postmenopausalwomenhave
similarglucoseandinsulinlevelsandarelativelyminordeteriorationinglucosetolerance,
but theyhave increased insulin resistance,produce less insulinandclear itmoreslowly
(Godsland2005).Thesechanges,alongwithdyslipidemiaandhypertension,areconsistent
withmetabolicsyndromeandpredictT2DM(Lorenzoetal.2003)andCHD(Rewersetal.
2004) in postmenopausal women. The results of several studies indicate that ET may
attenuate theaccumulationof central fat inpostmenopausalwomen (Gambacciani et al.
1997,Davis et al. 2000,Gambacciani et al. 2001, Sorensen et al. 2001) and thiswas also
reported in the metaanalysis (Salpeter et al. 2006b), where HT use was found to be
associatedwith an increase in lean bodymass and a decrease in abdominal fat, which
couldpartiallyexplainthereducedriskofDMinHTusers.HTcanhavefavorableeffects
onbody fatdistributionandcould, therefore,act toreduceDMriskvia thismechanism




that normally experienced at the time ofmenopause. In the PEPI trial (Espeland et al.
1997), less weight gain or increase in waist and hip circumferences were registered in
womenwho received EP therapy versus placebo. Similarly, in the Danish osteoporosis
preventionstudy(Jensenetal.2003),HTuseseemedtohaveaweightreducingeffect.In
the Heart and Estrogen/Progestin Replacement Study (HERS) (Kanaya et al. 2003),
hormone therapywas associatedwith a significantdecrease inwaist circumference, but
thischangedidnotmediate theeffectonHTonDMrisk. Inourstudy (and in theE3N
study)wewere not able to assess changes in abdominal fat or leanmass that could be
inducedbyHT.
 There are several mechanisms other than effects on adipose tissue and body fat
distributionbywhichHTmaybeprotectiveagainstDM.Inaprospectivestudyofolder
women not using HT, endogenous levels of bioavailable E2 and testosterone were
positively associated with levels of fasting glucose, insulin, and estimated insulin
resistance,whereasonlybioavailabletestosteronepositivelypredictedincidentDM(Ohet
al. 2002). Positive associations between bioavailable E2 and testosterone with insulin
resistancehavealsobeenobservedinacrosssectionalstudyofuntreatedpostmenopausal
women (Kalish et al. 2003). Low levels of sex hormonebinding globulin are related
negativelytoobesity,insulinresistance,andincidenceofDMinpostmenopausalwomen
(Lindstedt et al. 1991, Haffner et al. 1992, Haffner et al. 1993). Hyperandrogenicity in
womeniscloselyassociatedwithinsulinresistanceandriskfactorsofCVDandT2DM.
 Theprocesses underlying the changes in glucose and insulin levelswith exposure to
estrogen are not fully understood, but several mechanisms have been hypothesized.
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Estrogen may have a direct effect on secretion of insulin by the pancreas. Estrogen
receptorsarepresentinpancreaticbetacells(SutterDub2002),andestrogenincreasesthe




 Women taking estrogen have increased circulating growth hormone levels (Maw &
Wynn1972),butthisisseenonlywithoraladministrationandisnotaccompaniedbyany
increase in insulinlike growth factors (DawsonHughes et al. 1986). These changes in
growthhormoneconcentrationsarenotrelatedtochangesinglucosemetabolism(Maw&
Wynn1972), and insulinlikegrowth factor levels areunaffectedbyestrogens (Dawson
Hughesetal.1986).Favorableeffectsofestrogenonthepancreasareapparentfollowing







glucose concentrations and worsening glucose tolerance (Godsland et al. 1990, The
WritingGroupforthePEPITrial1995,Triusuetal.2000,Zhangetal.2002,Margolisetal.
2004). Basal levels of insulin are unchanged or reduced, whereas glucosestimulated
insulin is enhanced. In humans, estrogen deficiency (resulting, for example, from





the hyperglycemic action of glucagon, and following ovariectomy, estrogen
administrationdecreases thehyperglycemicactionofglucagon (AhmedSorour&Bailey














 The Social Insurance Institution (SII) carries out reimbursement of the costs of
medicines used for severe and chronic illnesses. The National Registry of Specially
Refunded drugs and the National Cause of Death Register have made it possible to
reliablydetermineCHDeventsbetter thanwouldbepossiblebywayofquestionnaires.
However,wecouldnotdeterminethedoseresponseeffectofcalciumsupplementationon
CHDmorbidity because use of calcium supplementswas based on selfreports, not on
registry data. The supplements contain different doses of calcium. Therefore, it was
difficult to determine the daily dose of calcium in this large populationbased cohort
study. Nonetheless, our main results suggest a harmful effect of the use of calcium
supplementationonCHDrisk.
 It is well known that CHD is a leading cause of death in postmenopausal women
around the world, and the incidence of CHD increases substantially after menopause.
Many postmenopausalwomen use calcium or calcium + vitaminD supplementation to
preventosteoporosis,andforalongtimetherehasbeenspeculationaboutHTandCHD
risk. However, in several recent clinical trials concerningHT, women have been given
calciumorcalcium+vitaminD.Infact,theadverseeffectofHTonCHDeventsinthese
trials may have been modified by calcium supplementation. The WHI investigators
published the resultsofa randomizedcontrolled trialon theeffectof calciumcarbonate
andvitaminDsupplementation(Hsiaetal.2007).Themainresultwasthattherewasno
overalleffectofcalcium/vitaminDsupplementsoncardiovascularevents.Amongwomen
taking calcium/vitaminD supplements, theHR formyocardial infarctionorCHDdeath
was 1.04 (95% CI 0.92–1.18). For the combined endpoint of MI, CHD death, coronary
arterybypassandpercutaneouscoronaryintervention,theHRwas1.08(95%CI0.99–1.91)
(Hsiaetal.2007).ItisgoodtoknowthattheWHIinvestigatorsusedlowdosevitaminD
supplements. Vitamin D deficiency has been associatedwith an increased risk of CVD




placebo (n=739) and they were followed for over 5 years. The effects of calcium
supplementation on MI, stroke and sudden death were determined. There was a
significant increase in the rates of vascular events in the women allocated to calcium
supplementation(Bollandetal.2008).Theresultsweresimilartothefindingsinastudy
byPrinceetal.(2006)whorandomized1460postmenopausalwomentocalciumcarbonate
orplacebo for5years. In thecalciumsupplementationgroup, the riskof ischemicheart
diseaseincreasedby12%(NS)(Princeetal.2006).
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 The results of a metaanalysis carried out by Bolland et al. (Bolland et al. 2010)
confirmedtheseresults. In thispooledanalysisconcerningaround12000participants in





risk ofMIwith calcium observed in six of the seven trials inwhich at least one event
occurred,althoughnoindividualtrialrevealedastatisticallysignificantlyeffect.Therisk
ofMIwith calcium tended tobegreater in thosewithdietary calcium intake above the
medianbutwasnotindependentofage,sex,andtypeofsupplement.Consistentwiththe
results reported by Bolland et al. and Prince and coworkers, we found that calcium
supplementationinCHDfreewomentendedtoincreasetheriskofCHD(by24%).
 In our study, it is impossible to verifywhether the increased risk of CHD is purely
relatedtocalciumorvitaminD.Inarandomized5yeartrialcarriedoutbyTuppurainen
etal.(Tuppurainenetal.1995)vitaminDsupplementationincreasedcholesterollevelsin
464 healthy postmenopausalwomen (a subgroup of theOSPTRE study population). In
addition,Heikkinenetal.(Heikkinenetal.1997)reportedthatcholecalciferol(300IU/day)
increased serum LDLcholesterol levels by 4.1% (p = 0.035) in healthy early
postmenopausalwomen.Theresultsofthesestudies(Tuppurainenetal.1995,Heikkinen
et al. 1997) confirmed the positive effect of HT with sequential estradiol valerate and
cyproteroneacetateonserumlipidconcentrations.However, thebeneficialeffectsofHT
on serum LDLcholesterol were reduced when estradiol valerate was combined with
vitaminD3(Heikkinenetal.1997).
 Therelationshipsbetweendietarycalciumintakeandcardiovasculareventshavealso






40%lowerrateofcardiovascularmortalitythanthose inthe lowest fourth(Bosticketal.
1999),andthoseinthehighestfifthofcalciumintakehada30–40%lowerriskofischemic




observational and interventional studies of calcium supplements, these observational
studies do not show increased cardiovascular riskswith higher dietary calcium intake.
Therefore, these differences suggest that cardiovascular risks from high calcium intake
mightberestrictedtouseofcalciumsupplements.
 Current findings are consistent with the results of trials among patients with renal




nonusers, was not increased significantly, although the relative risks for each fifth of
supplementintakerangedbetween1.02and1.07(AlDelaimyetal.2003).
 AlthoughtheconclusionsinametaanalysisbyBollandetal.(Bollandetal.2010)andin
a reviewbyWang et al. (Wang et al. 2010) are not convergent, their results concerning
calciumsupplementationaresimilar.Wangetal.publishedasystematicreviewinwhich
they reported that five prospective studies of patients receiving dialysis and one study
involving a general population showed consistent reductions in CVDmortality among
adultswhoreceivedvitaminDsupplements.Afurtherfourprospectivestudiesofinitially
healthy persons showed no differences in the incidence of CVD between calcium
supplement recipients and nonrecipients. The results of secondary analysis of 8
randomized trials showed a slight but statistically nonsignificant reduction inCVD risk
(pooledRR0.90,95%CI0.77–1.05)withvitaminDsupplementationatmoderatetohigh
doses(approximately1000IU/d)butnotwithcalciumsupplementation(pooledRR1.14,
95%CI 0.92–1.41), or a combinationofvitaminDand calciumsupplementation (pooled
RR 1.04, 95% CI 0.92–1.18) compared with placebo. Wang et al. concluded that the
evidence from limited data suggests that vitamin D supplements at moderate to high
doses may reduce CVD risk, whereas calcium supplements seem to have minimal





vitamin D) are associated with an increased risk of MI. The results of our study are





calcium supplements and cardiovascular risk. In the study Bolland and colleagues
explored the possibility that findings in theWHI studymay have beenmasked by the
widespreaduseofpersonalcalciumsupplements(Bollandetal.2011).Originally,theWHI
investigatorsreportednoeffectofcalciumandvitaminDsupplementsoncardiovascular
events, but most of the participants were taking personal, nonprotocol calcium
supplements at study entry. Among 16 718 women, 46% of whom were not taking
personal calcium supplements at randomization, the hazard ratios for cardiovascular
eventsinconnectionwithcalciumandvitaminDsupplementsrangedfrom1.13to1.22(p




triallevel data were available for 28072 participants from eight trials of calcium
77
supplements and WHI CaD participants not taking personal calcium supplements.
CalciumsupplementsandcalciumplusvitaminDsupplements increased the riskofMI
(RR1.24,95%CI1.07 to1.45,p=0.004)and thecompositeofMIor stroke (1.15,95%CI
1.03to1.27,p=0.009)(Bollandetal.2011).
 As Bolland and colleagues state, this analysis of theWHI CaD study data does not
provide definitive evidence of an adverse effect of calcium and vitamin D on
cardiovascularevents.However,whenthesedataarepooledwithpreviouslyunpublished
data from two other placebocontrolled trials of calcium and vitamin D, there are
consistent increases in the risk ofmyocardial infarction and stroke that are statistically
significant and are of similar size to the risks observedwith calcium supplements used
withoutvitaminD.Further,whentheresultsregardingcalciumandvitaminDaretaken
togetherwiththosefromtrialsofcalciumusedasmonotherapy, theyprovideconsistent
evidence from 13 randomized, placebocontrolled trials involving about 29 000
participants with about 1400 cases of myocardial infarction and stroke that calcium
supplementswithorwithoutvitaminDincreasetheriskofcardiovascularevents(Bolland
etal.2011).
 According to the results of animal experimental and human observational studies,





mechanisms by which calcium supplements could have possible negative effects on





associatedwith increased risks of cardiovascular events and death (Nilsson et al. 2002,
Vestergaardetal.2003).Ingestionofcalciumsupplementsmightaccountfortheabsence
of detrimental vascular effects of dietary calcium intake in the observational studies
reviewed (Green et al. 2003). Vascular calcification is predictive of vascular event rates
(Pletcher et al. 2004), and the process of vascular calcification is similar to osteogenesis
(Demer1995).Becausecalciumsupplementsincreasebonedensityitispossiblethatthey
mayalsoincreasevascularcalcificationandtherebyvascularevents.








 Rasouli andKiasari (Rasouli&Kiasari 2006) demonstrated in their study that serum
calciumandphosphoruswithintheirnormalconcentrationrangesareassociatedwiththe




 The results of our 7year populationbased followup study suggest that calcium
supplements are associatedwith an increased risk of CHD in postmenopausalwomen.
Our findings agreewith those of Bolland et al. (Bolland et al. 2008, Bolland et al. 2010,
Bollandetal.2011)suggestingthatthispotentiallydetrimentaleffectshouldbebalanced
against the benefits of calcium on bone, particularly in olderwomen. The results need














the accuracy of selfreports of HT use. Selfreporting via a postal inquiry is a reliable
methodof recording longtermHTuse inwomenbeforeoldage.Specificationofbrand
names improvesaccuracy.Selfreporting isnot reliable fordetecting shorttermHTuse,
and it may overestimate the overall duration of HT use. Higher educational status is
associatedwithahigherprevalenceofHTuseandmoreaccurateselfreportingofHTuse.
 The results suggest that a history ofHTdoes not affect overall orCHDmortality in
women.Morethan5yearsofHTmayincreasetheriskoffatalbreastcancer.Theresults
alsoshowthatuseofHTisprotectiveagainsttype2DM,and, inaddition,theysuggest
that use of calciumor calcium+ vitaminD supplements appears to increase the risk of
CHDamongwomenbeforeoldage.
 The present findings may help clinicians to explain the possible effects of HT on
menopausalwomen. IfHT is needed in connectionwithmenopausal symptoms and/or







 A postal inquiry is a reliable method of recording longterm use of HT. Higher
educational status is related to more frequent selfreporting and to a higher
prevalenceofHTuse.

 A history of HT use is not associated with overall or CHD mortality in
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KYKS ja Kuopion yliopisto aloittavat tänä vuonna tutkimuksen, 
jonka tarkoituksena on saada lisätietoa vaihdevuosi-ikäisten 
naisten luukadosta eli osteoporoosista, sen vaaratekijöistä ja 
ehkäisymahdollisuuksista. Tämä kyselylomake lähetetään kaikille 
Kuopion läänin 47-56 -vuotiaille naisille. 
 
Luukato on huomattava kansanterveysongelma. Se kehittyy hitaasti 
iän karttuessa, nopeammin naisilla vaihdevuosien jälkeen hor-
monitoiminnan vähentyessä. Vanhuksilla se on usein niin vaikea-
asteinen, että heidän luunsa murtuvat helposti. 
 
Tämä on tieteellinen tutkimus, jossa kaikki tiedot käsitellään 
ehdottoman luottamuksellisesti ja tulokset julkaistaan tilastoina 
siten, että henkilöllisyytenne pysyy salassa. 
 







Seppo Saarikoski Esko Alhava Risto Honkanen 
LKT, vs. professori LKT, apul.professori LKT, dosentti 
KYKS, naistentautien KYKS, kirurgian Suomen Akatemian 





Kysymyksiin vastataan rengastamalla Teille sopivan vaihtoehdon 
numero tai kirjoittamalla kysytty tieto selvästi sitä varten 
varattuun tilaan. Lukekaa ennen vastausta koko kysymys. Jos ette 










Jos vastausvaihtoehdon jälkeen on viiva, kirjoittakaa viivalle 




Onko Teille suoritettu SYNNYTINELINLEIKKAUKSIA? Merkitkää keisari-




2 Kyllä, keisarileikkaukset  19____, 19____, 19____, 19____ 
  sterilisaatio . . . . . . . . . . . . . . . 19____ 
  muut syyt ________________________________ 19____ 
  __________________________________________ 19____ 
  __________________________________________ 19____ 
 
Vastatkaa KAIKKIIN Teitä koskeviin kysymyksiin. Postittakaa 
täytetty lomake oheisessa palautuskuoressa. Postimerkki ei 
tarvita, sillä vastaanottaja maksaa postimaksun. (Säilyttäkää 





Jos nimenne, osoitteenne tai henkilötunnuksenne etusivun tarrassa 










Naistentauteihin liittyvät kysymykset 
 
 
 1. Onko Teillä vaihdevuosioireita (esim. hikoilua tai "kuumia 
aaltoja")? 
 
  1 Ei 
  2 Kyllä 
 
 
2. Mikä oli viimeisten kuukautistenne alkamispäivä? 
 
   ____.____.19____ 
 
 
 3. Kuinka kauan olette käyttänyt naishormoneja (ehkäisypillerit 
mukaan lukien) yhteensä? 
 
1 En ole käyttänyt koskaan (siirtykää kysymykseen 6) 
2 Olen käyttänyt yhteensä alle vuoden 
3 Olen käyttänyt yhteensä ____ vuotta 
 
4. Mihin tarkoituksiin olette hormoneja käyttänyt ja kuinka 
kauan? 
   1 Raskauden ehkäisy, tavalliset ehkäisypillerit ___ vuotta 
   2 Raskauden ehkäisy, minipillerit . . . . . .  ___ vuotta 
   3 Vaihdevuosioireet . . . . . . . . . . . . .  ___ vuotta 
   4 Munasarjojen poiston jälkeinen korvaushoito ___ vuotta 
   5 Muu tarkoitus, mikä ________________________ ___ vuotta 
5. Minkä nimisiä hormonitabletteja olette pääasiassa käyttänyt 
vaihdevuosioireisiinne? 
 
   __________________________________________________________ 
 6. Montako kertaa olette ollut raskaana yhteensä? _____ kertaa 
   
   raskaus päättyi lapsen syntymään  _____ kertaa 
  




7. Onko teille suoritettu SYNNYTINELINLEIKKAUKSIA? Merkitkää 
keisarileikkausten ja sterilisaation alle muiden leikkausten 
syyt (esim. myooma, munatorviraskaus, laskeuma, kohdun kaula-
osan syöpä tai munasarjan hyvänlaatuinen kasvain) ja leikkaus-
vuodet.  
 
   1 Ei (siirtykää kysymykseen 9.) 
   2 Kyllä, keisarileikkaukset 19____, 19____, 19____, 19____ 
     sterilisaatio . . . . . . . . . . . . . . 19____ 
     muut syyt _______________________________ 19____ 
     _________________________________________ 19____ 
     _________________________________________ 19____ 
     _________________________________________ 19____ 
 8. Mitä leikkauksissa poistettiin? (Merkitkää kaikki Teitä 
koskevat vaihtoehdot leikkausvuosineen). 
  
   1 Vain kohtu tai sen runko . . . . . . . . . . . .  19____ 
   2 Kohtu ja toinen munasarja  . . . . . . . . . . . 19____ 
   3 Kohtu ja molemmat munasarjat . . . . . . . . . .  19____ 
   4 Toinen munasarja tai sen osa . . . . . . . . . .  19____ 
   5 Molemmat munasarjat tai viimeinenkin 
    munasarja  . . . . . . . . . . . . . . . . . . . 19____ 
   6 Osa kohdun rungosta (esim. myooma) . . . . . . .  19____ 
   7 Kohdun kaula tai sen osa . . . . . . . . . . . .  19____ 
   8 Jokin muu synnytinelinten osa  . . . . . . . . . 19____ 
   9 Ei mitään yllämainituista 
  
 9. Oletteko saanut synnytinelimiin kohdistuvaa sädehoitoa? 
 
   1 En 












Elintapoihin ja terveyteen liittyvät kysymykset 
 10. Kuinka ruumiillisesti rasittava työnne on keskimäärin ollut 
VIIMEISEN 12 KUUKAUDEN aikana? 
 




5 Raskasta  
 
 
 11. Harrastatteko säännöllisesti kuntoliikuntaa? 
 
1 En 
2 Kyllä, keskimäärin ___ tuntia viikossa 
 
 
12. Oletteko tupakoinut koskaan elämänne aikana? 
 
   1 En (siirtykää kysymykseen 15) 
   2 Kyllä 
 
 13. Oletteko koskaan tupakoinut säännöllisesti (= lähes joka 
päivä ainakin vuoden ajan)? 
  
   1 En (siirtykää kysymykseen 15) 
   2 Kyllä, yhteensä ____ vuotta  
  
 
 14. Kuinka paljon poltatte nykyisin? 
 
   1 Olen lopettanut tupakoinnin vuonna 19 ___ 
   2 Poltan nykyisin keskimäärin ____ savuketta päivässä 
 
 15. Kuinka monta desilitraa maitotuotteita (esim. maitoa, piimää, 
jogurttia, viilejä ym.) käytätte päivässä? 
 
   keskimäärin  _______ desilitraa 
 
 
 16. Kuinka monta siivua juustoa syötte päivässä? 
 
   keskimäärin  _______ siivua 
 
 
 17. Pituutenne? _______ cm 
 
 









 19. Onko Teillä ollut luunmurtumia täytettyänne 15 vuotta? 
 
   1 Ei (siirtykää kysymykseen 20) 
   2 Kyllä, missä luissa? ___________________________ 19____ 
       ___________________________ 19____ 
      ___________________________ 19____ 
      ___________________________ 19____ 
      ___________________________ 19____ 
 
 20. Kuinka ja minä vuosina murtumat syntyivät? 
 
   1 Kaaduin . . . . . . . . 19_____, 19_____, 19_____ 19____ 
   2 Putosin . . . . . . . . . . .  . . . . . . . . .  19____ 
   3 Polkupyörätapaturma . . . . . . . . . . . . . . . 19____ 
   4 Auto-onnettomuus  . . . . . .. . . . . . . . . .  19____ 
   5 Muuten, miten? _________________________________  19____ 
    Muuten, miten? __________________________________ 19____ 
 
 21. Onko LÄÄKÄRI TODENNUT Teillä seuraavia sairauksia? (Rengas-
takaa kaikki Teitä koskevat sairaudet) 
 
   1 Lääkehoitoa vaativa verenpainetauti 
   2 Korkea veren rasvapitoisuus (kolesteroli) 
   3 Sepelvaltimotauti (sydänveritulppa tai angina pectoris) 
   4 Muu sydäntauti kuten vajaatoiminta tai läppävika 
   5 Aivohalvaus, aivoverenvuoto tai aivoveritulppa 
   6 Alaraajan laskimotukos 
   7 Keuhkoveritulppa 
   8 Insuliinihoitoinen sokeritauti 
   9 Krooninen munuaissairaus 
   10 Krooninen maksasairaus 
   11 Nivelreuma 
   12 Epilepsia 
   13 Astma tai muu pitkäaikainen keuhkosairaus 
   14 Maitosokerin imeytymishäiriö (laktoosi-intoleranssi) 
   15 Kilpirauhasen liikatoiminta 
   16 Lisäkilpirauhasen liikatoiminta 
   17 Alkoholismi 
   18 Pitkäaikainen mielisairaus 
   19 Luukato eli osteoporoosi 
   20 Syöpäsairaus, mikä? ____________________________________ 
   21 Muut pitkäaikaiset sairaudet, mitkä? ___________________ 
    ________________________________________________________ 











 22. Onko Teillä virtsanpidätyskyvyn ongelmia? 
 
   1 Ei 
 




 23. Käytättekö säännöllisesti LÄÄKÄRIN MÄÄRÄÄMIÄ lääkkeitä? Jos 
käytätte, merkitkää käytön syy, lääkkeen nimi ja hoidon kesto. 
 
   1 En 
 
   2 Kyllä 
 
    Käytön syy Lääkkeen nimi Hoidon kesto 
 
    _____________________ __________________ _____ vuotta 
    _____________________ __________________ _____ vuotta 
    _____________________ __________________ _____ vuotta 
    _____________________ __________________ _____ vuotta 
    _____________________ __________________ _____ vuotta 
    _____________________ __________________ _____ vuotta 
 
 24. Käytättekö (ilman lääkärin määräystä) kalsiumia tai D-
vitamiinia sisältäviä lääkkeitä tai luontaisvalmisteita? 
 
   1 En 
 
   2 Kyllä, mitä? _____________________ päiväannos ________ 
     mitä? _____________________ päiväannos ________ 
 
 
 25. Oletteko pitkäaikaisesti työkyvytön? 
 
   1 En 
   2 Kyllä, miksi? __________________________________________ 
 
 
 26. Oletteko sairaala- tai muussa laitoshoidossa tällä hetkellä? 
 
   1 En 
  











 27. Oletteko halukas saapumaan ilmaiseen luuntiheysmittaukseen 
(kivuton ja vaaraton röntgentutkimus) KYKS:iin? (Matkat Teidän 
on kustannettava itse). 
 
   1 Kyllä 
 




 28. Oletteko halukas osallistumaan 5 vuotta kestävään ehkäisytut-
kimukseen, jos Teillä on alkava luukato? 
 
  (Tutkimus suoritetaan siten, että halukkaat jaetaan arvalla 4 
ryhmään. Yksi ryhmä saa hormonihoitoa, toinen hormoni- ja D-
vitamiinihoitoa, kolmas D-vitamiinihoitoa ja neljäs ryhmä tab-
letteja, jotka eivät sisällä vaikuttavaa ainetta. Tutkittavat 
ja hoitohenkilökunta eivät tiedä, mihin ryhmään kukin kuuluu. 
Tutkimusryhmää seurataan vuosittain KYKS:n naistentautien 
poliklinikalla. Tutkimukset ovat ilmaisia. Teidän tarvitsee 
maksaa itse ainoastaan poliklinikkamaksut ja matkat.) 
 
   1 Kyllä 
 




 29. Oletteko halukas muuhun tätä aihetta käsittelevään kyselytut-
kimukseen? 
 
   1 Kyllä 
 




 30. Puhelinnumeronne kotiin: 9_____ - _______________ 
 

























KYS & Kuopion yliopisto 
10.5.1994 
Arvoisa Vastaanottaja 
Vuonna 1989 lähetimme jokaiselle 14000:lle silloin Kuopion läänissä asuvalle 47-56-
vuotiaalle naiselle kyselyn. Kyselyyn vastanneista valittiin arvalla 3200, joille suori-
tettiin luuntiheysmittaukset Kuopion yliopistollisesssa sairaalassa. Mitatut ovat vas-
tanneet myös tämän jälkeen kyselyihimme. Aktiivinen osallistumisenne on tehnyt 
tämän tutkimuksen mahdolliseksi ja lisää merkittävällä tavalla tietoa keski-ikäisten 
naisten luukadon ja murtumien syistä ja ehkäisystä. 
Tämänkertaisen kyselyn tarkoituksena on kerätä tietoa luunmurtumista ja muusta 
terveystilanteestanne. Olette saattanut jo vastata eräisiin nyt esitettäviin tai niitä muis-
tuttaviin kysymyksiin. Pyydämme Teitä jokaista nyt kuitenkin VASTAAMAAN KAIKKIIN 
KYSYMYKSIIN. Se on erittäin tärkeää tutkimuksemme onnistumisen kannalta.  
Antamanne tiedot käsitellään luottamuksellisesti ja julkaistaan vain tilastoina tieteel-
lisissä julkaisusarjoissa niin että henkilöllisyytenne pysyy salassa. Merkittävät tut-
kimustulokset tullaan julkistamaan myös niin että Te saatte niistä tietää. 
Kiitämme Teitä myönteisestä suhtautumisesta tutkimukseemme. 
Seppo Saarikoski   Esko Alhava   Risto Honkanen 
LKT, professori   LKT, professori  LKT, vs. professori 
KYS, naistentautien klinikka  KYS, kirurgian klinikka Kuopion yliopisto 
    Marjo Tuppurainen   Heikki Kröger 
    LL, apulaislääkäri   LKT, erikoislääkäri 
    KYS, naistentautien klinikka  KYS, kirurgian klinikka 
                                                      
Lomakkeen täyttöohjeet 
Kysymyksiin vastataan rengastamalla Teitä koskevan vastausvaihtoehdon numero ja 
kirjoittamalla kysytty tieto sitä varten varattuun tilaan. Mikäli kysymyksen vastaustila ei 
riitä, jatkakaa viimeiselle sivulle. Jos ette muista kysyttyä asiaa, arviokin riittää.
Esimerkki:  Onko äidillänne tai isällänne ollut lonkkamurtumaa? 
    0   ei   1   äidillä vuonna 19_____ 2   isällä vuonna 19_____ 
KYSYMYS-  JA  VASTAUSOSA  ALKAA 
 4. Kuinka  monta  kertaa  olette  ITSE  KAATUNUT  VIIMEKSI  KULUNEEN VUODEN (12 KK) 
AIKANA,  kun  mukaan  luetaan  nekin kaatumiset, joista selvisitte vammoitta? (Ellette ole
kaa tunut,  merkitkää  0  ja  siirtykää kysymykseen 11)
   _________ kertaa 
 5. Missä kuussa kaaduitte viimeksi?   
   1   Tammi 2   Helmi 3   Maalis   4   Huhti  5    Touko  6    Kesä     
   7   Heinä 8   Elo  9   Syys 10   Loka 11   marras   12   Joulu 
 6. Missä kaaduitte viimeksi?
          1   Kotona sisällä  2   Kotipihalla      3   Kadulla tai tiellä 
          4   Muualla sisällä   5   Muualla ulkona 
 7. Miten kaaduitte viimeksi?
   1   Kaaduin portaita ylös mennessä  4   Kompastuin   
   2   Kaaduin portaita alas mennessä  5   Kaaduin muuten, miten? ______________ 
   3   Liukastuin          __________________________________ 
 8. Millaiselle alustalle kaaduitte viimeksi?
   1  Kivikovalle (esim. kivi, betoni, kylpyamme, puhdas jää) 
   2 Puolikovalle (esim. parketti, muovimatto, kova soratie, luminen jää) 
   3   Pehmeälle (esim. paksu matto, luminen tie, nurmikko, pehmeä soratie) 
   4   Erittäin pehmeälle (esim. paksu lumi, heinä, sammal, hiekka) 
 9. Mihin ruumiinosaan kohdistui isku kaatuessanne viimeksi? 
   1   Päähän      4   Lonkkaan, pakaraan    
   2   Käteen, yläraajaan   5   Muuhun vartaloon             
   3  Jalkaan, alaraajaan   
10. Kävittekö lääkärissä viimeisen kaatumisenne vuoksi?
   1   En
   2   Kyllä, minkä vamman vuoksi? ______________________________________________ 
1.  Onko ÄIDILLÄNNE TAI ISÄLLÄNNE ollut LONKKAMURTUMAA? 
0   Ei     1   Äidillä vuonna 19______     2   Isällä vuonna 19______ 
2. Äitinne syntymävuosi ________   1   Äiti elossa           2   Kuollut vuonna _______ 
3. Isänne syntymävuosi ________  1   Isä elossa  2   Kuollut vuonna _______   
11. Onko  Teillä  ollut  LÄÄKÄRIN  TOTEAMIA LUUNMURTUMIA 1.1.1989 JÄLKEEN? Ilmoittakaa  
 jokaisesta murtumaan johtaneesta tapaturmasta allaolevan luettelon mukaiset tiedot.
(Ellette muista sattumisaikaa, arvioikaa kuukausi ja vuosi).
0   Ei luunmurtumia 1.1.89 jälkeen;  rengastakaa 0 ja siirtykää kysymykseen 12 
1.  LUUNMURTUMAAN JOHTANUT TAPATURMA Sattumisaika _____._____19_____
    Sattumistapa    1   polkupyörätapaturma 5   isku, iskeytyminen 
      2   auto-onnettomuus  6   muu putoaminen, miten  
      3   kaatuminen         korkealta?_______ metristä 
      4   putoaminen portaissa 7   muu, mikä?___________________ 
    Hoitopaikka 1   sairaala, mikä?__________________________________________ 
      2   terveyskeskus, mikä?_____________________________________ 
      3   muu, mikä?_____________________________________________ 
        Murtuneet luut _________________________________________________________
       Toteamistapa    1   röntgenkuva  2   lääkäri totesi muulla tavoin 
        Hoito  1   ei hoitoa 2    kipsi 3   leikkaus 4   muu 
       Lopputulos  1   parantunut  2   haittaa hieman 3   haitaa paljon   
   2.  LUUNMURTUMAAN JOHTANUT TAPATURMA Sattumisaika _____._____19_____
    Sattumistapa    1   polkupyörätapaturma 5   isku, iskeytyminen 
      2   auto-onnettomuus  6   muu putoaminen, miten  
      3   kaatuminen         korkealta?______ metristä 
      4   putoaminen portaissa 7   muu, mikä?___________________ 
    Hoitopaikka 1   sairaala, mikä?__________________________________________ 
      2   terveyskeskus, mikä?_____________________________________ 
      3   muu, mikä?_____________________________________________ 
        Murtuneet luut _________________________________________________________
       Toteamistapa    1   röntgenkuva   2   lääkäri totesi muulla tavoin 
        Hoito  1   ei hoitoa 2    kipsi  3   leikkaus 4   muu 
       Lopputulos  1   parantunut  2   haittaa hieman 3   haitaa paljon   
3.  LUUNMURTUMAAN JOHTANUT TAPATURMA Sattumisaika _____._____19_____
    Sattumistapa    1   polkupyörätapaturma 5   isku, iskeytyminen 
      2   auto-onnettomuus  6   muu putoaminen, miten  
      3   kaatuminen         korkealta?_______ metristä 
      4   putoaminen portaissa 7   muu, mikä?___________________ 
    Hoitopaikka 1   sairaala, mikä?__________________________________________ 
      2   terveyskeskus, mikä?_____________________________________ 
      3   muu, mikä?_____________________________________________ 
        Murtuneet luut _________________________________________________________
       Toteamistapa    1   röntgenkuva   2   lääkäri totesi muulla tavoin 
        Hoito  1   ei hoitoa 2    kipsi 3   leikkaus 4   muu 
       Lopputulos  1   parantunut  2   haittaa hieman 3   haitaa paljon   
4.  LUUNMURTUMAAN JOHTANUT TAPATURMA Sattumisaika _____._____19_____ 
    Sattumistapa    1   polkupyörätapaturma 5   isku, iskeytyminen 
      2   auto-onnettomuus  6   muu putoaminen, miten  
      3   kaatuminen         korkealta?_______ metristä 
      4   putoaminen portaissa 7   muu, mikä?___________________ 
    Hoitopaikka 1   sairaala, mikä?__________________________________________ 
      2   terveyskeskus, mikä?_____________________________________ 
      3   muu, mikä?_____________________________________________ 
        Murtuneet luut _________________________________________________________
       Toteamistapa    1   röntgenkuva   2   lääkäri totesi muulla tavoin 
        Hoito  1   ei hoitoa 2    kipsi 3   leikkaus 4   muu 
       Lopputulos   1   parantunut               2   haittaa hieman 3   haitaa paljon  
21. Oletteko KOSKAAN ELÄMÄNNE AIKANA tupakoinut säännöllisesti ( = lähes joka päivä aina-
 kin vuoden ajan)?
0   En ole koskaan tupakoinut säännöllisesti;  siirtykää kysymykseen 23 
1   Olen tupakoinut yhteensä ________ vuotta keskimäärin ________ savuketta päivässä 
22. Tupakoitteko NYKYISIN? 0   En  1   Kyllä, keskimäärin______ savuketta päivässä 
23. Nykyinen painonne?  __________ kg 
18. Montako lasillista (lasillinen on 2 dl) maitoa ja piimää yhteensä käytitte päivässä 11-17 VUO- 
 DEN IÄSSÄ?  
  Keskimäärin _______ lasillista 
19. Harrastitteko 11-17 VUODEN IÄSSÄ LIIKUNTAA KOULULIIKUNNAN LISÄKSI? 
0   En  
1   Kyllä, kuntoliikuntaa; laji __________________________________  ______ vuoden ajan 
2   Kyllä, kilpaurheilua; laji ___________________________________  ______ vuoden ajan 
20. Tupakoitteko 11-17 VUODEN IÄSSÄ? 
0   En tupakoinut lainkaan 
1   Tupakoin keskimäärin ______ savuketta päivässä  ______ vuoden ajan 
12. Merkitkää tähän lastenne syntymävuodet (myös kuolleena syntyneiden). 
0   En ole synnyttänyt; rengastakaa 0 ja siirtykää kysymykseen 13 
1   Olen synnyttänyt vuosina 19____   19____   19____   19____   19____   19____ 
       19____   19____   19____   19____   19____   19____  
13. Mikä oli viimeisten kuukautistenne alkamispäivä?    ______.______.19______ 
14. Jos  kuukautisenne  ovat  nyt  olleet  poissa vähintään 6 kk, oliko kuukautisten loppuminen  
 luonnollinen vai leikkauksella aiheutettu?
1   Luonnollinen   
2   Leikkauksella aiheutettu 
3   Muu loppumissyy, mikä? ___________________________________________________ 
4   Kuukautiset jatkuvat tai ovat olleet poissa vähemmän kuin 6 kk 
15. Onko Teiltä poistettu molemmat munasarjat? 
0   Ei 
     1   Kyllä; viimeisen munasarjan poistovuosi 19_______ 
16. Onko Teiltä poistettu kohtu? 
0   Ei 
1   Kyllä, vuonna 19_______, leikkaussyy? _______________________________________
17. Oletteko käyttänyt naishormonihoitoa tabletteina, geelinä tai laastarina 1.6.89 jälkeen?
 (Jos olette käyttänyt, merkitkää kullekin vuodelle käyttökuukausien luku 0 - 12) 
          0   En ole käyttänyt lainkaan; rengastakaa 0 ja siirtykää kysymykseen 18 
          1   Olen käyttänyt  _______ kk 1989  _______ kk 1992 
       _______ kk 1990  _______ kk 1993 
        kk 1991  kk 1994 
24. Kuinka  monta  desilitraa  maitotuotteita  (esim.  maitoa,  piimää,  jogurttia,  viileja ym.) käy- 
 tätte päivässä NYKYISIN? 
  Keskimäärin _____ desilitraa 
25. Kuinka monta viipaletta juustoa syötte päivässä nykyisin?   Keskimäärin  _____ viipaletta 
26. Montako kupillista kahvia juotte päivässä nykyisin?  Keskimäärin  _____ kupillista 
27. Mikä on KUUKAUDESSA käyttämänne alkoholijuomien määrä? 
  Olutta  keskimäärin  ________  pulloa 
  Viinejä  keskimäärin  ________  lasillista 
  Väkeviä  keskimäärin  ________  ravintola-annosta (4cl=0.4 dl) 
28. Kuinka  monta  kilometriä  VIIKOSSA olette KÄVELLYT TAI JUOSSUT VIIMEKSI KULUNEEN 
 VUODEN (12 KK) AIKANA kaiken kaikkiaan mukaan lukien työmatkat ja liikkuminen työssä?
  Keskimäärin _______ km viikossa talvella ja  ________ km viikossa kesällä 
29. Oletteko  harrastanut säännöllisesti VAPAA-AJAN kuntoliikuntaa viimeksi kuluneen vuoden 
 aikana? 
0   En                  
1   Kyllä, keskimäärin _____ tuntia _____ minuuttia viikossa talvella  
             ja _____ tuntia _____ minuuttia viikossa kesällä 
30. Mitkä ovat olleet pääasialliset VAPAA-AJAN liikuntamuotonne tärkeysjärjestyksessä 
viimeksi kuluneen vuoden aikana? 
  Talvella  ___________________________________________________________________ 
  Kesällä  ___________________________________________________________________ 
31. Kuinka  rasittavaa ruumiillisesti  on  VAPAA-AJAN  liikuntanne  ollut viimeksi kuluneen vuo-
  den aikana?
Talvella      1   Kevyttä      2   Rasittavaa  Kesällä 1  Kevyttä       2   Rasittavaa 
32. Mikä on nykyinen tai oli viimeinen ammattinne?  _____________________________________
33. Kuinka rasittava tämä työ  on/oli ruumiillisesti ? 
1   Istumatyö  2  Kevyt 3   Keskiraskas  4  Raskas 
34. Milloin viimeksi olette ollut tässä työssä?   Vuonna 19_____ 
35. Montako vuotta olette tehnyt tätä työtä kaiken kaikkiaan? _______vuotta 
36. Mikä on nykyinen työllisyys- ja eläketilanteenne? 
1   Työssä 
2   Työtön 
3   Työkyvytön, mutta ei eläkkeellä, sairaus? _______________________________________
4   Työkyvyttömyyseläkkeellä, 
sairaus?____________________________________________ 
5   Yksilöllinen varhaiseläke, sairaus?_____________________________________________
6   Varhennettu tai tavallinen vanhuuseläke 
37. Mistä vuodesta lukien olette ollut eläkkeellä? 
38. Mikä on liikuntakykynne nykyisin? Merkitkää liikuntarajoituksen syy. 
0   Olen täysin liikuntakykyinen   
1   Pystyn kävelemään rajoituksetta mutta en juoksemaan, syy? ______________________ 
2   Pystyn liikkumaan korkeintaan kilometrin, syy? _________________________________ 
3   Pystyn liikkumaan korkeintaan 100 metriä, syy? _________________________________
4   Olen liikuntakyvytön tilapäisesti, syy?_________________________________________
5   Olen liikuntakyvytön pysyvästi, syy? __________________________________________
39. Onko oma terveydentilanne mielestänne muihin samanikäisiin verrattuna
1   erittäin hyvä  2   hyvä   3    kohtalainen 
4   huonohko   5   huono    
40. Onko  LÄÄKÄRI  TODENNUT  Teillä  seuraavia  sairauksia?  (Rengastakaa  kaikki Teitä 
koske-vat vaihtoehdot ja merkitkää sairauden toteamisvuosi) 
  No. Sairaus                                       Toteamisvuosi 
     1 Liikkumista haittaava näkövika ..................................... _______________ 
     2  Lääkehoitoa vaativa verenpainetauti ............................. _______________  
     3  Sepelvaltimotauti  (sydänveritulppa tai rasitusrintakipu) . _______________ 
      4 Muu sydäntauti kuten vajaatoiminta tai läppävika ......... _______________ 
      5  Aivohalvaus, aivoverenvuoto tai aivoveritulppa ............ _______________ 
     6  Insuliinihoitoinen sokeritauti ............................... ........... _______________ 
     7 Tablettihoitoinen sokeritauti .......................................... _______________ 
      8  Kilpirauhasen liikatoiminta ............................................  _______________ 
      9  Kilpirauhasen vajaatoiminta .......................................... _______________ 
   10 Keliakia  ....................................................................... _______________ 
    11  Mahalaukun leikkauksen jälkitila ................................... _______________ 
   12 Krooninen munuaissairaus ............................................ _______________ 
 13  Krooninen maksasairaus ............................................... _______________ 
   14  Liikkumista haittaava nivelkuluma eli nivelrikko ............ _______________ 
   15  Nivelreuma ................................................................... _______________ 
   16 Pitkäaikainen selkäkipu ................................................ _______________ 
 17  Epilepsia ...................................................................... _______________ 
   18  Keuhkoastma ............................................................... _______________ 
   19  Muu pitkäaikainen keuhkosairaus .................................. _______________ 
   20  Alkoholismi .................................................................. _______________ 
 21  Pitkäaikainen mielisairaus ...........................................    _______________ 
   22  Syöpä, mikä? _________________________________  _______________ 
 23 Muut pitkäaikaiset tai vakavat sairaudet, mitkä?______ _______________ 
    _____________________________________________ _______________ 
    _____________________________________________ _______________ 
    _____________________________________________ _______________ 
     24  Ei mitään yllämainituista eikä muita pitkäaikaisia tai vakavia sairauksia
41. Käytättekö  NYKYISIN  LÄÄKÄRIN  MÄÄRÄÄMIÄ  LÄÄKKEITÄ?  Jos käytätte, merkitkää 
lääkkeen nimi,  sairaus ja hoidon kesto. 
0   En käytä; siirtykää kysymykseen 42
1   Käytän 
   Lääkkeen nimi   Sairaus     Hoidon kesto  
   __________________________ ______________________________ _____ vuotta 
   __________________________ ______________________________ _____ vuotta 
   __________________________ ______________________________ _____ vuotta 
   __________________________ ______________________________ _____ vuotta 
   __________________________ ______________________________ _____ vuotta 
42. Oletteko   koskaan   käyttänyt   KORTISONIA   tabletteina   (esim.  Prednisolon,  Medrol)  tai 
keuhko- tai nenäsumutteena (esim. Pulmicort, Becotide) vähintään viikon ajan? 
0  En; siirtykää kysymykseen 44 1  Kyllä, ensi kerran vuonna 19______ 
43. Kuinka  monta  vuotta  tai  kuukautta yhteensä elämänne aikana olette käyttänyt kortisonia? 
 Arvioidaan laskemalla yhteen vähintään viikon mittaiset käyttöjaksot 
  ______ vuotta _______ kuukautta kortisonitabletteja 
  ______ vuotta _______ kuukautta kortisonikeuhko- tai nenäsumutinta 
44. Oletteko   koskaan  käyttänyt  LÄÄKÄRIN  MÄÄRÄÄMIÄ  SÄRKYLÄÄKKEITÄ  vähintään  1 kk
 ajan? 
0   En 
1   Kyllä, yhteensä  _______  vuotta ______ kk, mitä valmisteita eniten? _________________ 
   _________________________________________________________________________
45. Kuinka  monta  vuotta  yhteensä  elämänne aikana olette käyttänyt TYROKSIINI-kilpirauhas- 
 hormonia? (Merkitkää 0, jos ette ole käyttänyt) 
  ______ vuotta    
46. Kuinka  monta  vuotta  yhteensä  elämänne aikana olette käyttänyt NESTEENPOISTOLÄÄK- 
 KEITÄ (esim. Hydrex, Diurex, Furesis)? (Merkitkää 0, jos ette ole käyttänyt)
  ______ vuotta; mitä valmisteita eniten? ______________________________________ 
      _________________________________________________________ 
47. Käytättekö  nykyisin päivittäin KALSIUMIA tai D-VITAMIINIA sisältäviä lääke- tai luontaisval- 
 misteita? 
0   En 
1   Kyllä, mitä valmisteita? ___________________________________________________   
       ___________________________________________________ 
48. Kuinka monta vuotta yhteensä elämänne aikana olette päivittäin käyttänyt KALSIUMIA tai D- 
 VITAMIINIA sisältäviä valmisteita? (Merkitkää 0, jos ette ole käyttänyt)
  ______ vuotta 
53. Mikä on puhelinnumeronne?     Koti _________ - ___________________________ 
                                    Työ  _________ - ___________________________ 
54. Vastauspäivämäärä   ______.______. 1994 
55. Lopuksi pyydämme Teitä vielä antamaan allekirjoituksellanne suostumuksenne sairaus-
kertomustietojenne käyttöön tätä tutkimusta varten. Saatamme tarvita näitä tietoja tutkies-
samme luukadon ja murtumien syitä ja ehkäisyä 
 SUOSTUMUS 
 Annan Luukadon Ehkäisytutkimukselle luvan sairauskertomustietojeni käyttöön. 
 ______________________________________ 
     allekirjoitus 
KIITOS VASTAUKSISTANNE 
Taittakaa  lomake  ja  postittakaa  se mieluiten toukokuun aikana oheisessa  palautus-





49. Onko Teille suoritettu muita kuin synnytinelinten leikkauksia? 
0   Ei; siirtykää kysymykseen 51  1   Kyllä 
50. Merkitkää  tähän  kolme  suurinta  muuta  kuin  synnytinelinten  leikkausta vuosineen ja syi-
 neen
  Leikkaus    Vuosi  Leikkaussyy (sairaus) 
  _____________________________ 19______ _______________________________ 
  _____________________________ 19______ _______________________________ 
  _____________________________ 19______ _______________________________ 
51.   Onko Teillä koskaan ollut yli viikon mittaisia osastohoitoja sairaaloissa? 
0   Ei; siirtykää kysymykseen 53
1   Kyllä  
52. Merkitkää tähän kolmen pisimmän osastohoidon vuosi, kesto ja syy. 
  Vuosi Kesto   Syy (sairaus) 
  19______   ________viikkoa ____________________________________________ 
  19______   ________viikkoa ____________________________________________ 















Luukadon ehkäisytutkimus    - 10-vuotiskysely
KYS & Kuopion yliopisto
10.05.1999
Arvoisa Vastaanottaja 
KYS:n ja Kuopion yliopiston Luukadon Ehkäisytutkimus eli Osteoporoosiprojekti (OSTPRE) 
käynnistettiin vuonna 1989 lähettämällä kysely kaikille Kuopion läänin vuosina 1932-41 synty-
neille 14 000 naiselle. Te kuuluitte tähän joukkoon. Vuonna 1994 tehtiin 5-vuotiskysely. Kum-
paankin kyselyymme vastasi teistä yli 90%. Kiitämme Teitä myönteisestä suhtautumisestanne. 
Arvalla valituille 3000 naiselle suoritetaan lisäksi luuntiheysmittaukset 5 vuoden välein. 
OSTPREn tarkoitus on tutkia paitsi luukatoa myös naisten terveydentilaa yleensä ja siihen vai-
kuttavia tekijöitä. Tämä on mahdollista, jos meillä on käytössämme kysely- ja mittaustietoja se-
kä terveistä että sairaista pitkältä ajalta. 
Nyt on 10-vuotiskyselyn aika. Pyydämme Teitä ystävällisesti täyttämään kyselylomakkeen ja 
vastaamaan jokaiseen kysymykseen rengastamalla Teitä koskeva vastausvaihtoehto ja kirjoit-
tamalla pyydetty tieto sitä varten varattuun tilaan. Ellette muista kysyttyä asiaa, arviokin riittää. 
On tärkeää että kaikki vastaavat riippumatta siitä asuvatko enää Pohjois-Savossa vai eivät. Jos 
haluatte apua lomakkeen täytössä, voitte soittaa numeroon (017) 162 978. Antamanne tiedot 
käsitellään luottamuksellisesti ja julkaistaan tilastotaulukkoina niin että henkilöllisyytenne pysyy 
salassa.
Kiitämme Teitä jo etukäteen vaivannäöstänne. 
PS. Oheisena lähetämme myös OSTPREn tähänastisia tuloksia pähkinänkuoressa. 
Seppo Saarikoski Esko Alhava Risto Honkanen 
LKT, professori LKT, professori LKT, dosentti 
KYS, naistentautien klinikka KYS, kirurgian klinikka Kuopion yliopisto 
 Heikki Kröger Marjo Tuppurainen 
 LKT, dosentti LT, erikoislääkäri 
 KYS, kirurgian klinikka KYS, naistentautien klinikka 
KYSYMYSOSA ALKAA
PERHETIEDOT
1. Onko äidillänne ollut ranne- tai lonkka-
murtuma?
  1 Ei 
  2 Kyllä, rannemurtuma 
  3 Kyllä, lonkkamurtuma 
  4 Kyllä, sekä ranne- että lonkkamurtuma 
2. Onko äidillänne todettu rintasyöpä? 
  1 Ei 
  2 Kyllä, _____-vuotiaana 
3. Elääkö äitinne?
  1 Kyllä 
  2 Ei, hän kuoli _____-vuotiaana 
4. Onko isällänne ollut ranne- tai lonkka-
murtuma?
  1 Ei 
  2 Kyllä, rannemurtuma 
  3 Kyllä, lonkkamurtuma 
  4 Kyllä, sekä ranne- että lonkkamurtuma 
5. Elääkö isänne? 
  1 Kyllä 
  2 Ei, hän kuoli _____-vuotiaana 
6. Montako sisarta ja veljeä Teillä on? 
  ____sisarta   ja   ____veljeä 
7. Onko sisarillanne ollut ranne- tai lonk-
kamurtuma?
  1 Ei 
  2 Kyllä, rannemurtuma ____-vuotiaana 
  3 Kyllä, lonkkamurtuma 
  4 Kyllä, sekä ranne- että lonkkamurtuma 
8. Onko sisarillanne todettu rintasyöpä? 
  1 Ei 
  2 Kyllä, ____-vuotiaana 
9. Onko veljillänne ollut ranne- tai lonkka-
murtuma?
  1 Ei 
  2 Kyllä, rannemurtuma _____-vuotiaana 
  3 Kyllä, lonkkamurtuma 
  4 Kyllä, sekä ranne- että lonkkamurtuma 
OMAT TIEDOT 
Luunmurtumat
10. Onko Teillä ollut lääkärin toteamia 
luunmurtumia 1.5.94 jälkeen? 
  0 Ei, Siirtykää kysymykseen 11
  1 Kyllä, missä luissa ja milloin? 
   ________________________  ___.___19___ 
   ________________________  ___.___19___ 
   ________________________  ___.___19___ 
   ________________________  ___.___19___ 
   ________________________  ___.___19___ 
   ________________________  ___.___19___ 
  Kuinka saitte yllämainitsemanne murtumat? 
  1 Kaaduin, liukastuin  …… 19____      19____  
  2 Kaaduin, muuten ……… 19____      19____ 
  3 Putosin, ____metriä…………….       19____ 
  4 Polkupyörätapaturma …………..       19____ 
  5 Auto-onnettomuus ………………       19____ 
  6  Muulla tavoin, miten?____________________  
  _________________________________19____ 
  _________________________________19____ 
  Missä yllämainitsemanne murtumat todettiin ja 
hoidettiin? 
  ______________________________19_______ 
  ______________________________19_______ 
  ______________________________19_______ 
  ______________________________19_______ 
  ______________________________19_______ 
  ______________________________19_______ 
Kaatumiset ja putoamiset 
11. Oletteko kaatunut tai pudonnut viimeis-
ten 12 kuukauden aikana?
  0 En, Siirtykää kysymykseen 16
 1 Kyllä, kuinka monta kertaa? 
  ______ kertaa 
12. Missä kuussa kaaduitte tai putositte viimeisen 
kerran?
  1   Tammi  5   Touko  9   Syys 
  2   Helmi  6   Kesä  10   Loka 
  3   Maalis  7   Heinä  11   Marras 
  4   Huhti  8   Elo  12   Joulu 
13. Missä kaaduitte tai putositte viimeisen kerran? 
  1 ulkona 
  2 sisällä 
14. Miten kaaduitte tai putositte viimeisen kerran? 
 1 portaissa 
 2 putosin muualla, kuinka monta metriä?___metriä 
 3 liukastuin ja kaaduin 
 4 kompastuin ja kaaduin 
 5 kaaduin muuten, miten? ___________________ 
  ______________________________________ 
15. Kävittekö lääkärissä viimeisen kaatumisen tai 
putoamisen vuoksi ? 
  1 En 
  2 Kyllä, luunmurtumaa ei todettu 
  3 Kyllä, luunmurtuma todettiin 
Kuukautiset
16. Minkä ikäinen olitte, kun Teillä oli en-
simmäiset kuukautiset?
 ______-vuotias 
17. Minkä ikäinen olitte, kun Teillä oli vii-
meiset luonnolliset (muut kuin hor-
monihoidon aiheuttamat) kuukautiset?
  ______-vuotias 
Jos hormonihoito aloitettiin ennen kuukautisten 
loppumista, merkitkää rasti tähän
Jos kohtu poistettiin ennen kuukautisten lop-
pumista, merkitkää rasti tähän
Elämäntilanne
18. Tuntuuko Teistä siltä että Teidän elä-
männe on juuri nyt hyvin kiinnostavaa, 
melko kiinnostavaa, melko ikävää vai 
hyvin ikävää? 
  1 hyvin kiinnostavaa 
  2 melko kiinnostavaa 
  3 melko ikävää 
  4 hyvin ikävää 
  5 en osaa sanoa 
19. Tuntuuko Teistä että Teidän elämänne 
on juuri nyt hyvin onnellista, melko on-
nellista, melko onnetonta vai hyvin on-
netonta?
  1 hyvin onnellista 
  2 melko onnellista 
  3 melko onnetonta 
  4 hyvin onnetonta 
  5 en osaa sanoa  
20. Tuntuuko Teistä siltä, että Teidän elä-
männe on juuri nyt hyvin helppoa, mel-
ko helppoa, melko kovaa vai hyvin ko-
vaa?
  1 hyvin helppoa 
  2 melko helppoa 
  3 melko kovaa 
  4 hyvin kovaa 
  5 en osaa sanoa 
21. Tuntuuko Teistä siltä, että Te juuri nyt 
olette hyvin yksinäinen, melko yksi-
näinen vai ettekö ollenkaan yksinäi-
nen?
  1 hyvin yksinäinen 
  2 melko yksinäinen 
  3 en lainkaan yksinäinen 
  4 en osaa sanoa 
22. Mikä on nykyinen siviilisäätynne?
  1 naimaton 
  2 avoliitossa 
  3 avioliitossa 
  4 eronnut 
  5 leski 
Työ, työkyky ja eläke
23. Mikä on työtilanteenne tällä hetkellä? 
  1 olen työssä 
  2 olen työtön  
  3 olen eläkkeellä  
  4  olen pitkäaikaisesti työkyvytön mutta en 
vielä eläkkeellä 
  5 olen työssä ja osaeläkkeellä 




25. Kuinka monta vuotta yhteensä olette 
ollut tässä työssä? 
 _________vuotta 
26. Kuinka rasittava tämä työ on/oli ruu-
miillisesti ? 
  1 istumatyö (esim. sihteeri, opettaja)
  2 kevyt (esim. sairaanhoitaja, myyjä)
  3 keskiraskas (esim. siivooja, perushoitaja) 
  4 raskas (esim. karjanhoito, varastotyö) 
Kysymys vain eläkkeellä oleville
27. Mistä syystä olette eläkkeellä?
  1 iän perustella 
  2 työkyvyttömyyden perusteella 
  3 iän ja terveydentilan perusteella (yksilöl-
linen varhaiseläke)
  4 työttömyyden perusteella 
Kysymys vain työkyvyttömyyseläkkeellä oleville







29. Kuinka pitkä olitte noin 25 vuoden iäs-
sä?
  ________cm 
30. Kuinka pitkä olette tällä hetkellä?
  ________cm 
31. Mikä oli painonne noin 25 vuoden iäs-
sä?
  ________kg 
32. Mikä on painonne tällä hetkellä?
  ________kg 
33. Mikä on vyötärönympärysmittanne? (Mi-
tataan allaolevasta mittauslinjasta seisten, vaat-
teitta, normaalin uloshengityksen lopussa ja ki-
ristämättä vyötäröä mittanauhalla)
  _______cm 
  alin kylkiluu 
  mittauslinja  
                napa 
  suoliluun harja 
Terveystavat
34. Tupakoitteko nykyisin? 
  0 En 
  1 Kyllä, noin______savuketta päivässä
35. Kuinka monta desilitraa maitotuotteita 
(esim. maitoa, piimää, jogurttia, viilejä 
ym.) käytätte päivässä nykyisin?
 keskimäärin________dl 
36. Kuinka monta siivua juustoa syötte 
päivässä nykyisin?
 keskimäärin_______siivua 
37. Mikä on kuukaudessa käyttämänne al-
koholijuomien määrä? (Merkitkää 0, jos 
ette käytä lainkaan)
  Olutta keskimäärin ____pulloa 
  Viinejä keskimäärin ____lasillista 
  Väkeviä keskimäärin____ravintola-annosta 
38. Mikä on nykyinen liikuntakykynne?
  1 täysin liikuntakykyinen 
  2 liikuntakykyinen, mutta en voi juosta 
  3 pystyn kävelemään enintään 1 km 
  4 pystyn kävelemään enintään 100 m 
  5 pystyn liikkumaan vain sisätiloissa 
  6 olen liikuntakyvytön 
39. Kuinka monta kilometriä viikossa olette 
kävellyt tai juossut viimeksi kuluneen 
vuoden (12 kk) aikana kaiken kaikkiaan 
mukaan lukien työmatkat ja liikkuminen 
työssä?
  Keskimäärin 
  ______ km viikossa talvella  
  ______ km viikossa kesällä 
40. Oletteko harrastanut säännöllisesti va-
paa-ajan kuntoliikuntaa viimeksi kulu-
neen vuoden aikana? (esim. kävely, sau-
vakävely, pyöräily, hiihto, uinti, tanssi, voimis-
telu, hölkkä/juoksu, pallopelit)
  1  En 
  2 Kyllä, kuinka monta tuntia viikossa? 
  keskimäärin _____ tuntia viikossa talvella  
  keskimäärin _____ tuntia viikossa kesällä 
41. Mitkä ovat olleet pääasialliset vapaa-
ajan liikuntamuotonne tärkeysjärjes-
tyksessä viimeksi kuluneen vuoden ai-
kana?




42. Kuinka rasittava vapaa-ajan liikuntanne 
on ollut? (rasittava = hikoilua tai hengästymistä 
aiheuttava)
Talvella
  1   kevyt (esim. kävely, voimistelu)  
  2   kohtalainen (esim. ripeä kävely, tanssi) 
  3   rasittava (esim. uinti, pallopelit) 
  4   hyvin rasittava (esim. juoksu, kova hiihto)
Kesällä
  1   kevyt (esim. kävely, voimistelu)  
  2   kohtalainen (esim. ripeä kävely, pyöräily) 
  3   rasittava (esim. uinti, pallopelit) 
  4   hyvin rasittava (esim. juoksu, kova hiihto) 
Terveydentila
43. Mikä seuraavista vaihtoehdoista kuvaa 
mielestänne parhaiten nykyistä tervey-
dentilaanne muihin samanikäisiin ver-
rattuna?
  1 erittäin hyvä 
  2  hyvä 
  3 keskinkertainen 
4 huono 
  5 erittäin huono 
44. Mikä oli mielestänne terveydentilanne 5 
vuotta sitten muihin samanikäisiin verrat-
tuna?
  1 erittäin hyvä 
  2  hyvä 
  3 keskinkertainen 
  4 huono 
  5 erittäin huono 
45. Onko lääkäri todennut Teillä seuraavia 
sairauksia? (Rengastakaa kaikki Teitä 
koskevat vaihtoehdot ja merkitkää sairau-
den ensimmäinen toteamisvuosi).
    Toteamis-
        vuosi 
 1 Liikkumista haittaava näkövika ……... 19____ 
 2 Lääkehoitoa vaativa verenpainetauti.. 19____ 
 3 Sepelvaltimotauti (sydänveritulppa 
  tai rasitusrintakipu) ……………..….... 19____ 
 4 Muu sydäntauti kuten vajaatoiminta… 19____ 
 5 Aivohalvaus ………………………...… 19____ 
 6 Aivoverisuonitukos ……………….…... 19____ 
 7 Aivoverenvuoto …………………….…. 19____ 
 8 Aivoveritulppa ……………………...…. 19____ 
 9 Korkea veren kolesteroli …………..… 19____ 
 10 Alaraajan laskimotukos …………..….. 19____ 
 11 Insuliinihoitoinen sokeritauti ……...…. 19____ 
 12 Tablettihoitoinen sokeritauti …………. 19____ 
 13 Kilpirauhasen liikatoiminta ……….…... 19____ 
 14 Kilpirauhasen vajaatoiminta ……..….. 19____ 
 15 Laktoosi-intoleranssi ……………..….. 19____ 
 16 Keliakia ………………………………... 19____ 
 17 Mahalaukun leikkauksen jälkitila ……. 19____ 
 18 Krooninen munuaissairaus ………..… 19____ 
 19 Krooninen maksasairaus ……..….….. 19____ 
 20 Nivelreuma ……………………….…… 19____ 
 21 Nivelkuluma eli nivelrikko ………….… 19____ 
 22 Pitkäaikainen jalkaan säteilevä  
  selkäkipu eli iskias ……………………. 19____ 
 23  välilevytyrän aiheuttama iskias ….. 19____ 
 24  selkäydinkanavan ahtauma-iskias  19____ 
 25 Muu pitkäaikainen selkäkipu ………… 19____ 
 26 Epilepsia ………………………….…… 19____ 
 27 Keuhkoastma …………………………. 19____ 
 28 Muu pitkäaikainen keuhkosairaus ….. 19____ 
 29 Alkoholismi …………………….……... 19____ 
 30 Pitkäaikainen mielisairaus ………...… 19____ 
 31 Rintasyöpä  ………………………..…. 19____ 
 32 Kohtusyöpä …………………………… 19____ 
 33 Kohdun kaulaosan syöpä …………… 19____ 
 34 Muu syöpä, mikä?_______________ 
  ______________________________ 19____ 
 35 Muut pitkäaikaiset tai vakavat sairaudet, 
  mitkä? ________________________ 19____ 
  ______________________________ 19____ 
  ______________________________ 19____ 
  ______________________________ 19____ 
  ______________________________ 19____ 
  ______________________________ 19____ 
  ______________________________ 19____ 
 0 Ei mitään yllämainituista eikä muita pitkäaikai-
sia tai vakavia sairauksia
46. Jos Teillä on/oli nivelkuluma eli nivel-
rikko, niin missä nivelissä ja minä 
vuonna ensi kerran muutokset todet-
tiin?
  1 lonkka ………………….….. 19____ 
2 polvi …………………….…. 19____ 
  3  selkäranka ………………… 19____ 
  4  kaularanka …………….….. 19____ 
  5  sormet …………………….. 19____ 
  6  muut nivelet mitkä?_______ 19____ 
  _________________________ 19____ 
  _________________________ 19____
47. Kuinka pitkä on ollut elämänne pisin 
yhtäjaksoinen sairasloma selkäkivun 
vuoksi?
1 en ole ollut sairaslomalla selkäkivun 
vuoksi
2 viikon tai lyhyempi
3 yli viikon mutta alle kuukauden 
  4 1-3 kuukautta 
  5 yli 3 kuukautta 
48. Onko Teillä viimeisten 12 kk aikana ol-
lut äkillistä yli kuukauden kestävää sel-
käkipua?
  0 Ei 
  1  Kyllä, yläselässä 
  2  Kyllä, alaselässä 
Lääkkeet
49. Käytättekö tällä hetkellä lääkärin mää-
räämiä lääkkeitä? Merkitkää alle käyt-
tämienne lääkkeiden nimet ja montako 
vuotta olette käyttänyt lääkettä? 
 0 En käytä 
 1 Käytän 
  Lääkkeiden nimet Käytön kesto 
    vuosina 
  _________________________ _______ 
  _________________________ _______ 
  _________________________ _______ 
  _________________________ _______ 
  _________________________ _______ 
  _________________________ _______ 
50. Oletteko koskaan käyttänyt kortisonia 
tabletteina (esim. Prednisolon, Medrol) 
vähintään viikon ajan? 
  1 En 
  2 Kyllä, ensimmäisen kerran v. 19 _____ 
51. Oletteko koskaan käyttänyt kortisonia
keuhko- tai nenäsumutteena vähintään 
viikon ajan? 
  1 En  
  2 Kyllä, ensimmäisen kerran v. 19____ 
52. Kuinka monta vuotta tai kuukautta yh-
teensä elämänne aikana olette käyttä-
nyt kortisonia? Arvioidaan laskemalla 
yhteen vähintään viikon mittaiset käyt-
töjaksot.
 ____vuotta ____ kuukautta tabletteina 
 ____vuotta ____ kuukautta keuhko / ne-
näsumutteena
53. Oletteko käyttänyt estrogeenihormonia 
tabletteina, laastarina tai geelinä 1.5.94 
jälkeen esimerkiksi vaihdevuosioirei-
siin tai luukadon hoitoon (Mukaan ei 
lueta emätintabletteja, -salvoja eikä -puik-
koja)?
  1 En 
  2 Kyllä; merkitkää alle kuinka monta kuu-
kautta kunakin vuonna käytitte estro-
geenihormonia?
     Valmisteen nimi 
  1994_____kuukautta _______________
  1995_____kuukautta _______________ 
  1996_____kuukautta _______________ 
  1997_____kuukautta _______________ 
  1998_____kuukautta _______________ 
  1999_____kuukautta _______________ 
54. Käytättekö estrogeenihormonia tablet-
teina, laastarina tai geelinä tällä hetkel-
lä?
  1 En 
  2 Kyllä 
55. Käytättekö tällä hetkellä kalsiumia eli 
kalkkia lääkkeenä tai luontaisvalmis-
teena?
  1 En 
  2 Kyllä, käytän apteekkivalmistetta 
  3  Kyllä, käytän luontaisvalmistetta 
  4 Kyllä, käytän sekä apteekki- että luon-
taisvalmistetta 
  Valmisteiden nimet ___________________ 
  __________________________________ 
56. Käytättekö tällä hetkellä D-vitamiinia?
  1 En 
  2 Kyllä 
  Valmisteiden nimet___________________ 
  __________________________________ 
57. Käytättekö tällä hetkellä jotain muuta 
luukato- eli osteoporoosilääkettä (esim. 
Fosamax, Didronate, Miacalcic, Bonefos, 
Evista, Livial, Skelid, Bondronate)? 
  1 En 
  2 Kyllä, lääkkeen nimi_______________ 
   Käytön kesto ____vuotta____kuukautta 
Leikkaukset
58. Onko teiltä poistettu kohtu 1.5.94 jäl-
keen?
  1 Ei 
  2 Kyllä, vuonna 19____ 
59. Onko Teiltä poistettu molemmat mu-
nasarjat
  1 Ei 
 2 Kyllä, viimeisen munasarjan poisto 
vuonna 19_____ 
60. Oletteko koskaan ollut selkäleikkauk-
sessa?
  1 En 
  2 Kyllä, vuosina 19____, 19____, 19____ 
61. Oletteko koskaan ollut tekonivel- tai 
nivelen asennonkorjausleikkauksessa
  1  En 
  2  Kyllä, lonkka…..…….… vuonna 19___ 
  3 Kyllä, polvi…………..… vuonna 19___ 
  4 Kyllä, muu nivel ………. vuonna 19___ 
   mikä nivel?_______________________ 
62. Oletteko ollut muussa leikkauksessa
1.5.94 jälkeen? 
  1 En 
  2 Kyllä, vuosina 19____, 19____ 
   Mitä leikattiin_____________________ 
   ________________________________ 
   ________________________________ 
Muut osastohoidot sairaalassa
63. Oletteko ollut muusta syystä kuin leik-
kauksen vuoksi sairaalassa osastohoi-
dossa 1.5.94 jälkeen? 
  1 En 
  2 Kyllä, vuosina 19____, 19 ___, 19____ 
  Sairaudet?_________________________ 
  __________________________________ 
  __________________________________ 
Yhteystietonne?
Puhelinnumero
 Koti tai kännykkä _____-________________ 
 Työ  _____-________________ 
 Muu  _____-________________ 
Osoite (vain jos väestörekisterikeskukselta saa-






  [ lomaketarra tähän ] 
SUOSTUMUS 
Lopuksi pyydämme Teitä vielä antamaan allekirjoi-
tuksellanne suostumuksenne sairaskertomustie-
tojenne käyttöön. Saatamme tarvita näitä tietoja 
tutkiessamme luukatoon ja terveydentilaan vaikut-
tavia tekijöitä. 
Annan Luukadon ehkäisytutkimusprojektil-
le luvan sairaskertomustietojeni käyttöön. 
Allekirjoitus
_________________________________________
Vastauspäivämäärä?  ______.______1999 
KIITOS VASTAUKSISTANNE
Tarkistakaa vielä, että vastasitte kaikkiin kysy-
myksiin, taittakaa lomake ja postittakaa se ohei-
sessa palautuskuoressa mahdollisimman pian. 
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Effects of Hormone Therapy
and Calcium Supplementation
on Morbidity and Mortality in
Postmenopausal Women
Kati Pentti
Effects of Hormone Therapy 
and Calcium Supplementation 
on Morbidity and Mortality in 
Postmenopausal Women
During and after the perimenopausal 
years, hormone therapy (HT) is pre-
scribed to alleviate chronic climacteric 
symptoms, to improve quality of life, 
and to prevent osteoporosis. Under-
standing the risks and benefits of HT 
is critical to clinical decision making 
around menopause and beyond. In 
this large population-based study we 
investigated whether HT has effects on 
mortality and diabetes morbidity and 
whether calcium or calcium + vitamin 
D supplementation affect CHD mor-
bidity in postmenopausal women.
 
